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(C18 RP-)HPLC (octadecyl carbon chain reverse phase) high 
performance liquid chromatography 
ABC ATP-binding cassette  
Ac acetyl 
ActM actin from Microcystis aeruginosa PCC 7806 
APS ammonium peroxodisulphate 
ATP adenosine triphosphate 
bi bicyclic  
bp base pair(s) 
BSA bovine serum albumin 
DMSO dimethyl sulfoxide 
DNA desoxyribonucleic acid 
dNTPs desoxynucleotide triphosphates 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
gDNA genomic DNA 
HEPES 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid 
HIV human immunodeficiency virus 
IC50 half maximal inhibitory concentration 
IPTG isopropyl β-D-thiogalactoside 
KDa (kilo) dalton 
LB lysogeny broth 
M. aeruginosa Microcystis aeruginosa 
MALDI-TOF MS matrix-assisted laser desorption ionization–
time of flight mass spectrometry 
 Abbreviations 
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MALDI-TOF/TOF MS  matrix-assisted laser desorption ionization–
tandem time of flight mass spectrometry  
MCS multiple cloning site 
mdn (L, L1, L2, L3) microviridin (L, L1, L2, L3) 
mdnA/B/C/D/E microviridin biosynthetic genes A/B/C/D/E 
mdnJ microviridin J 
MndA/B/C/D/E microviridin A/B/C/D/E protein 
mono monocyclic  
MS mass spectrometry 
Mvn microvirin 
MWCO molecular weight cut off 
N298 Nies298 
N843 Nies843 
Nies298 Microcystis aeruginosa Nies298 
Nies843 Microcystis aeruginosa Nies843 
NRP nonribosomal peptide 
NRPS(s) nonribosomal peptide synthetase(s) 
OD optical density 
ORF open reading frame 
PBS phosphate buffered saline 
PBS-T phosphate buffered saline with Tween20 
PCC Pasteur Culture Collection 
PCR(s) polymerase chain reaction(s) 
PIPES 1,4-piperazinediethanesulfonic acid 
PK polyketide 
PKS(s) polyketide synthase(s) 
PMSF phenylmethylsulfonylfluorid 
POD peroxidase from horseradish 
 Abbreviations 
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PSD post source decay 
Qc Quik change  
RNA ribonucleic acid 
rpm rounds per minute 
RT room temperature 
SDS sodium dodecyl sulfate 
SDS-PAG sodium dodecyl sulfate polyacrylamide gel 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
Sec Sec protein  
SPR surface plasmon resonance 
TAE Tris-acetate-EDTA 
Tat twin-arginin translocation 
TBS-T Tris buffered saline with Tween20 
TE Tris-EDTA 
TEMED tetramethylethylendiamin 
TES Tris-EDTA-saccharose  
TFA trifluoroacetic acid 
tri tricyclic  
Tris Tris(hydroxymethyl)aminomethane 
TusA sulfurtransferase TusA 
UV/VIS ultraviolet-visible  
X-Gal 5-bromo-4-chloro-3-indolyl- beta-D-
galactopyranoside 
 Nomenclature in HPLC chromatograms 
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Nomenclature of microviridins 
Nr. name crosslink amino acid sequence m/z, ion charge 
1 mdnL tri Ac-YGGTFKYPSDWEDY 1737.7 [M+Na]+ 
2 mdnL1  tri Ac-GGTFKYPSDWEDY 1574.6 [M+Na]+ 
3 mdn L2 tri PSPEPTYGGTFKYPSDWEDY 2303.9 [M+H]+ 
4 mdnL3 tri IKSPSPEPTYGGTFKYPSDWEDY 2610.1 [M+Na]+ 
5 mdnL1 bi Ac-GGTFKYPSDWEDY 1570.7 [M+H]+ 
6 mdnL bi Ac-YGGTFKYPSDWEDY 1733.7 [M+H]+ 
7 mdnJ tri Ac-ISTRKYPSDWEEW 1684.7 [M+H]+ 
8 mdnL3 bi PSPEPTYGGTFKYPSDWEDY 2299.9 [M+H]+ 
9 mdnL1 KYPAD mono Ac-GGTFKYPADWEDY 1572.7 [M+H]+ 
10 mdnL TFTL type tri Ac-YGGTLKYPSDWEDY 1703.7 [M+Na]+ 
11 mdnL1 TFTL type tri Ac-GGTLKYPSDWEDY 1540.6 [M+Na]+ 
12 mdnL KWPSD type tri Ac-YGGTFKWPSDWEDY 1760.7 [M+Na]+ 
13 mdnL1 KWPSD type tri Ac-GGTFKWPSDWEDY 1597.8 [M+Na]+ 
14 mdnL KFPSD type tri Ac-YGGTFKFPSDWEDY 1721.7 [M+Na]+ 
15 mdnL1 KFPSD type tri Ac-GGTFKFPSDWEDY 1558.9 [M+Na]+ 
16 mdnL KYPSDS type tri Ac-YGGTFKYPSDSEDY  1616.5 [M+H]+ 
17 mdnL1 KYPSDS type tri Ac-GGTFKYPSDSEDY 1453.3 [M+H]+ 
18 mdnL field Y type  tri Ac-YNVTLKYPSDWEEY 1794.9 [M+H]+ 
19 mdnL1 field Y type tri Ac-NVTLKYPSDWEEY 1631.7 [M+H]+ 
20 mdnL field F type  tri Ac-YNVTLKYPSDWEEF 1778.8 [M+H]+ 
21 mdnL1 field F type tri Ac-NVTLKYPSDWEEF 1615.7 [M+H]+ 
22 mdnL PCC7822-2 type bi Ac-YQNTLKYPSDWEDY 1827.8 [M+H]+ 
23 mdnL1 PCC7822-2 type bi Ac-QNTLKYPSDWEDY 1664.7 [M+H]+ 
24 mdnL PCC7822-3 short 
type 
bi PIFTLKFPSDWEDS 1645.7 [M+H]+ 
25 mdnL PCC7806-4 short 
type 
bi WTWKWPSDWEDS 1586.6 [M+H]+ 
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Microviridine sind cyanobakterielle, trizyklische Depsipeptide mit ungewöhnlich 
käfigartiger Struktur. Die Gene mdnABCDE kodieren für die ribosomale Biosynthese dieser 
Peptide. Zwei neuartige ATP-grasp Ligasen, MdnB und MdnC, katalysieren die Bildung von 
Lacton- und Lactamringen durch die Einführung von zwei -Ester-und einer sekundären -
Amidbindung. Die Prozessierung wird von einer bislang unbekannten Peptidase 
durchgeführt. Neben den filamentösen Nostoc und Planktothrix gehört die einzellige, 
blütenbildende Cyanobakteriengattung Microcystis zu den Microviridin produzierenden 
Bakterien. Die potente inhibitorische Aktivität gegenüber Serinproteasen verleiht 
Microviridinen ökologische und pharmazeutische Relevanz. 
Im Rahmen der vorliegenden Arbeit wurde eine kleine, stabile Microviridin 
Expressionsplattform konstruiert. Ein neuartiges Microviridin Gencluster aus Microcystis 
aeruginosa Nies843 wurde heterolog in E. coli exprimiert, bioinformatisch analysiert und 
mutiert. Das hochkonservierte PFFARFL-Motiv im Precursorpeptid MdnA wurde als 
Erkennungssequenz für die ATP-grasp Ligasen identifiziert. Manipulationen am C-Terminus 
des leader-Peptids führten zu einer Inhibierung der Aktivität von MdnB. Peptid-Protein-
Interaktionen zwischen MdnA und den ATP-grasp Ligasen wurden untersucht. Es wurde 
gezeigt, dass der ABC-Transporter MdnE essentiell für die Zyklisierung und Prozessierung 
von Microviridinen ist, da er höchstwahrscheinlich einen Microviridin Biosynthesekomplex 
an der inneren Membran stabilisiert. Schließlich werden zwei mögliche Modelle für die 
Peptiderkennung und Prozessierung im putativen Biosynthesekomplex vorgeschlagen. 
Punktmutationen in der Microviridin core-Sequenz offenbarten Flexibilität des Microviridin-
Biosyntheseapparates für das peptide engineering. Es wurde eine Mutante konstruiert, 
deren inhibitorische Aktivität gegen Elastase um den Faktor >100 verbessert wurde. Durch 
die Konstruktion einer Precursoraustauschplattform konnten bisher kryptische Microviridine 
produziert werden. Diese Methode hat Potential für den Bau von Microviridinbibliotheken. 







Microviridins are the largest known cyanobacterial oligopeptides that are synthesized 
through a unique ribosomal route. These peptides comprise an unrivaled multicyclic cage-
like structure, carrying two characteristic -ester and one amide bond, which are 
introduced by the two novel ATP-grasp ligases MdnB and MdnC. In addition to the 
filamentous species Nostoc and Planktothrix, the unicellular, bloom-forming 
cyanobacterium Microcystis aeruginosa Nies843 is one of the microviridin producer strains. 
The potent serine protease inhibitory activity contributes to both ecological and 
pharmacological relevance of microviridins. 
During this work, a small expression platform carrying the microviridin gene cassette 
mdnABCDE was established. The novel microviridin gene cluster was heterologously 
expressed in E. coli and analyzed using bioinformatics and mutational analysis. The strictly 
conserved PFFARFL motif in the precursor peptide MdnA was identified and characterized 
as a binding sequence for the ATP-grasp ligases. Manipulations of the C-terminal part of the 
leader peptide abolished lactam ring formation of microviridins. Protein interactions of 
MdnA with B and C were studied. The ABC-transporter MdnE was unveiled to be crucial for 
cyclization and processing of microviridins, probably holding and stabilizing a putative 
microviridin maturation complex at the inner membrane. Two initial models for the 
peptide recognition and processing have been proposed. 
Point mutations in the microviridin core sequence showed some flexibility of the 
microviridin biosynthetic pathway to be used for peptide engineering. The exchange of a 
phenylalanine against a leucine in position 5 of the coding sequence resulted in more than 
a 100-fold increased inhibitory activity against the attractive drug target elastase. The 
possibility to express cryptic microviridin precursor peptides in a precursor exchange 
platform showed the potential to create peptide libraries. Finally, a hypothesis about the 





1.1 Background about cyanobacteria 
Cyanobacteria are a group of Gram-negative cosmopolitan prokaryotes. Findings of 
microfossils, stromatolites and chemical biomarkers in Australia and South Africa indicated 
cyanobacterial appearance about 2.8 billion years ago [Olson, 2006]. Belonging to the 
ancient colonizers of the earth, they played a key role as important primary producers of 
the oxygenic environment and their ability to nitrogen fixation further increased the 
biological capacity of the oceans and soils [Herrero and Flores, 2008]. 
Historically termed as blue-green algae, due to the prominent aquatic living space and the 
bluish-green color caused by green chlorophyll and the blue pigment phycocyanin, 
cyanobacteria were first classified botanically before they were proposed to be placed 
under the rules of the Bacteriological Code [Stanier, et al., 1978].  
Cyanobacteria exhibit an unusual wide range of morphologies, including single-cell, 
colonial and filamentous forms. Cells differ in size from 0.5-60 µm diameter and thus are 
among the largest-sized cells known from prokaryotes, easily visible with the naked eye 
[Madigan and Brock, 2000]. Some species appear in balls (Nostoc sp.), other are able to 
form mats (Oscillatoria) (Figure 1-1) or blooms (Microcystis, Anabaena) (Figure 1-2).  
Another feature of some planktonic cyanobacteria is the presence of gas vesicles that 
afford buoyancy and thus enable the bacteria to flow up and down to reach zones to 
conduct photosynthesis and find best nutrition [Walsby, 1994].  
Cyanobacteria can colonize almost all habitats on earth. These adaptable microorganisms 
can conquer ecological niches that range from hot springs [Ionescu, et al., 2010], deserts 
[Lacap, et al., 2011], Antarctic ponds [Quesada and Vincent, 1997], rocks and soil 
[Rehakova, et al., 2011] to fresh and brackish water [Harke, et al., ; Lehtimaki, et al., 
2000]. Forms of endosymbiosis with plants, protists and lichens [Dworkin, et al., 2006: ; 





Figure 1-1: Diverse appearances of cyanobacteria 
A) unicellular Gloeothece sp., B) filaments of Nostoc sp. PCC7120, C) cross section through the stem 
of Gunnera with arrows indicating pockets of Nostoc punctiforme, D) Oscillatoria mat formation, E) 
free-living ball–like colonies of Nostoc in a fresh water pond in southern Oregon with a size of about 
0.5 to 1.0 cm in diameter, F) a microbial mat in a hot spring in Oregon, containing cyanobacteria; 
picture sources are given in the appendix 
1.1.1 Cyanobacterial metabolites  
As a consequence of living in a variety of environments, cyanobacteria exhibit a broad 
spectrum of secondary metabolites with a wide range of useful characteristics, helpful for 
the producer to survive and fascinating for researchers and industry with regard to 
potential pharmaceutical, agricultural and biotechnological application. Major compounds 
that have been reported are the photoprotective scytonemins [Sorrels, et al., 2009], 
storage polymers as cyanophycin and poly-β-hydroxybutyrate [Wu, et al., 2001: ; Ziegler, 
et al., 1998], several odourous metabolites [Watson, 2003], iron chelators as the 
dihydroxamate siderophore schizokinen [Goldman, et al., 1983: ; Murphy, et al., 1976], 
toxins and carcinogens like microcystin and cylindrospermopsin [Dittmann, et al., 1997: ; 
Falconer and Humpage, 2006], and compounds with cytotoxic [Ishida, et al., 2000], 
antibiotic [Schlegel, et al., 1998], antimalarial [Linington, et al., 2009], anti-HIV [Huskens, 
et al., 2010] and proteinase inhibiting activities [Ishitsuka, et al., 1990: ; Kodani, et al., 
1998], some of them already in clinical phases. Although the great potential of these 
compounds is recognized for bioindustrial applications, the analysis, large scale production 
and especially the manipulation of these compounds often needs to be analyzed in 
heterologous hosts, as most cyanobacteria belong to the slow growing organisms that are 
frequently resistant to genetic manipulation, due to effective restriction barriers 




Microcystis belongs to the unicellular, gas-vacuolated, toxic bloom-forming cyanobacteria, 
which have a coccoid cell shape and may aggregate to form colonies [Otsuka, et al., 2001].  
The genus Microcystis produces a variety of secondary metabolites including the 
hepatotoxin microcystin [Tillett, et al., 2000], the chymotrypsin inhibitor cyanopeptolin 
[Bister, et al., 2004], the angiotensin-converting enzyme inhibitor microginin [Okino, et 
al., 1993], the cytotoxic microcyclamides [Ishida, et al., 2000] and the serine protease 
inhibitor microviridin [Ishitsuka, et al., 1990: ; Okino, et al., 1995]. These metabolites are 
synthesized via the ribosomal or nonribosomal route in Microcystis. 
 
Figure 1-2: Microcystis and two representative compounds 
A) Microcystis colony, B) bloom formation by Microcystis, C) structure of microcystin-LR, D) 
structure of microginin; picture sources are given in the appendix 
1.2 The benefits of small cyclic compounds 
The vast majority of bioactive cyanobacterial metabolites including microcystin, 
anabaenopeptin, cyanopeptolin and aeruginosin are products of either a multimodular 
nonribosomal peptide (NRP), polyketide (PK) or hybrid NRP-PK biosynthetic pathway 
[Dittmann, et al., 2001]. Over the past years the discovery of more and more ribosomally 
synthesized peptides, including the cyanobacterial microviridins and microcyclamides, has 
been seen [Velasquez and van der Donk, 2010]. In former times less celebrated as small-
medicines for humans, compared to the nonribosomal peptides, the benefits including a 
stable cyclic composition, an attractive bioactive diversity, a short biosynthetic pathway 
and the possibility for peptide engineering of these scaffolds are just beginning to be 
appreciated [McIntosh, et al., 2009]. Mainly the cyclic composition of small ribosomally 
synthesized peptides confers to bioactivity, decreases the likelihood of proteolytic 
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degradation and improves thermal and chemical stability. Cyclic peptides have reduced 
conformational flexibility and therefore allow a greater preorganization of binding 
elements in comparison to linear molecules.  
The advantages of ribosomal synthesis are obvious when compared to total synthesis of 
cyclic compounds. Total synthesis of cyclic natural peptides with interesting bioactivities 
and uniquely complex structures still presents formidable challenges. The processes are 
often time-consuming and expensive. Postranslational extremely modified compounds 
carrying intramolecular cyclizations occurring in nature are still difficult to be 
reconstructed. Extensive synthetic efforts are necessary to synthesize products with 
multiple chiral carbon centers and altering ring sizes [Marko, 2001]. As the product yields 
are often low, total synthesis is rarely a good alternative. In contrast, heterologous 
expression of ribosomal pathways in suitable hosts, leading to cyclic, highly modified 
bioactive peptides has been used in the study of several lantibiotics [Nagao, et al., 2007: ; 
Widdick, et al., 2003] and was shown to result in high product yields for microviridins 
[Ziemert, et al., 2010]. The commercial use of about 60 therapeutic peptides is reported 
and more than 150 are in clinical trials [Velasquez and van der Donk, 2010]. Ribosomal 
peptides are produced from a variety of living organisms, including eukaryotes, plants, 
fungi and archaea that afford similarities to the bacterial ribosomal peptides. 
1.2.1 Peptides derived from ribosomal origin and their producers 
The eucaryocins, peptide antibiotics produced by eukaryotes are typically small, 
thermostable, cationic peptides. They are often rich in cysteines and are able to form 
-sheets or amphipathic helices [O'Connor and Shand, 2002]. Among the eukaryotic 
producers, poisonous mushrooms of the genera Amanita, Galerina, Lepiota and Conocybe 
produce bicyclic octa- and heptapeptides of 6-10 amino acids, referred to as amatoxins 
and phallotoxins. Both contain tryptophane-cysteine crossbridges, known as tryptathionine 
(Figure 1-3) [Walton, et al., 2010]. Cyclotides from plants of the genera Violaceae and 
Rubiaceae are head-to-tail macrocyclized mini-proteins of 28-37 amino acids with a cyclic 
cystine knot. They exhibit a wide spectrum of activities, ranging from antiinsecticidal, 
anti-HIV and cytotoxic to antimicrobial [Herrmann, et al., 2008]. Cone snails produce a 
repertoire of disulfite rich neurotoxins with potential pharmaceutical application. 
Ziconotide is the most prominent example, being on market to treat severe chronic pain 
[Garber, 2005]. Up to 140,000 other conopeptides last to be characterized [Lewis, et al., 
2009]. Spiders and scorpions are expected to produce thousands of small useful peptides 
that have evolved for 400 million years [Bulaj, 2008]. 
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Archaeocins, including the halocins and sulfolobicins, are peptide antibiotics and toxins 
produced from halophilic and hyperthermophilic archaebacteria. Halocins are hydrophobic 
compounds. They are noncationic and do not fold into -helices, which indicates their 
mechanism of action is novel and potentially interesting for pharmaceutical effects. Only a 
few compounds as the small microhalocins S8 and HalR1 are characterized, but not 
exhaustively. Halocins exhibit a broad inhibitory spectrum against different haloarchaea, 
but not against bacteria. Sulfolobicin activity is also restricted to close related producers 
[O'Connor and Shand, 2002: ; Price and Shand, 2000]. 
Among the peptides produced from prokaryotes, the most intensively studied group 
includes the antimicrobial polypeptides called bacteriocins. They divide into lantibiotics, 
thioether amino acid and lanthionine-containing antibiotics, produced from Gram-positive 
and the microcins from Gram-negative bacteria. The best understood lantibiotic out of a 
group of 50 is nisin (Figure 1-3) from Lactococcus lactis, which has been used as a food 
preservative for more than 40 years now [Willey and van der Donk, 2007]. Moreover it is 
able to inhibit cell wall biosynthesis [Brotz, et al., 1998]. Lantibiotics as cinnamycin from 
Streptomyces strains show phospholipase-inhibiting characteristics and duramycin 
increases the chloride secretion in lung epithelium [Okesli, et al., 2011: ; Oliynyk, et al., 
2010]. Carbacyclic labyrinthopeptins from Actinomadura namibiensis show antiviral 
activity and efficacy against neuropathic pain [Meindl, et al., 2010: ; Müller, et al., 2010]. 
The group of structural diverse microcins that mostly act as defensive peptides is secreted 
by enterobacteria and is rather small with about 15 representatives identified since their 
discovery in 1976 [Asensio and Perez-Diaz, 1976]. Some microcins, like the lasso peptide 
microcin J25 (Figure 1-3), contain only natural amino acids, others are extremely 
modified, as the DNA gyrase targeting linear microcin B17, being highly rich in glycine and 
containing eight pharmaceutically interesting heterocyclic oxazole and thiazole rings in the 
backbone [Jack and Jung, 2000]. A recent work examined the genetic potential for 
bacteriocin production in cyanobacteria and disclosed an enormous uncovered source 
[Wang, et al., 2011].  
More than hundred unique small cyclic peptides composed of 7-20 amino acids that often 
contain oxazoles and thiazoles are known from the family of cyanobactins mainly produced 
by free living cyanobacteria, marine invertebrates sheltering symbiotic cyanobacteria and 
sponges [Donia, et al., 2008]. The best known representatives are the patellamides (Figure 
1-3), being the first identified cyanobactins to be produced via the ribosome and thus 
leading to the inclusion into the ribosomally synthesized peptide group [Schmidt, et al., 
2005]. Furthermore, trunkamides with potent antitumor activity [Salvatella, et al., 2003], 
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cytotoxic microcyclamides [Ziemert, et al., 2008] and others have been reported [Sivonen, 
et al., 2010].  
Thiopeptides, containing nitrogen heterocycles, are known from several Bacillus, 
Streptomyces and Frankia strains. Thiocillin is the main representative. The enourmous 
number of 13 posttranslational modification reactions convert the thiocillin precursor 
molecule into the antibacterial antibiotic that inhibits protein biosynthesis [Wieland 
Brown, et al., 2009]. 
 
Figure 1-3: Representative structures from ribosomally synthesized peptides 
Structures of cyclic bacterial ribosomally derived peptides are shown in A), B) and C), representing 
the lantibiotics (nisin A), the cyanobactins (patellamide C) and the microcins (microcin J25). A cyclic 
peptide produced by a eukaryotic mushroom is given in D) (-amanitin). Postranlational 
modifications are highlighted with the following colors: (methyl)lanthionine bridges are shown in 
red; heterocyclization, as the formation of oxazoles, is given in purple; thiozoles are illustrated in 
blue; head to tail macrocyclizations are shown in orange and green; a cysteine-tryptophane 
crossbridge (trypthationin) is shown in claret-red. 
The microviridins produced from cyanobacteria such as Microcystis, Planktothrix and 
Nostoc display an outstanding group among the ribosomally synthesized peptides. They 
comprise a unique cage-like tricyclic architecture that has been seen for no other 
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ribosomally synthesized candidate before. As microviridins are the central topic of this 
study, they will be explained in more detail starting with chapter 1.3. 
1.2.2 Ribosomal peptide synthesis 
The ribosomal peptide synthesis is restricted to the 20 proteinogenic amino acids. 
Ribosomal proteins so far reported share common features as they are synthesized from 
short precursor molecules, which are translated on the ribosome and extensively modified 
leading to remarkable structural diversity of the mature compounds. Bacterial precursor 
peptides often cluster with the genes involved in posttranslational modifications and 
secretion. At least one proteolytic step is needed to release a smaller active product. 
Leader peptides may carry recognition sequences to direct the modifying enzymes or to 
identify the proteolytic cleavage site (Figure 1-4). Ribosomal peptide synthesis is a 
relatively short pathway. A further major benefit is the clear link between the amino acid 
sequence and the final product. The exchange of only one amino acid or a few codons 
results in a modified compound providing opportunities to generate novel bioactive 
metabolites through rational pathway engineering [McIntosh, et al., 2009: ; Velasquez and 
van der Donk, 2010] (see also chapter 1.2.2.5). 
 
Figure 1-4: Schematic of ribosomal protein biosynthesis [McIntosh, et al., 2009] 
A gene, encoding for a precursor molecule (orange) is located in the close vicinity of genes encoding 
for posttranslationally modifying enzymes (black). The precursor peptide is modified by these 
enzymes in both, the leader (blue arrow) and the core region (emphasized using asteriks). 
Ultimately the leader peptide is removed from the core by proteolytic cleavage.  
1.2.2.1 Precursors  
Some precursor peptides contain more than one core region plus flanking recognition 
sequences as seen for cyanobactins and amatoxins. Some eukaryotic precursor peptides, as 
those for conopeptides, contain a signal sequence at the N-terminus of the leader peptide 
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to direct it to the endoplasmic reticulum for further modifications [Oman and van der 
Donk, 2009]. 
 
Figure 1-5: Schematic representation of leader and signal peptides 
A) A typical precursor peptide of bacterial or eukaryotic origin is composed of a leader peptide and 
a core region. The leader peptide is assumed to be involved in different functions. N-terminal signal 
sequences, present in higher organisms, direct peptides to the endoplasmic reticulum. C-terminal 
recognition sequences are optionally. Core peptides are modified posttranslationally [Oman and van 
der Donk, 2009]. The typical composition of a standard signal peptide, used in combination with the 
Sec-dependent and Tat-pathway is represented in B). The signal peptide is divided into 3 regions, a 
rather polar n-region at the N-terminus, a hydrophobic h-region and the polar C-terminal c-region 
[Nothwehr and Gordon, 1989]. The protein to be translocated is attached to the signal peptide. 
Black arrows indicate cleavage sites in both peptides. 
Several functions have been proposed for leader peptides. The most common is that of a 
secretion signal. Most leader peptides for natural product biosynthesis have humble 
similarity to the signal peptides from plants and microorganisms. They are necessary to 
initiate transport across the cytosolic membrane using the Sec-translocation pathway to 
transport unfolded proteins or the twin arginine pathway (Tat-pathway) for the 
translocation of folded secretory proteins across biological membranes. Standard signal 
peptides consist of an N-terminal rather polar region (n-region) with a positive net charge 
that is joined to the hydrophobic core region (h-region) comprising 2-15 amino acid 
residues, most essential for the targeting and membrane insertion. On the C-terminal side 
the hydrophobic core is flanked by a relatively polar region (c-region), which often 
contains helix-breaking residues as prolines or glycines and a signal that is recognized by a 
signal peptidase. Leader peptides may also carry recognition sequences for the 
posttranslational modification and/or export enzymes such as ABC-transporters. The 
double glycine or glycine-alanine motif of bacteriocins is well known as the recognition 
sequence for peptidase C39 domains of the cognate ABC- transporters [Dirix, et al., 2004: ; 
Michiels, et al., 2001]. Leader peptides may also participate in correct folding of the 
precursor. Furthermore, they are supposed to mediate stability against proteolytic 
degradation. Leader peptides may have a protective function for the producer cell. Some 
compounds gain their bioactivity once the leader is cleaved off, which usually happens 
during secretion [Lee, et al., 2006: ; Natale, et al., 2008: ; Oman and van der Donk, 2009: 
; Pugsley, 1993]. This cooperation between the leader and the cognate processing and 
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export machinery is essential, as shown for nisin [Kuipers, et al., 2004]. In vitro studies 
demonstrated that microviridin K biosynthesis can only occur from a precursor peptide 
composed of a leader and a core sequence. A precursor peptide lacking the leader 
sequence was not a suitable substrate [Philmus, et al., 2008].  
Until today comparatively little is known about the molecular secrets behind the 
recognition of the leader peptides by their modifying enzymes. A few recognition 
sequences were proposed for different bacteriocins, including nisin [van der Meer, et al., 
1994], microcin J25 [Duquesne, et al., 2007] and lacticin 481 [Patton, et al., 2008]. 
1.2.2.2 Posttranslational modifying enzymes  
As the ribosomal biosynthesis is restricted to the proteinogenic amino acids, which 
somehow limits the structural diversity, the myriad of characteristics is introduced through 
posttranslational modifications, leading to an enormous diversity of compounds 
compareable to the number of nonribosomally synthesized products. Modifications include 
reactions such as macro- and heterocyclization, lanthionine synthesis, prenylation, 
formylation, acylation and rather rarely occurring epimerization and glycosylation 
reactions. Proteolysis is the one modification almost all leader peptide derived ribosomal 
peptides have in common [McIntosh, et al., 2009]. Some enzymes are highly tolerant 
towards their substrate specificity, as shown for the cyanobacterium Prochlorococcus 
MIT9313. Up to 29 precursor molecules were transformed into a polycyclic peptide library, 
which emphasizes the extraordinary potential to create numerous new compounds by 
genetic engineering [Li, et al., 2010]. Similarly, the hypervariable PatE protein from 
symbiotic Prochloron spp. bacteria is tailored by a fixed set of enzymes [Donia, et al., 
2006] 
1.2.2.3 Bifunctional ABC-transporters and proteolytic cleavage recognition 
motifs 
ATP-binding cassette transporters (ABC-transporters) are ubiquitous integral membrane 
proteins that use ATP-binding and hydrolysis to translocate a variety of different 
substrates, not only to acquire nutrients and excrete waste products across membranes, 
but also to fulfill a multitude of regulatory functions. ABC-transporters are mainly reported 
from prokaryotes, but eukaryotic examples are also known. In Gram-negative bacteria they 
transport proteins via the periplasm through the two membranes into the extracellular 
space. Some transporters need the help of specific substrate-binding proteins in the 
periplasm [Higgins, 1992].  
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ABC-transporters are often recognized in the close vicinity to a ribosomal peptide encoding 
gene cluster. They are minimally composed of 4 domains, 2 transmembrane-spanning 
transport channel forming domains and 2 cytosolic nucleotide-binding domains (Figure 
1-6, A), which are designated through their characteristic Walker A ((GXXXXGKT/S) with X 
being any amino acid) and B motifs. These two cooperatively acting domains of about 150 
amino acids are significantly involved in ATP-binding and hydrolysis [Rees, et al., 2009]. 
The loss of function of one domain results in a complete breakdown of transport function 
[Schneider, 2000]. However, the domains can be also fused into larger, multifunctional 
polypeptides. 
 
Figure 1-6: Simplified representation of an ABC-transporter 
A) Modular composition of a bacterial ABC-transporter. The transporter consists of two 
transmembrane (light gray) and two nucleotide-binding domains (dark gray), which are located on 
the cytosolic side. The transport function depends on ATP hydrolysis. Assisting proteins in the 
periplasmic space, as mentioned in the text, are not shown. A schematic representation of an ABC-
transport protein containing a C39 peptidase domain at the N-terminus (blue), followed by a 
membrane-spanning and a nucleotide-binding domain (gray) is shown in B). 
Some of these transporters hold a bifunctional role. Beside the ATP-dependent transport 
they act as the maturation peptidase with an N-terminal C39 peptidase domain (Figure 
1-6, B) that is missing from other ABC-transporters [Dirix, et al., 2004: ; Havarstein, et al., 
1995]. During secretion, these transporters recognize a double glycine motif, the rather 
rarely occurring glycine-alanine or a glycine-serine motif in the corresponding leader 
peptides from group II lantibiotics and nonlantibiotic bacteriocins, to cleave and release 
the correctly processed active product [Havarstein, et al., 1994: ; Michiels, et al., 2001]. 
As not all ribosomal precursor peptides contain double glycine motifs, there are other 
options to liberate the mature compound. Specified enzymes are good candidates, as 
reported for the cyanobactins. A subtilisin-type protease PatA, encoded in the patellamide 
gene cluster, was shown to sequentially remove the two peptide cassettes present in 
cyanobactin precursor peptides [Schmidt, et al., 2005]. The protease starts from the C-
terminus by probably using a recognition motif located in the recognition sequences (as 
shown in Figure 1-5). Cyclotides from plants are proposed to be cleaved similarly to the 
cyanobactins but by an asparagine peptidase [Saska, et al., 2007]. The core region of the 
amatoxin precursor peptide, encoding a mushroom poison from Conocybe albipes, is 
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cleaved N- and C-terminally by a proline oligopeptidase [Luo, et al., 2009]. Proline-specific 
peptidases can cover almost all situations were a proline is present and thus are 
recognized to be potential candidates for precursor processing [Cunningham and O'Connor, 
1997]. Aberrantly proteases might be located in the chromosome of the producing bacteria 
and not in the respective gene cluster, as shown for microcin B17 [Duquesne, et al., 2007] 
and assumed for type III lantibiotics [Meindl, et al., 2010]. 
1.2.2.4 The formation of biosynthetic complexes 
The formation of a biosynthetic complex, involving the posttranslational modifying 
enzymes, the transporter, scaffolding proteins and a precursor peptide has been observed 
to be essential for the biosynthesis of a number of ribosomally synthesized peptides. The 
nisin biosynthesis and immunity requires 11 clustered genes nisABTCIPRKFEG, whereupon 5 
are necessary to form a membrane-associated multimeric complex involving NisABCTP, as 
shown in Figure 1-7 [van den Berg van Saparoea, et al., 2008]. 
  
Figure 1-7: The formation of a membrane-associated biosynthetic complex using the example of 
nisin biosynthesis [van den Berg van Saparoea, et al., 2008] 
The nisin precursor peptide (prenisin) is targeted to the cytoplasmic membrane (CM) associated 
biosynthesis complex consisting of a dehydratase NisB, a cyclase NisC and NisT, an ABC-type 
transporter. The mature nisin is secreted by NisT and cleaved ousite the cell by NisP, to release the 
active nisin. 
Microcin B17 biosynthesis was the first biosynthetic pathway of a ribosomally synthesized 
peptide that has been reconstituted in vitro. At least 3 gene products are necessary to 
introduce oxazole and thiozole rings into the precursor peptide McbA in vitro. McbD is the 
prime recognition site for the substrate McbA that is correctly positioned through the 
polyglycine linker. McbB and McbC finally process microcin B17 by cyclization and 




Figure 1-8: The formation of a membrane-associated biosynthetic complex using the example of 
microcin B17 biosynthesis. This figure is partially adopted from [Duquesne, et al., 2007]. 
The microcin B17 synthetase consists of 3 proteins. McbD is responsible for initial substrate 
recognition and precursor stabilization. The posttranslationally modifying enzymes McbB and McbC 
are responsible for cyclization and dehydration of the precursor peptide McbA. McbB is zink 
dependent. OM: outer membrane. IM: inner membrane. Zn: zink 
1.2.2.5 Engineering of ribosomally synthesized peptides 
Engineering gene-encoded peptides offers both, the possibility to unlock information 
surrounding structure-activity relationships and to generate new classes of compounds with 
improved bioactivities, stabilities, aquaeus solubilities and pharmakoginetics. Ribosomal 
synthesis permits methods to alter the structure of a peptide much easier compared to 
other natural products. In general, subtle changes in the core of different precursors, as 
mentioned below, showed once in a while a beneficial impact for the production of new 
and improved peptides, whereas broad and profound manipulations rather led to a 
knock-down of the complete biosynthetic pathway. Alterations to residues involved in 
cross-linking or bridge formation have been shown to result predominantly in a loss or at 
least a decrease of bioactivity and production [Cooper, et al., 2008: ; Philmus, et al., 
2009].  
The possibility to manipulate ribosomally synthesized products using in vivo mutagenesis 
has been demonstrated in several cases. The four contigious identical precursor genes 
tclE-H in the thiocillin gene cluster were exchanged against a single plasmid based copy of 
tclE. Thiocillin production was rescued. The introduction of a series of mutations into the 
thiocillin core peptide led to a number of variants, including two with 2-4-fold improved 
activity against methicillin-resistant Staphylococcus aureus [Acker, et al., 2009]. A variant 
generating system for the lantibiotic actagardine has been recently constructed. The 
deletion of the garA gene from Actinoplanes garbadinensis generated a mutant incapable 
of producing actagardine. Co-expression of a cassette of the actagardine encoding gene 
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garA from a plasmid restored the production. Although peptides with enhanced activity 
were so far not detected from the small screened library, the potential for the rapid 
construction of new variant is given [Boakes, et al., 2009]. Several other lantibiotics 
including the prototype lantibiotic nisin [Field, et al., 2008], nukacin ISK-1 [Islam, et al., 
2009] and mersacidin [Appleyard, et al., 2009] have been successfully manipulated for 
increased bioactivity, which led to the assumption that the `Golden era´of lantibiotic 
bioengineering is entered [Field, et al., 2010].  
To overcome problems of intolerance of the biosynthetic machinery to certain changes or 
toxicity to the producer due to novel bioactivities during in vivo expression, reconstitution 
and manipulation of biosynthetic pathways ultimately led to in vitro systems. In vitro 
mutasynthesis of lacticin 481 produced the most interesting mutants to date. Two lacticin 
481 manipulated candidates with enhanced bioactivity contain nonproteinogenic amino 
acid substitutions [Levengood, et al., 2009], which is an anomaly that is impossible to be 
obtained using in vivo methodologies. An in vitro investigation into the mechanism of the 
cross-linking enzymes in microviridin K biosynthesis has been made to analyze the 
potential for engineering new microviridin-like or even unrelated peptides and proteins 
using two unprecedented ligases. MvdD, an ester ligase, has been shown to exhibit 
substrate tolerance to a certain degree. Bioactivity tests of the obtained mutants were not 
conducted [Philmus, et al., 2009]. Similarely, the nisin cyclase NisC has been shown in vivo 
to process a wide array of unrelated and designed peptides [Rink, et al., 2007].  
Irrespective of the difficulties using total synthesis some attempts were made to construct 
potentially promising new classes of small cyclic thiazole and oxazole containing peptides, 
albeit with comparatively low yields. Investigations concerning their properties and 
application are still in progress [Haberhauer and Rominger, 2002: ; Pattenden and 
Thompson, 2001]. 
For the construction of designer peptides, leader peptide mutagenesis and manipulation of 
the posttranslationally modifying enzymes have been considered in literature [Field, et al., 
2010]. The introduction of alternative cleavage sites at the C-terminus of the nisin leader 
peptide has been shown, without hampering the modifying enzymes [Plat, et al., 2010]. 
Designed and unrelated peptides were fused to the nisin leader and analyzed using the 
corresponding posttranslationally modifying enzymes, including NisBTC. Ring formation was 
demonstrated for most of these peptides, enabling the use of these enzymes for 
biotechnological production of therapeutic peptides with modulated activities and 




1.3 Microviridins  
Microviridins are ribosomally synthesized cyanobacterial depsipeptides that comprise a 
unique and novel cage-like architecture. Microviridins are exclusively composed of 13-14 
proteinogenic L-amino acids, with the one exception of the N-terminal acetic acid that is 
commonly present. The first microviridin, named microviridin A, has been isolated in 1990 
from a bloom of Microcystis viridis Nies102 [Ishitsuka, et al., 1990]. Until this study started 
14 microviridins were detected (Figure 1-9) and strains of Nostoc and Planktothrix were 
identified as additional producers [Philmus, et al., 2008: ; Reshef and Carmeli, 2006]. The 
highly unusual multicyclic structure is established by two ω-ester and a secondary ω-amide 
bond, which are formed between amino acid side chains.  
 
Figure 1-9: Detected microviridins with their amino acid sequence and type of cyclization 
The figure shows the 14 microviridin sequences so far uncovered from cyanobacteria belonging to 
Microcystis, Planktothrix and Nostoc. The sequence of microviridin A is composed of 14 amino acids, 
as shown in the numbers above the sequence, and has been used to illustrate the basic structural 
properties. All other microviridins are shown comparatively to microviridin A, which means only 
differences are given. The KYPSD motif (light blue) is highly conserved among microviridins. The 
amino acids involved in crosslink formation are shown in black brackits. The color coded asteriks 
indicate the number and type of cyclization. Hyphen: not present, oMeE: methyl ester of glutamate 
in position 12, HD: β-hydroxy aspartic acid. 
The main peptide ring consists of seven amino acids. The large lactone ring is established 
between the 4-carboxy group of aspartate (D) in position 10 and the hydroxy group of 
threonine (T) in position 4 (Figure 1-9 and Figure 1-10). The smaller lactone ring is formed 
involving position 9 and 12, comprising a serine (S) and a glutamate (E) (Figure 1-9 and 
Figure 1-10). The lactame ring is built between the 6-amino group of lysine (K) in position 
6 and the 4-carboxy group of glutamate (E) or aspartate (D) in position 13 (Figure 1-9 and 
Figure 1-10) [Welker and Von Döhren, 2006]. All so far detected microviridins show a highly 
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conserved TxKYPSD motif (with x being L, M, Y or W) in their core sequence (shown in light 
blue in Figure 1-9), whereas the N- and C-terminus display a higher variability. Some of the 
detected microviridins are bicyclic or monocyclic, whereas the majority of them are 
tricyclic.  
 
Figure 1-10: Structure of tricyclic microviridin A 
The main peptide ring is shown in green. The two ester bonds are highlighted in light gray and the 
amide bond in darker gray. Ac: acetylation 
1.3.1 The genetic basis of microviridin biosynthesis 
The genetic basis of microviridin production was incipiently assumed to be a nonribosomal 
peptide synthetase (NRPS) as cyanopeptolins, belonging to a cyanobacterial depsipeptide 
family, were proven to be assembled using this biosynthetic pathway [Martin, et al., 1993: 
; Tooming-Klunderud, et al., 2007]. Recently, Ziemert and coworkers showed that 
heterologously expressed microviridin B from Microcystis aeruginosa Nies298 is produced 
via the ribosomal peptide assembly line. A gene cluster of about 6 kb containing 5 genes, 
named mdnABCDE, was identified and supposed to be required in this constellation for the 




Figure 1-11: Microviridin mdnABCDE gene cluster for the production of microviridin B from 
Microcystis aeruginosa Nies298 
The genes encode for: A) microviridin precursor, B/C) ATP-grasp ligases, D) GCN5-related 
N-acetyltransferase (GNAT), E) ABC (ATP-binding cassette)-transporter 
1.3.2 Posttranslational modifications by two ATP-grasp ligases  
MdnA encodes the precursor molecule for microviridin production. It consists of a leader 
peptide and a core peptide with the microviridin sequence at the C-terminus, as commonly 
reported for ribosomal precursor peptides (see chapter 1.2.2.1) (Figure 1-12). MdnA is 
processed by the tailoring enzymes encoded in the microviridin gene cluster.  
The ligases MdnB and MdnC belong to a superfamily of enzymes, which is characterized 
through an unusual binding fold referred to as palmate or ATP-grasp fold. These enzymes 
conduct ATP-dependent carboxylate-amine or thiol ligase activity, whereupon primary or 
secondary amines might be used to create the peptide bond. Furthermore, their activity 
depends on the presence of Mg2+ and GTP or ATP. Several other enzymes, as the 
D-alanine-D-alanine ligases involved in cell wall biosynthesis, the glutathione synthetase 
responsible for glutathione biosynthesis, or the biotin carboxylase involved in fatty acid 
biosynthesis, are known to belong to this enzyme family. A large sequence analysis of the 
ATP-grasp domains showed that the amino acid residues, which interact with ATP, are 
highly conserved within the majority of sequences [Galperin and Koonin, 1997]. A 
phylogenetic study revealed the microviridin ligases create an independent branch on a 
phylogenetic tree and subdivide again into those belonging to the MdnC ester ligase and 
the MdnB amide bond forming type from different cyanobacteria and the proteobacterium 
Alteromonas [Ziemert, 2009].  
MdnB and MdnC catalyze the ring closures in microviridin biosynthesis. MdnC introduces 
successively two lactone rings starting with the larger one. MdnB depends on the activity 
of MdnC and can establish the peptide bond only once the ester bond formations are 
completed. Microviridin production in vivo and in vitro minimally depends on the genes 
mdnABC [Philmus, et al., 2008: ; Philmus, et al., 2009: ; Ziemert, et al., 2008]. 




Figure 1-12: Schematic representation of microviridin B biosynthesis in Microcystis (similar as 
seen in [Ziemert, et al., 2008] 
MdnC catalyzes the formation of the two lactone rings. MdnB catalyzes the formation of the lactam 
ring. MdnD encodes for a GNAT type acetyltransferase. MdnE encodes for an ABC-transporter. The in 
vivo function of mdnD and E was only assumed. The ester and amide bonds are highlighted in gray. 
Ac: acetyl group 
1.3.3 An N-acetyltransferase encoded by mdnD 
At the beginning of this study, the N-acetyltransferase MdnD, belonging to the group of the 
GCN5-related N-acetyltransferases (GNAT), was known to acetylate completely processed 
microviridins at their N-terminus in vitro [Philmus, et al., 2008] (Figure 1-12). In vivo 
studies have not been conducted until then. Additional functions of MdnD were not 
reported.  
The GNAT superfamily is one of the largest enzyme families with more than 10,000 
representatives today, distributed in all kingdoms. These enzymes use acyl-CoAs as a donor 
to acetylate their cognate substrates, which is the acceptor at the N-terminal primary 
amine. N-acetylation has been discussed in the past to function in a number of pathways in 
both prokaryotes and eukaryotes, including antibiotic resistance, transcriptional activation 
and DNA replication and neurohormone melatonin synthesis [Dyda, et al., 2000]. As a 
general benefit from prokaryotic acetylation mainly stabilization and protection of 
proteins against proteolytic processes has been discussed [Soppa, 2010]. An example 
showing the opposite function in eukaryotes has been published by Hwang and coworkers, 
who showed N-acetylation functions as a specific degradation signal [Hwang, et al., 2010]. 
Recently a bifunctional role for an N-acetyltransferase, participating in polyketide 
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synthesis with a decarboxylase/acetyltransferase activity has been discovered [Gu, et al., 
2007]. Beside N-acetylation internal acetylation at lysine residues occurs in prokaryotes to 
down-regulate protein activities in phases of starvation [Yu, et al., 2008]. 
1.3.4 An ABC-transporter encoded by mdnE 
MdnE, encoding for an ABC-transporter was assumed to be involved in proteolytic cleavage 
and/or translocation of microviridins (Figure 1-12). Microviridins were only completely 
processed, which means cleaved from the leader and acetylated at their N-terminus, when 
the entire gene cluster containing the genes mdnABCDE was expressed in E. coli. In 
absence of the ABC-transporter only incompletely processed microviridins were detected 
[Ziemert, et al., 2008]. 
A dual transporter peptidase function has been discussed for Nostoc sp. PCC7120 carrying a 
cryptic microviridin gene cluster and for Alteromonas sp. B-10-31 producing microviridin 
related marinostatins from a precursor molecule with a double glycine motif (see also 
chapter 1.2.2.3). MdnE was proposed to be the closest candidate for microviridin transport 
and cleavage, as it was located within the microviridin gene cluster and the removal of 
mdnE resulted in incompletely processed peptides. However, characteristic features 
including a recognition sequence and a peptidase domain were not detected until then 
[Dirix, et al., 2004: ; Michiels, et al., 2001: ; Ziemert, et al., 2008]. 
1.3.5 The potential of microviridins as protease inhibitors 
Almost all microviridins reported so far show potent inhibitory activity in vivo and in vitro 
against serine proteases, such as trypsin, chymotrypsin and elastase. Some microviridins 
are active already in the nanomolar range (Table 1-1). Additionally microviridin J has been 
shown to exhibit toxicity against daphnia by causing a lethal disruption in the molting 
process of this zooplankton [Rohrlack, et al., 2003].  
Proteases are involved in many biological processes, including food digestion, signaling 
cascades and lysosome associated degradation. They catalyze the irreversible disruption of 
peptide bonds and therefore necessitate a strict regulation and control by their 
corresponding naturally occurring inhibitors. Protease inhibitors are classified into serine 
(serpin), cysteine, aspartyl, threonine and metalloprotease inhibitors with some of them 
interfering with different types of proteases. As malfunction in protease production and 
regulation in human systems cause severe effects on the physical health, there is a major 
interest on the identification of potent protease inhibitors useful as pharmaceutical drugs. 
Several inhibitors, including those for the treatment of HIV and those to reduce blood 
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pressure are already in use, whereas other highly potent candidates are in clinical trials. 
Therapeutic agents against hepatitis C, cancer and diabetis mellitus are currently in phases 
I-III [Fear, et al., 2007]. Protease inhibitors are further discussed as future antibiotics. As 
almost all antibiotics in use target the bacterial cell-wall or protein biosynthesis, a 
different mode of action to overcome the emergence of antibiotic resistance guides drug 
generation to bacterial proteinase inhibitors [Travis and Potempa, 2000]. 
Not all of the protease inhibitors currently in pharmaceutical use are nonhazardous. 
Alpha-1-antitrypsin is a human glycoprotein. It is isolated from pooled human plasma of 
assured healthy donors. This proteinase inhibitor is indicated for chronic replacement 
therapy of patients having a congenital alpha-1-antitrypsin deficiency, leading to 
progressive pulmonary emphysema. There is no procedure available for a guaranteed 
removal of all viral infectivity from pooled human plasma (http://www.talecris-
pi.info/inserts/Prolastin-C.pdf). The scarcity of the raw material, the challenging 
manufacturing procedure [Reh, et al., 2002], the insufficient safety towards unknown 
pathogens and the need for patients to administer an weekly intravenous dosage demands 
new and better elastase inhibitors. Multiple efforts to generate recombinant human 
alpha-1-proteinase inhibitors have been reported. Heterologous production resulted in 
aberrant glycosylation patterns, which is considered to decrease protein stability with the 
result of rapid clearance from the circulation. So far not a single recombinant 
alpha-1-antitrypsin acquired therapeutic importance [Karnaukhova, et al., 2006]. 
Microviridins, produced from a bacterial origin, have high therapeutic potential as 
alternative candidate drugs for elastase inhibition [Murakami, et al., 1997: ; Okino, et al., 
1995: ; Ziemert, et al., 2008]. Chymotrypsin inhibitory activity is discussed in literature for 
an application in the elucidation of pancreatitis pathogenesis [Imada, et al., 1986]. 




Table 1-1: Selected data about the inhibitory activities of known microviridins (similar as seen 
in [Ziemert, et al., 2010]) 
  inhibitory activity (IC50) in µmol/l  
microviridin mass 
(Da) 
elastase chymotrypsin trypsin reference 
A 1.730 >58 >58 >58 [Ishitsuka, et al., 1990] 
B 1.722 0.026 1.5 34 [Okino, et al., 1995] 
C 1.754 0.048 2.8 18 [Okino, et al., 1995] 
D 1.802 0.388 0.7 >55 [Shin, et al., 1996] 
E 1.666 0.360 0.7 >60 [Shin, et al., 1996] 
F 1.682 3.4 >59 >59 [Shin, et al., 1996] 
G 1.805 0.010 0.78 >55 [Murakami, et al., 1997] 
H 1.837 0.017 1.6 >54 [Murakami, et al., 1997] 
I 1.764 0.193 nd nd [Fujii, et al., 2000] 
J 1.684 >6.0 1.7 0.020-
0.090 
[Rohrlack, et al., 2003] 
SD1684 1.684 nd inactive inactive [Reshef and Carmeli, 
2006] 
SD1634 1.634 nd 15.7 8.2 [Reshef and Carmeli, 
2006] 
SD1652 1.652 nd inactive inactive [Reshef and Carmeli, 
2006] 
nd: not determined; >: no inhibitory activity has been detected below this concentration 
1.3.6 Physicial mechanism and ecological function of microviridins 
The mode of action of microviridins is still a secret. There are no details or systematic 
studies about the precise physicial mechanism or preferential target specificities for these 
protease inhibitors. It might be due to the fact that microviridins and generally the 
ribosomally synthesized peptides just came into the center of interest several years ago. 
Commonly, it is known that proteolytic inhibitors use two strategies including either 
covalent trapping or a reversible tight-binding reaction to the active site of the target 
[Rawlings, et al., 2004]. 
The main focus following the isolation of a novel compound is concentrated on the 
bioactivity in terms of promising commercial application as a drug to cure or at least 
relieve human diseases. Very little is known about the fundamental role of microviridin in 
the physiology and ecology of the producing cyanobacterium. Microviridin J shows toxicity 
to daphnia by lethally disrupting the molting process, which has an impact on the whole 
ecosystem. Based on that information, microviridin has been proposed as a compound of 
chemical defense against these grazers [Rohrlack, et al., 2004]. In a study conducted by 
[Makower, 2010], microviridins have been assumed to be rather involved into intracellular 
processes then acting in quorum sensing based interspecies interactions.  
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For the majority of cyanobacterial compounds the function and benefit for the producer 
remains unknown. A few studies considered these metabolites as allelochemicals 
influencing the growth and development of neighboring species, including green algaes 
[Mason, et al., 1982], plants [Hirata, et al., 2003] and cyanobacteria [Jüttner, et al., 2001: 
; Singh, et al., 2001].  
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2 Thesis objectives 
The main objective for this study was to analyze a new microviridin gene cluster from 
Microcystis aeruginosa Nies843, to characterize and manipulate the biosynthetic pathway 
of these unique ribosomally synthesized tricyclic compounds. In general, bioinformatic 
analysis of microviridin gene clusters suggested a novel type of processing machinery 
encoded in the microviridin genes mdnABCDE compared to other ribosomally synthesized 
peptides. Two ATP-grasp ligases, MdnB and MdnC, were previously shown to sequentially 
introduce -ester and -amide bonds into the linear precursor peptide MdnA to yield the 
rare and fascinating cage-like architecture [Philmus, et al., 2008: ; Philmus, et al., 2009].  
This work was aimed on the construction of a minimal expression system to gain new 
insight into the mechanism of microviridin production. One of the goals was to investigate 
the leader peptide of MdnA by bioinformatic and mutational strategies for the presence of 
recognition motifs for the ATP-grasp ligases, the ABC-transporter and/or another 
peptidase. The proposed function of MdnD as an N-acetyltransferase ought to be confirmed 
in vivo by knockout mutagenesis. About the role of MdnE has been speculated as a 
transporter peptidase before [Ziemert, et al., 2008]. To clarify this assumption, the 
subcellular localization of microviridins and the cleavage from the leader peptide had to 
be analyzed in presence and absence of MdnE and by mutagenesis in the Walker A motif of 
the ATP-binding domain. An in vitro reconstitution of microviridin biosynthesis and initial 
studies of protein interactions were intended. 
Another goal was to analyze the microviridin core motif in terms of flexibility for amino 
acid exchanges that could guide the creation of compound libraries with improved and 
redesigned bioactivities. Bioactivity tests for the constructed mutants were intended. 
Furthermore, it was destined to exchange the Nies843 precursor peptide against examples 
taken from the natural library. 
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3 Experimental design 
3.1 Initial studies into the mechanism of microviridin production 
Initial studies of the mechanism behind microviridin production were made using a fosmid 
expression system and Duet vectors, alone or in combination of both systems, as given in 
the following schematic. 
 
Figure 3-1: Fosmids and Duet vectors to analyze microviridin production 
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3.2 Advanced studies into the mechanism of microviridin production 
A small microviridin expression platform was constructed and served as a template for a 
site-directed mutagenesis approach in the genes mdnA, B and E. Protein interactions were 
studied using SPR. The role of the ABC-transporter in microviridin L biosynthesis was 
determined to estimate his function in transport and as a putative scaffolding protein, as 
presented in the following diagram. 
 
Figure 3-2: Advanced studies into the mechanism of microviridin biosynthesis 
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3.3 Compound driven analysis of microviridin production 
The microviridin precursor molecule has been manipulated in the highly conserved part of 
the coding region in order to determine the flexibility against amino acid exchanges and 
the influence on the bioactivity of the resulting compounds. A complete exchange of the 
precursor molecule as well as certain amino acid exchanges should show the potential to 
create microviridin peptide libraries. Figure 3-3 presents an overview of the procedure. 
 
Figure 3-3: Manipulation of the microviridin coding region and expression of cryptic precursor 
molecules 
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4 Materials 
4.1 Bacterial strains 
All bacterial strains used in this study are listed in the following table.  
Table 4-1: Bacterial strains 
bacterial strains  description/origin reference 
Microcystis aeruginosa  
Nies843 toxic, bloom-forming, 
microviridin L producer/ Lake 
Kasumigaura Ibaraki Japan, 1997 
[Kaneko, et al., 2007], 
[Ziemert, et al., 2010] 
Nies298 toxic, bloom-forming, 
microviridin B producer/ Lake 
Kasumigaura, Ibaraki, Japan, 1982 
[Cadel-Six, et al., 2008] 
PCC7806 toxic, bloom-forming/ Braakman 
reservoir, The Netherlands, 1972 
Pasteur Culture Collection, 
Paris, France 
Escherichia coli   
BL21 (DE3) chemically or electro competent 
cells for heterologous expression 
Merck Chemicals Ltd., 
Nottingham, UK 
Top10 chemically competent cells for 
routine cloning procedures 
Invitrogen, Carlsbad, CA, 
USA 
XL1 Blue chemically competent cells for 
routine cloning procedures 
Agilent Technologies, La 
Jolla, CA, USA 
XL10 Gold ultra competent cells in use with 
Quik change II XL Site-Directed 
Mutagenesis Kit 
Agilent Technologies, La 
Jolla, CA, USA 
Epi300T1R fosmid library host strain Epicentre Biotechnologies, 
Madison, WI, USA 
4.2 Genomic DNA 
Genomic DNA of Cyanothece sp. PCC7822 and Nostoc sp. PCC7120 (Pasteur Culture 
Collection, Paris, France) has been used for PCR amplification of mdnA orthologs. 
4.3 Plasmids and fosmids 
pACYCDuet-1 Merck Chemicals Ltd., Nottingham, UK 
pETDuet-1 Merck Chemicals Ltd., Nottingham, UK 
 Materials and methods 
 44 
pCOLADuet-1 Merck Chemicals Ltd., Nottingham, UK 
pET40b(+) Merck Chemicals Ltd., Nottingham, UK 
pET15b Merck Chemicals Ltd., Nottingham, UK 
pCC1FOS EPICENTRE Biotechnologies, WI, USA 
pDrive  Qiagen, Hilden, Germany 
pRedET Gene Bridges GmbH, Heidelberg, Germany 
MRC-derived fosmid [Ziemert, et al., 2008] 
4.4 Media 
Bacto agar  BD, Sparks, MD, USA 
Bg11 [Rippka, et al., 1979] 
LB-agar CARL ROTH GMBH + CO. KG, Karlsruhe, 
Germany 
LB-broth CARL ROTH GMBH + CO. KG, Karlsruhe, 
Germany 
LB-broth +10mM MgSO4 25 g/ L LB-broth, 10 mM MgSO4, autoclaved 
M9 medium with thiamine-HCl and L-leucine 200 ml M9 salt solution 
(64 gNa2HPO4 x 2 H2O, 15 g KH2PO4, 2.5 g 
NaCl, 5 g NH4Cl per liter), 2 ml 1 M MgSO4, 
20 ml 20 % (w/ v) glucose, 100 µl CaCl2, 1 g 
thiamine-HCl, 60 mg L-leucine, adjusted to 
1 liter, separately autoclaved or filter 
sterilized 
E. coli minimal medium  A) salt solution: 13.3 g/l KH2PO4, 4.0 g/l 
(NH4)2HPO4, 1.7 g/l citric acid, 60 mg/l Fe-
III-citrate, 2.5 mg/l CoCl2x6H2O, 15.0 mg/l 
MnCl2x4H2O, 1.5 mg/l CuCl2x2H2O, 2.5 mg/l 
Na2MoO4x2H2O, 8.0 mg/l 
Zn(CH3COO)2x2H2O, 3.0 mg/l H3BO3, 8.4 
mg/l EDTA; B) 1.2 g/l MgSO4x7H2O; C) 25 g/l 
glucose; D) 4.0 mg/l thiamine-HCl; E) 
50 mg/l L-leucine; pH 6.7-7.0 
NZY+-broth 10 g N-Z-amine A, 5 g yeast extract, 5 g 
NaCl, pH 7.5, adjusted to 1 liter; 
additionally added: 12.5 ml 1 M MgCl2, 
12.5 ml 1 M MgSO4, 10 ml of 2 M glucose 
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4.5 Antibiotics 
Ampicillin-sodium salt CARL ROTH, Karlsruhe, Germany 
Chloramphenicol CARL ROTH, Karlsruhe, Germany 
Kanamycin sulfate CARL ROTH, Karlsruhe, Germany 
Streptomycin sulfate CARL ROTH, Karlsruhe, Germany 
Tetracycline-hydrochloride CARL ROTH, Karlsruhe, Germany 
4.6 Primers 
DNA oligonucleotides were purchased from Sigma-Genosys (Steinheim, Germany) or 
Eurofins MWG Operon (Ebersberg, Germany). A summary of primers used in this study is 
given in the appendix. 
4.7 Markers and dyes 
6 x DNA Loading Dye Fermentas Life Sciences, St. Leon-Rot, Germany 
Lambda DNA-PstI digest Fermentas Life Sciences, St. Leon-Rot, Germany 
PageRuler Prestained Protein Ladder Fermentas Life Sciences, St. Leon-Rot, Germany 
5x SDS-loading dye with 2-
mercaptoethanol 
250 mM Tris pH 6.8, 0.5 % bromphenol blue, 10 % 
(w/v) SDS, 50 % (w/v) glycerol, 500 mM 
2-mercaptoethanol  
4.8 Enzymes  
Factor Xa Protease Promega Corporation, Madison, WI, USA 
Lysozyme from chicken egg white Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
Pfu DNA polymerase Qiagen, Hilden, Germany 
PfuUltra HF DNA polymerase Agilent Technologies, Waldbronn, Germany 
Phusion High-Fidelity DNA polymerase Thermo Fisher Scientific GmbH, Dreieich, 
Germany 
Proteinase K Fermentas Life Sciences, St. Leon-Rot, 
Germany 
restriction endonucleases Fermentas Life Sciences, St. Leon-Rot, 
Germany; New England Biolabs, 
Frankfurt/Main, Germany 
RNase A/T1 Mix Fermentas Life Sciences, St. Leon-Rot, 
Germany 
Sequencing grade modified trypsin Promega GmbH, Mannheim, Germany 
 Materials and methods 
 46 
T4 DNA ligase Fermentas Life Sciences, St. Leon-Rot, 
Germany 
Taq DNA polymerase Qiagen, Hilden, Germany 
Thermus aquaticus DNA polymerase Kindly provided by the lab of Prof. C. 
Schmitz-Linneweber, Humboldt University 
of Berlin, Germany; [Desai and Pfaffle, 
1995] 
4.9 Chemically synthesized peptides 
The microviridin precursor sequences including MvdE from Planktothrix agardhii 
(MSKNVKVSAPKAVPFFARFLAEQAVEANNSNSAPYGNTMKYPSDWEEY), MdnA(1)-original Nies843 
precursor (MSKNVKVSAPKAVPFFARFLAEQAVEANNSNSAPYGNTMKYPSDWEEY), MdnA(2)—triple 
PFFARFL manipulated precursor from Nies843 
(MAYPNDQQGKALPGFLRALSVSKEESSIKSPSPEPTYGGTFKYPSDWEDY) and MdnA-original Nies298 
precursor (MAYPNDQQGKALPFFARFLSVSKEESSIKSPSPEPTFGTTLKYPSDWEEY) from Microcystis 
aeruginosa strains Nies298 and Nies843 were purchased from Genescript, NJ, USA.  
4.10 Proteins 
Mvn GenBank: CAO86269.1; kindly provided by 
Dr. Jan-Christoph Kehr, group of Prof. 
Dittmann, University of Potsdam, Germany 
ActM  GenBank: CAM57974.1, kindly provided by 
Arthur Guljamow, group of Prof. Dittmann, 
University of Potsdam, Germany 
TusA [Ikeuchi, et al., 2006]; kindly provided by 
Angelika Lehmann, group of Prof. 
Leimkühler, University of Potsdam, 
Germany 
POD  Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
BSA (Albumin Fraktion V) CARL ROTH, Karlsruhe, Germany 
4.11 Chemicals 
2-Mercaptoethanol Ferak-Berlin  GmbH, Berlin, Germany 
Acetic acid CARL ROTH, Karlsruhe, Germany 
Acetonitrile ROTISOLV HPLC grade CARL ROTH, Karlsruhe, Germany 
Ammonium hygrogen carbonate (NH4HCO3) Sigma-Aldrich Chemie Gmbh, Munich, 
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Germany 
APS CARL ROTH, Karlsruhe, Germany 
ATP Fermentas Life Sciences, St. Leon-Rot, 
Germany 
Biozym-LE-Agarose Biozym Scientific GmbH, Hessisch 
Oldendorf, Germany 
Boric acid CARL ROTH, Karlsruhe, Germany 
Chloroform CARL ROTH, Karlsruhe, Germany 
Citric acid Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
Cobald(II) chloride ICN Biomedicals Inc., Ohio, USA 
Copper chloride CARL ROTH, Karlsruhe, Germany 
CopyControl Induction Solution EPICENTRE Biotechnologies, Madison, WI, 
USA 
D (+)-sucrose CARL ROTH, Karlsruhe, Germany 
D-Glucose Merck, Darmstadt, Germany 
Diammonium hydrogen phosphate 
(NH4)2HPO4 
CARL ROTH, Karlsruhe, Germany 
DMSO CARL ROTH, Karlsruhe, Germany 
Di-potassium hydrogen phosphate trihydrate 
(K2HPO4 x 3 H2O) 
CARL ROTH, Karlsruhe, Germany 
Di-sodium hydrogen phosphate 
(Na2HPO4 x 2 H2O ) 
CARL ROTH, Karlsruhe, Germany 
D-Maltose SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
dNTP Mix, 10 mM each Fermentas Life Sciences, St. Leon-Rot, 
Germany 
Ethanol Berkel AHK Alkoholhandel, Berlin, Germany 
Ethidium bromide Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
EDTA CARL ROTH, Karlsruhe, Germany 
Gel-Code  Blue Safe Protein stain Thermo Fisher Scientific GmbH, Dreieich, 
Germany 
Glycerol CARL ROTH, Karlsruhe, Germany 
HEPES CARL ROTH, Karlsruhe, Germany 
Hydrochloric acid 37 % CARL ROTH, Karlsruhe, Germany 
Hydroxylamine hydrochloride FLUKA Feinchemikalien GmbH, Neu-Ulm, 
Germany 
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Imidazol CARL ROTH, Karlsruhe, Germany 
IPTG CARL ROTH, Karlsruhe, Germany 
Isoamylalcohol  CARL ROTH, Karlsruhe, Germany 
Isopropanol CARL ROTH, Karlsruhe, Germany 
L-arabinose Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
Liquid nitrogen AIR LIQUIDE Deutschland GmbH, Berlin, 
Germany 
Magnesium  sulfate CARL ROTH, Karlsruhe, Germany 
Magnesium chloride CARL ROTH, Karlsruhe, Germany 
Methanol ROTISOLV HPLC gradient grade CARL ROTH, Karlsruhe, Germany 
Monosodium phosphate-2-hydrate 
(NaH2PO4x2H2O) 
CARL ROTH, Karlsruhe, Germany 
N,N-Dimethylformamide (DMF) Merck, Darmstadt, Germany 
Ni-NTA agarose Qiagen, Hilden, Germany 
Nonidet P-40 Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
N-Z-amine A Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
Phenol-Chloroform-Isoamylalcohol 25:24:1 CARL ROTH, Karlsruhe, Germany 
PMSF CARL ROTH, Karlsruhe, Germany 
PIPES CARL ROTH, Karlsruhe, Germany 
Potassium chloride SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
potassium dihydrogen phosphate (KH2PO4) CARL ROTH, Karlsruhe, Germany 
Protein Assay Bio-Rad, Munich, Germany 
Rotiphorese Gel30 (37.5:1) CARL ROTH, Karlsruhe, Germany 
SDS ultra pure CARL ROTH, Karlsruhe, Germany 
Skim milk powder FLUKA Feinchemikalien GmbH, Neu-Ulm, 
Germany 
Sodium acetate CARL ROTH, Karlsruhe, Germany 
Sodium azide CARL ROTH, Karlsruhe, Germany 
Sodium carbonate anhydrous CARL ROTH, Karlsruhe, Germany 
Sodium chloride CARL ROTH, Karlsruhe, Germany 
Sodium hydroxide CARL ROTH, Karlsruhe, Germany 
Sodium molybdate CARL ROTH, Karlsruhe, Germany 
sorbitol CARL ROTH, Karlsruhe, Germany 
S-protein agarose Merck Chemicals Ltd., Nottingham, UK 
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TEMED CARL ROTH, Karlsruhe, Germany 
TFA FLUKA Feinchemikalien GmbH, Neu-Ulm, 
Germany 
Thiamine-HCl SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Tris CARL ROTH, Karlsruhe, Germany 
Triton X Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
Tween20 Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
Urea M.P. Biomedicals Inc., Eschwede, Germany 
X-Gal CARL ROTH, Karlsruhe, Germany 
Yeast extract  SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Zink acetate SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
4.12 Buffer compositions 
All buffer components were calculated for the volume of 1 liter. Sometimes stock solutions 
were prepared and later diluted to the concentration needed in the appropriate 
experiment. The pH was adapted using HCl 37 %, NaOH or acedic acid. 
10x PBS pH 7.4 80 g NaCl, 2.0 g KCl, 17.8 g 
Na2HPO4 x 2 H2O, 2.4 g KH2PO4, H2O 
10x PBS-T pH 7.4 80 g NaCl, 2.0 g KCl, 17.8 g 
Na2HPO4 x 2 H2O, 2.4 g KH2PO4, 10 ml 
Tween20, H2O 
10x SDS running buffer 30.3 g Tris base, 144 glycine, 10 g SDS, H2O 
10x TBS-T 500 ml 1 M Tris-HCl pH 7.5, 300 ml 5 M 
NaCl, 10 mL Tween 20, 190 ml H2O 
1x Transfer buffer with methanol 200 ml 5 x transfer buffer, 200 ml 
methanol, 600 ml H2O 
50x TAE pH 8.0 242 g Tris base, 57.1 g acetic acid, 100 ml 
EDTA pH 8.0, H2O 
5x Transfer buffer  15 g Tris base, 72 g glycine, H2O 
Buffer B 100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, 
H2O, pH 8.0 
 Materials and methods 
 50 
CaCl2-solution 60 mM CaCl2, 15 % glycerol, 10 mM PIPES, 
H2O, pH 7.0 
Elution buffer pH 8.0 50 mM NaH2PO4, 300 mM NaCl, 250 mM 
imidazol, H2O 
Factor Xa reaction buffer 20 mM Tris-HCl, 50 mM NaCl, 1 mM CaCl2, 
H20, pH 6.5 
HEPES 0.1 M, KCl, NaCl, pH 8.0 23.8 g HEPES, 0.2 g KCl, 8.0 g NaCl, H2O  
Lysis buffer pH 8.0 50 mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazol, H2O 
P1 50 mM Tris-HCl,10 mM EDTA, H2O, pH 8.0 
P2 (lysis buffer) 200 mM NaOH, 1 % SDS, H2O, pH 8.0 
P3 (neutralization buffer) 3 M sodium acetate, H2O, pH 5.5 
Phage-dilution buffer 10 ml 1 M Tris-HCl pH 8.3, 5.84 g NaCl, 
2.0 g MgCl2 x 6 H2O, H2O 
Plasmolysis buffer for cyanobacteria 91.1 g sorbitol, 10 ml 1 M Tris-HCl pH 7.6, 
116 mg NaCl, H2O 
Separating gel buffer pH 8.8 750 mM Tris pH 8.8, 0.2 % SDS, H2O 
Sodium acetate buffer 10 mM, pH 4.0 0.82 g sodium acetate, H2O 
Stacking gel buffer pH 6.8 250 mM Tris pH 6.8, 0.2 % SDS, H2O 
TE-buffer pH 8.0 10 ml 1 M Tris-HCl pH 8.0, 2 ml 0.5 M EDTA 
pH 8.0, H2O 
TES buffer 50 mM Tris-HCl, 100 mM EDTA, 25 % sucrose, 
H2O, pH 8.0 
Tris-HCl 1 M pH 6.8-8.0 121.14 g Tris, H2O 
Tris-HCl-30 % sucrose pH 8.0 30 ml Tris-HCl 1 M pH 8.0, 300 g 
D (+)-sucrose, H2O 
Wash buffer pH 8.0 50 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidazol, H2O 
4.13 Kits 
CopyControl Fosmid Library Production Kit EPICENTRE Biotechnologies, Madison, WI, 
USA 
Counter-Selection BAC Modification Kit Gene Bridges GmbH, Heidelberg, Germany 
GeneJET PCR Purification Kit Fermentas Life Sciences, St. Leon-Rot, 
Germany 
JETSORB Gel Extraction Kit Genomed, Löhne, Germany 
QIAGEN PCR Cloning Kit Qiagen, Hilden, Germany 
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QIAGEN Plasmid Mini Kit Qiagen, Hilden, Germany 
Quik Change II XL Site-Directed Mutagenesis 
Kit 
Agilent Technologies, Waldbronn, Germany 
E3 Lysogenization Kit Merck, Darmstadt, Germany 
4.14 Membranes, filters, cartridges, chip 
Acrodisc 4mm Syringe Filter, 0.45 µm Nylon 
membrane 
Pall, Dreieich, Germany 
Amersham Hybond-C Extra GE Healthcare Europe GmbH, Munich, 
Germany 
Amicon Ultra-0.5 ml 30K Millipore GmbH, Schwalbach/Ts., Germany,  
CM5 sensor chip GE Healthcare Europe GmbH, Munich, 
Germany 
Glas beads, 0.1-0.11 mm Sartorius AG, Göttingen, Germany 
Glas beads, 0.25-0.50 mm CARL ROTH, Karlsruhe, Germany 
Kimwipe tissue KIMBERLY-CLARK PROFESSIONAL, Rosewell, 
GA, USA 
Polypropylene columns (1 ml) Qiagen, Hilden, Germany 
Sep-Pak Plus C18 cartridge 55-105 µm Waters GmbH, Eschborn, Germany 
Syringe filters FP30/0.2 CA-S, 0.2 µm Whatman GmbH, Maidstone, UK 
Syringe filters FP30/0.45 CA-S, 0.45 µm Whatman GmbH, Maidstone, UK 
Visking dialysis tubing 20/32, diameter: 
16 mm 
SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Whatman chromatography paper 3 mm  Whatman GmbH, Maidstone, UK 
4.15 Antibodies 
Anti-MdnB produced in rabbit, polyclonal [Ziemert, 2009] 
Anti-rabbit IgG horseradish peroxidase 
conjugate, produced in goat 
Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
Monoclonal Anti-poly histidine antibody 
produced in mouse 
Sigma-Aldrich Chemie Gmbh, Munich, 
Germany 
Mouse IgG, horseradish peroxidase linked 
whole antibody (from sheep) 
GE Healthcare Europe GmbH, Munich, 
Germany 
s-protein HRP conjugate Merck Chemicals Ltd., Nottingham, UK 
4.16 Installations and special equipment 
BIACORE 2000 GE Healthcare Europe GmbH, Munich, 
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Germany 
TE 22 Mini Transfer Tank Hoefer, Inc., Holliston, MA, USA 
Gel Doc XR with Quantity One 4.6.2 
software 
Bio-Rad, Munich, Germany 
Gene Pulser  Bio-Rad, Munich, Germany 
Lumi-Imager with LumiAnalyst software Boehringer Ingelheim Pharma GmbH & Co. 
KG, Ingelheim am Rhein,Germany 
Mini-Protean system Bio-Rad, Munich, Germany 
Nanodrop ND-1000 with ND V 3.7.0 software PEQLAB Biotechnologie GMBH, Erlangen, 
Germany 
PU 8625 UV/VIS Philips, Hamburg, Germany 
RP-HPLC consisting of 
SCL-10A system controller 
LC 10AD liquid chromatograph 
FCV-10AL, DGU-14A degasser 
SPD-M10A diode array detector 
SIL 10AD auto injector 
FRC 10A fraction collector 
Columns: SymmetrieShield Sentry Guart 
column (3.5 µm, 3.9 x 20 mm) and a 
SymmetrieShield RP18 (3.5 µm, 4.6 x 100 
mm) 
Solvent A: water-TFA 0.05 % 
Solvent B: acetonitrile-TFA 0.05 % 
Software: Class-VP 
Shimadzu Europa GmbH, Duisburg, Germany 
Savant SC210A Speedvac concentrator with 
MZ2C pump 
Thermo Fisher Scientific GmbH, Dreieich, 
Germany; Germany; VACUUBRAND GMBH + 
CO KG, Wertheim, Germany 
T3000 Thermocycler Biometra GmbH, Göttingen, Germany 




5.1 Media and cultivation of cyanobacteria 
Cyanobacteria were cultured under permanent low light conditions of about 30 µmol 
photons m-2s-1 at 23 °C in BG11 medium [Rippka, et al., 1979]. Cultures were grown under 
gentle agitation of 110 rpm. 
5.2 Media and cultivation of E. coli cultures 
E. coli cultures were grown under standard conditions at 30 °C or 37 °C and 220 -240 rpm 
in LB-medium for at least 5 hours to overnight. Solid agar plates contained 1.5 % agar and 
were grown overnight under similar conditions but without agitation. 
E. coli Top10 and XL1 Blue cells were used for routine cloning procedures and for the 
expression of any microviridin expression platform vector. E. coli BL21 (DE3) cells were 
used for heterologous expression of proteins from Duet-1, pET15b or pET40b(+) vectors. 
Epi300T1R was used as a host strain for the fosmid library and for co-expression 
experiments with fosmids and plasmids. E. coli XL10 Gold cells were used in combination 
with the Quik change XLII mutagenesis kit following the manufacturing company’s 
recommendations.  
LB medium was used for the recovery of E. coli following transformation. 
LB was supplemented with the appropriate amount of antibiotics to maintain a plasmid and 
to select for resistance, as shown in the following table. 
Table 5-1: Antibiotic concentrations 
plasmid/fosmid antibiotic mg/l liquid and solid LB 
pCC1FOS chloramphenicol 12.5 
pCC1FOS knockouts chloramphenicol 12.5 
 kanamycin 50 
 streptomycin 15 
pACYCDuet-1 chloramphenicol 34 
pCOLADuet-1 kanamycin 30 
pETDuet-1 ampicillin 50 
pET40b(+) kanamycin 30 
pET15b ampicillin 50 
pRedET tetracycline 3 
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5.3 Glycerol stocks 
Frozen stocks of all constructs and strains, except cyanobacterial strains, were prepared in 
LB containing 50 % glycerol. Tubes were stored at -80 °C. 
5.4 Total genomic DNA preparation from cyanobacteria 
25 ml of any cyanobacterial culture, grown in BG11 medium was centrifuged at 4000 x g 
for 10 min. The pellet was resuspended in 500 µl of TES buffer and incubated for 2 hours at 
4 °C. About 5 mg/ml lysozyme were added and the mixture was further incubated for 
1 hour at 37 °C. 10 µl of 20 mg/ml Proteinase K, 0.05 M EDTA and SDS to a final 
concentration of 2.5 % were added, followed by incubation over night at 37 °C. The DNA 
preparation mixture was extracted twice with phenol/ chloroform/ isoamylalkohol 
(25:24:1), followed by chloroform/ isoamylalkohol (24:1). DNA was precipitated within 
30 min using isopropanol. The pellet was washed again with 80 % ethanol, dried in vacuo, 
resuspended in 50 µl TE buffer and incubated for 5 min at 55 °C. Finally 1 µl of RNase 
A/T1 Mix was added and the DNA was incubated at 37 °C for 1 hour. 
5.5 Plasmid and fosmid extraction 
Plasmids isolation was carried out using a QIAprep Spin Miniprep Kit. Fosmid DNA was 
purified using alkaline lysis with buffer P1, P2 and P3 similar to the method previously 
described [Morelle, 1989]. 
5.6 Quantification of DNA 
DNA concentration was measured using the NanoDrop ND-1000 as recommended by the 
manufacturer. 
5.7 DNA agarose gel extraction 
DNA was purified from agarose gels using the JETSORB Gel Extraction Kit following the 
manufacturer’s instruction. 
5.8 Routine cloning procedure 
Qiagen PCR cloning kit has been used for direct cloning of PCR products, amplified by Taq 
DNA polymerase, via TA cloning strategy. Purification of PCR products prior to cloning has 





Ligations were conducted with T4 DNA Ligase and the appropriate buffer from Fermentas 
as indicated in the enzymes manual. Commonly, ligations were made overnight in the 
refrigerator at approximately 8 °C. 
5.10 Restriction digests 
Restriction digests were practiced under optimum conditions for each enzyme in single and 
double digests with enzymes purchased from either Fermentas or New England Biolabs.  
5.11 DNA agarose gel electrophoresis 
Conventional agarose gel electrophoresis was carried out with 1 % agarose in 1x TAE. Gels 
were run between 80-120 V. For some analysis a concentration of 0.7 % agarose was used. 
Ethidium bromide with a final concentration of 0.05 mg/ml was added to the gels. DNA 
samples were mixed with 6x loading dye from Fermentas. A Lambda-PstI digest was used as 
a size standard. 
5.12 Primers 
Primers were ordered from Sigma-Genosys (Munich, Germany) or Eurofins MWG Operon 
(Ebersberg, Germany). A list of primers is given in the appendix. Restriction sites and other 
nonannealing parts of a primer are shown in lower case. 
5.13 Polymerase chain reaction 
PCR was performed in a T3000 thermocycler from Biometra. Tubes contained 20-50 µl 
reaction cocktail, including Taq DNA Polymerase (Qiagen), Thermus aquaticus DNA 
polymerase [Desai and Pfaffle, 1995], Phusion (Thermo Scientific) or Pfu DNA Polymerase 
(Qiagen) and their corresponding buffers system. dNTPs were purchased from Fermentas. 
Genomic or plasmid DNA was used as a template. The amplification for most types of PCRs 




Table 5-2: Standard PCR amplification conditions 
cycles temperature in °C time in min relevance 
1 95 3 initial denaturation 
30 
95 0.5 denaturation 
primer dependent 0.5-1 annealing 
72 1-7 (1 kb/min) extension 
1 72 10 final extension 
1 15  storage 
5.14 Sequencing  
Sequencing was carried out commercially in the laboratory of Dr. Martin Meixner (SMOLBIO) 
at Humboldt University of Berlin, Germany. 
5.15 DNA and protein computer analysis 
DNA sequence data was analyzed using BIOEDIT version 7.0.9.0 and the programs of NCBI 
BLAST [Altschul, et al., 1990]. Protein sequences for alignments were retrieved from the 
NCBI data base. Protein sequences were analyzed using ExPASy Proteomics server 
(http://expasy.org/). Multiple sequence alignments were accomplished by CLUSTALW 
(http://www.genome.jp/tools/clustalw/). The presence of signal peptides was analyzed 
by the following program: http://www.cbs.dtu.dk/services/SignalP. Subcellular 
localization of peptides was predicted by http://www.psort.org/.  
5.16 Chemical structure and plasmid map design 
Chemical structures were drawn using Isis Draw 2.4 and Chem Sketch 12.01. Plasmid maps 
were designed using SimVector 4.2. Final adaptations were made by Adobe Illustrator CS2. 
5.17 Preparation of electro competent E. coli 
A starter culture of E. coli was grown in LB overnight at 37°C under vigorous agitation. 
30 µl of this culture were transferred to a fresh tube containing 1.4 ml LB. Cells were 
grown for 3 hours, removed from the incubator and chilled on ice. Cells were centrifuged 
for 30 s at 11000 rpm in a microcentrifuge and washed twice with 1 ml sterile water. 20-




5.18 Preparation of chemically competent E. coli 
400 ml LB were inoculated with 1 ml overnight culture of E. coli and incubated at 37 °C 
until OD600=0.6. Cells were chilled on ice and centrifuged at 3000 x g. The pellet was 
resuspended in 100 ml of sterile CaCl2-solution and centrifuged as before. Resuspension 
and centrifugation were repeated, the supernatant was removed and the cells were 
resuspended in 10 ml CaCl2-solution. Cells were immediately used for transformation or 
aliquots of 100 µl were transferred to liquid nitrogen and finally kept at -80 °C.  
5.19 Transformation of E. coli 
Electrotransformation was performed using a Bio-Rad Gene Pulser. 1-2 µl DNA were mixed 
with 50 µl cells, incubated briefly on ice, transferred to a chilled electroporation cuvette 
and pulsed at 1.8 kV, 200 Ω and 25 µF. If transformation was performed using chemically 
competent E. coli, 10-100 µl cells were mixed with 1-20 µl of any plasmid, briefly chilled 
on ice, followed by heat shock for 30-75 s using a water bath at 42°C. 200-1000 µl LB were 
immediately added and the cells were kept for 1 hour recovery at 37°C before spreading 
on selective plates. Sometimes 40 µl X-Gal (20 mg/ml) and 40 µl IPTG (0.1 M) were added 
to 25 ml solid LB to obtain blue and white clones for selection. 
5.20 Lysogenization of E. coli  
The Lambda DE3 Lysogenization kit (Merck) has been used to integrate Lambda DE3 
prophage into the E. coli Epi300T1R genome following the manufacturer’s instructions. 
5.21 Construction and screening of a fosmid library  
The fosmid library has been constructed using the CopyControl Fosmid Library Production 
Kit and genomic DNA of Microcystis aeruginosa Nies843. As minor change from the 
manufacturer’s instructions, T4 DNA ligase from Fermentas has been used to ligate 
pCC1FOS with 30-40 kb of gDNA. 
Screening of the library was conducted by a PCR-based strategy using the Taq DNA 
polymerase (Qiagen) and the primer pair mdnBfw and mdnBrv. DNA was amplified under 
the following conditions: 94° C for 3 min, 94°C for 30 s, 55°C for 1 min, 72°C for 2 min, 34 
cycles, 72°C for 10 min. Clones were first analyzed in pools of 12 overnight cultures of 
E. coli EPI300T1R carrying fosmids. PCR pools were made using 1 µl from each of 12 
overnight cultures. 2.5 µl of these pools were used in each pool PCR. If primers amplified a 
product in a pool PCR, each of the corresponding individual overnight culture was analyzed 
separately using 2.5 µl culture as a template in a single-clone PCR. Fosmids were 
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sequenced from both ends with primer pair FW-pCC1/pEpiFOS and RV-pCC1/pEpiFOS. 
Sequence data were analyzed using NCBI BLAST [Altschul, et al., 1990]. 
5.22 Heterologous expression of microviridin from fosmids 
250 ml of LB containing 12.5 mg/l chloramphenicol were inoculated with 25 ml of an 
overnight culture of E. coli Epi300T1R carrying a fosmid. Cultures were immediately 
induced to a high copy number using Copy Control Induction Solution as recommended by 
the manufacturer. Cells were commonly harvested after 5 hours. 
5.23 Fosmid knockouts using Lambda Red system 
Fosmid knockouts were created by the Counter-Selection BAC Modification Kit from Gene 
Bridges. The genes mdnA, mdnB, mdnC, mdnD and mdnE were knocked out according to 
the manual. Primers are listed in the appendix. Epi300T1R served as the host strain. 
5.24 Duet vector system 
The genes mdnA, mdnB, mdnC, mdnD and mdnE from Microcystis aeruginosa Nies298 were 
amplified by Taq DNA polymerase (Qiagen) with primers P91 to P100 and first cloned into 
pDrive cloning vector (Qiagen). Primer sequences are listed in the appendix. Gene products 
were excised with appropriate restriction enzymes, as shown in the table below, to be 
cloned in frame into the compatible Duet-1 vectors (Merck) with individual cloning sites 
and T7 promoters for every single gene. Single vectors or combinations of them were 
expressed in E. coli BL21 cells, as described in paragraph 5.41. Test protein expression was 
conducted as further explained in paragraph 5.42. Test protein purification was made from 
50-100 ml E. coli cultures using Ni-NTA agarose or S-protein agarose, as described in 
paragraphs 5.43 and 5.44. 
Table 5-3: Cloning of mdn genes into Duet vectors 
Duet vector cloned gene restriction site 




pACYCDuet-1 mdnB BamHI/EcoRI or NdeI/BglII 
 mdnC NdeI/BglII 
pCOLADuet-1 mdnD BamHI/EcoRI 




5.25 Construction of mdnE partial deletion mutants in pCOLADuet-1 
A PCR based strategy, using primer pairs P99-P149 and P100-P151 was applied to amplify 
mdnE from Microcystis aeruginosa Nies298 lacking 138 bases from the N-terminus or a 108 
bases of sequence from the C-terminus. Amplified genes were cloned in frame into 
pCOLADuet-1-mdnD to obtain the following plasmids: pCOLADuet-1-mdnD/Edeletion3 and 
pCOLADuet-1-mdnD/Edeletion4. These constructs were transformed to E. coli Epi300T1R 
carrying the MRC-derived fosmid. The cultures were expressed and analyzed by HPLC. 
5.26 Co-expression of fosmid and plasmid  
The co-expression of a fosmid and a plasmid was achieved by transferring the plasmid via 
transformation into the fosmid host strain EPI300T1R. Cells were grown under standard 
conditions in the presence of the appropriate antibiotics to maintain both DNA elements. 
5.27 Construction of a microviridin expression platform in pDrive 
The microviridin biosynthetic gene cluster has been amplified from genomic DNA of 
Microcystis aeruginosa Nies843 using Taq DNA polymerase (Qiagen). Primer pair P166-P167 
amplified the genes mdnABCDE with a short promoter region of 169 bases. The genes 
mdnABCDE including a long promoter region of 714 bases were amplified using primers 
P173-P167. Primer pair P173-P97 amplified the microviridin cassette from mdnABCD, 
lacking mdnE, but carrying the same 714 bp long promoter region, as described before. All 
PCR fragments were agarose gel-purified using JETSORB Gel Extraction Kit and ligated into 
pDrive, as described in 5.8. 
5.28 Heterologous expression of microviridins from pDrive 
400 ml LB supplemented with 50 mg/l ampicillin were inoculated with 30-40 ml overnight 
culture of E. coli Top10 or XL1 Blue cells carrying any microviridin expression platform. 
Cultures were grown under standard conditions, commonly for 5 hours, as described in 5.2. 
5.29 Isolation of microviridins for HPLC analysis 
Commonly, 400 ml of E. coli cultures were harvested by centrifugation at 4 °C, 5000 x g for 
10 min. The pelleted cells were washed once with Tris-HCl, pH 7.4 and resuspended in 5 ml 
deionized water. Cell lysis was achieved by sonication for 90 s. The samples were 
centrifuged again and purified on C18-Sep-Pak cartridges (Waters). Cartridges were 
equilibrated with 2-5 ml of 100 % methanol and washed with 2-5 ml of water. Samples were 
transferred to the columns. Before elution with 2 ml 100 % methanol, cartridges were 
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washed once with 2 ml 5 % methanol. Eluted compounds were dried in vacuo, resuspended 
in 200-400 µl 50 % methanol and again filtered over Acrodisc 4 mm syringe filters (Pall). 
5.30 HPLC analysis 
HPLC was performed using a Shimadzu C18 RP-HPLC with a Symmetrie Shield Sentry Guart 
column (3.5 µm, 3.9x20 mm), a SymmetrieShield RP18 (3.5 µm, 4.6x100 mm) column and a 
UV/VIS detector. Water-0.05 % TFA as solvent A and acetonitrile-0.05 % TFA as solvent B 
were used as a mobile phase with gradient conditions as follows: Flow rate 1 ml/min, 
1 min of loading to 20 % solvent B, a linear gradient to 52 % solvent B within 30 min, 
followed by a linear gradient to 100 % solvent B in 1 min enduring for 2 more minutes, 
before returning to 20 % solvent B in 3 min, holding for 5 minutes. The injection volume 
was 55 µl per run, if not indicated otherwise. 
5.31 Standards for HPLC analysis 
HPLC purified microviridin B from Microcystis aeruginosa Nies298 and microviridin L from 
Microcystis aeruginosa Nies843 were used as standards. Both peptides were isolated from a 
recombinant source (E. coli). 
5.32 Mass spectrometry 
Structure elucidation off all microviridins has been carried out in cooperation with Dr. 
Keishi Ishida from the Leibniz Institute for Natural Product Research and Infection Biology 
e.V. Hans-Knöll-Institute (HKI) in Jena by mass spectrometry. MALDI-TOF MS and 
MALDI-TOF/ TOF MS (PSD) were performed with a Bruker Ultraflex from Bruker Daltonics. 
Data were analyzed by flexAnalysis and illustrated using the Adobe illustrator software. 
Taniguchi et al. 2005 
5.33 Protease inhibition assays 
Protease inhibition assays were made in cooperation with Dr. Keishi Ishida (HKI Jena), as 
previously described [Shin, et al., 1996]. Additionally subtilisin has been included and the 
assay has been performed by the modified method [Taniguchi, et al., 2005]. 
5.34 Microviridin quantification 
Microviridins were quantified by HPLC in triple biological replicates and calculated based 
on the peak height. Arrow bars indicate the standard deviation. 
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5.35 Quik change II XL mutagenesis 
The Quik change XLII mutagenesis kit (Agilent) has been used to mutate any microviridin 
expression platform in pDrive as recommended by the manufacturer’s instruction with the 
following PCR conditions for all primer combinations: 95 °C for 1 min, 18 x (95 °C for 50 s, 
60 °C for 50 s), 68 °C for 10 min 30 s, 68 °C for 7 min, cooled to 15 °C. A list of primers is 
given in the appendix. 
5.36 Factor Xa Protease treatment of microviridins 
Digests with Factor Xa Protease were conducted similar as described in “The 
QIAexpressionist, June 2003” from Qiagen. A Factor Xa Protease cleavage site –IEGRI- was 
inserted at the C-terminus of the leader sequence (30-PSPEPTIEGRIYGGTFKYPSDWEDY) in 
the microviridin platform vector using the Quik change XLII site-directed mutagenesis kit, 
as described in paragraph 5.35. Isolated microviridin extracts were digested using 95 µl 
Factor Xa reaction buffer and 5 µl enzyme at room temperature or 37 °C for 16 h. Digests 
were analyzed by HPLC and mass spectrometry. 
5.37 Hydroxylamine hydrochloride cleavage of microviridins  
Digests with hydroxylamine hydrochloride were performed as previously described 
[Crimmins, et al., 2001]. A hydroxylamine cleavage site was constructed by the exchange 
of threonine (Y) against asparagine (N) in the microviridin coding sequence of MdnA 
(YGGTFKYPSDWEDYNGGTFKYPSDWEDY) in the microviridin platform vector using the Quik 
change XLII site-directed mutagenesis kit, as described in paragraph 5.35. Isolated 
microviridin extracts were cleaved and analyzed by HPLC and mass spectrometry. 
5.38 Trypsin cleavage of microviridins 
An arginine (R) residue, as a trypsin cleavage site, was introduced at the C-terminus of the 
microviridin leader peptide (30–PSPEPTRYGGTFKYPSDWEDY) in the small microviridin 
expression platform using Quik change mutagenesis. Purified microviridins from this 
construct were treated with trypsin under various conditions. First of all, isolated 
microviridin extracts were incubated with 45-49 µl of 25 mM NH4HCO3 and 1-5 µl 
sequencing grade trypsin (1 µg/µl) for 1 or 2 hours at 37°C or 50 °C. Secondly, 
microviridins were digested following [Riviere and Tempst, 2001]. Microviridin extracts 
were resuspended in 25 mM NH4HCO3 containing 1 % SDS, heated to 95 °C for 10 min, 
before again 100 µl NH4HCO3 and 5 µl trypsin were added. The reaction was incubated for 
1 hour at 50 °C. SDS was precipitated using guanidine-HCl and removed by centrifugation. 
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And thirdly, microviridin extracts were digested using 80 µl 25 mM NH4HCO3, 20 µl 
acetonitrile and 5 µl of trypsin for 1 hour at 50 °C. All digests were analyzed by HPLC and 
mass spectrometry. 
5.39 Microviridin localization in Microcystis aeruginosa  
300 ml of Microcystis aeruginosa Nies843 (OD750=0.342) were harvested by centrifugation at 
5000 x g for 10 min at 4 °C. Periplasmic proteins were isolated similar to the method 
described by [Fulda, et al., 1999] using 10 M Tris-HCl (pH 7.6) and plasmolysis buffer for 
cyanobacteria with 2 mM NaCl. The osmotic shock supernatant, representing the 
periplasmic fraction, was collected and the remaining cell pellet was washed once with 
water. 1 ml of water and the same volume of glass beads were added to the pellet and the 
mixture was placed in liquid nitrogen. Cells were thawed in a water bath at 42 °C. Cells 
were disrupted using a Retsch mixer mill for 10 min. The freeze, thaw and disruption 
procedure was repeated 3 times. After centrifugation the supernatant, containing the 
cytoplasmic fraction, was collected and the pellet was washed again with water, before 
4 ml of methanol were added to extract the membrane fraction. Total cell extracts were 
made from 300 ml of an identical culture using the same procedure as described for the 
cytosolic fraction. Microviridins from isolated membrane fraction together with 
cytoplasmic, periplasmic and total extract were purified on C18 Sep-Pak cartridges, as 
described in paragraph 5.29. The BG11 growth medium has been analyzed for the presence 
of microviridins by the same C18 Sep-Pak purification procedure. 
5.40 Microviridin localization in E. coli carrying the small expression platform  
400 ml of E. coli Top10, carrying a microviridin expression platform vector as well as plain 
Top10 cells were grown under standard conditions for 5-7 hours. Cells were harvested by 
centrifugation at 4000 x g for 20 min. The pellet was resuspended in Tris-HCl-30 % sucrose 
(pH 8.0) at 80 ml per gram wet weight. Cells were kept on ice and EDTA was added to a 
final concentration of 1 mM. Cells rested for 10 min on ice under slightly agitation, 
followed by centrifugation for 20 min, 8000 x g at 4 °C. The pellet was resupended in the 
same volume of ice cold 5 mM MgSO4 and stirred for 10 min on ice. The cell suspension was 
again centrifuged as before. The resulting supernatant was the osmotic shock fluid 
containing the periplasmic proteins. This fraction was collected and the pellet was washed 
again with 1 M Tris-HCl pH 7.4. 5 ml of deionized water were added to resuspend the 
pellet. Cell lysis was achieved by sonication for 90 s. Cells were centrifuged again and the 
supernatant was collected, representing the cytoplasmic protein fraction. The remaining 
pellet, representing the membrane fraction, was washed once with water. Resuspension 
was achieved by the addition of 5 ml methanol and a pulse of sonication. The supernatant 
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was collected. For the comparison of subcellular localization of microviridin in periplasmic, 
cytoplasmic and membrane extract with the total cell extract, 400 ml of E. coli cells were 
centrifuged at 4000 x g for 20 min. The pellet was washed once with Tris-HCl pH 7.4, 
centrifuged and resuspended in 5 ml deionized water. Sonication was used to achieve 
complete cell lyses. Centrifugation was repeated and comprised the total cell extract. 
Microviridins from the total extract and from all supernatant fractions were purified for 
HPLC analysis, as described in paragraph 5.29. In some cases PMSF was added to the lyses’ 
steps to prevent protein degradation. 
5.41 Protein over-expression in E. coli 
Cultures were grown in LB medium, containing the appropriate antibiotics, at 18-37 °C and 
240 rpm until OD600 = 0.6-0.8. Cells were induced with IPTG to a final concentration of 
0.4-1 mM and further grown for 3-4 hours. Cultures were centrifuged for 10 min at 5000 x g 
and the pellets were washed with Tris-HCl pH 7.5. Sometimes pellets were kept at -20 °C 
overnight.  
5.42 Preparation of E. coli lysates under denaturing conditions 
Cell pellets from 2 ml cultures, grown similar to the procedure described under 5.41, were 
resuspended in 500 µl buffer B and the same volume of glass beads. Pellets were disrupted 
using a Retsch mixer mill for 10 min. The resulting protein extract was mixed with SDS-
loading dye, heated to 95°C for 5 min and run on an SDS-polyacrylamid gel.  
5.43 Protein purification using S-Agarose 
Proteins were purified under native conditions using S-protein Agarose, as recommended by 
Merck. 3 M MgCl2 was used as an eluent. S-protein agarose was recycled several times. 
Aliquots of each fraction were mixed with SDS-loading dye, heated to 95°C for 5 min and 
run on an SDS-polyacrylamid gel. 
5.44 Protein purification using Ni-NTA Agarose 
His-tag fusion proteins from pETDuet vectors were purified under native conditions using 
Ni-NTA agarose, as described by the manufacturer (Qiagen). Lysis buffer contained 10 mM 
imidazol, wash and elution buffer contained 30 and 250 mM imidazol, respectively. Aliquots 





5.45 Periplasmic protein purification using Ni-NTA Agarose 
Periplasmic proteins were over-expressed in E. coli and purified under native conditions 
using Ni-NTA agarose (Qiagen), following the instructions given in “The QIAexpressionist, 
June 2003” from Qiagen. Dialysis was performed using Visking dialysis tubing 20/32 and 5 l 
lysis buffer, containing 10 mM imidazole. Wash and elution buffer contained 30 and 250 mM 
imidazol, respectively. Aliquots of each fraction were mixed with SDS-loading dye, heated 
to 95°C for 5 min and run on an SDS-polyacrylamid gel. 
5.46 Bradford protein assay 
The protein concentration was measured at 595 nm by the method of Bradford [Bradford, 
1976] using Protein Assay solution from Bio-Rad. 
5.47 SDS-PAGE 
Size separation of proteins was performed as previously described by [Laemmli, 1970] on 
gels in the size of 7x8 cm using the Mini-Protean system from Bio-Rad. Stacking gels, 
containing 4 % and separating gels containing 12.5 % acrylamid, respectively, were 
prepared using Rotiphorese Gel30 (37.5:1), stacking (pH 6.8) and separating gel buffer 
(pH 8.8), TEMED, 10 % APS and H2O. Protein extracts were mixed with 5x SDS-loading dye 
containing 2-mercaptoethanol and heated to 95 °C for 5 min. Samples were transferred to 
the gel and PageRuler Prestained Protein Ladder was additionally load as a size standard. 
Gels were run under following conditions: 20 V for 20 min, followed by 200 V for 35-
45 min. Subsequently gels were washed 3 times for 5 min with water, before they were 
incubated for 1 h with Gel-Code Blue Safe Protein stain. Afterwards gels were destained 
with water within 1 hour by addition of a Kimwipe tissue or overnight.  
5.48 Western blot analysis and immunodetection 
SDS-polyacrylamid gels, stained with Gel-Code Blue Safe Protein stain were 3 times 
alternately destained with 50 % acetonitrile for 20 min and rehydrated in water for 20 min, 
incubated for 30 min in 2 % SDS followed by incubation for 30 min in SDS running buffer. 
Proteins were transferred at 380 mA for 1 h to a Hybond-C membrane (GE Healthcare) 
using a tank blotter (Hoefer) filled with 1x transfer buffer. Afterwards membranes were 
removed from the blotting sandwich and blocked with 5 % skim milk powder in TBS-T or 
PBS-T for 1 hour at RT. Membranes were incubated with the appropriate primary and if 
necessary secondary antibody. Membranes were washed 3 times for 5 min in TBS-T or PBS-T 
prior to the addition of any secondary antibody and as a final washing before visualization, 
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which was performed using SuperSignal West Pico Chemiluminescent Substrate kit (Pierce) 
and a Lumi-Imager (Boehringer). A list of antibodies and their incubation conditions is given 
below.  
Table 5-4: Incubation conditions for antibodies 
antibody incubation 
time in min 
incubation 
temperature in °C 
buffer 
Anti-MdnB (rabbit) 60 RT TBS-T 
Anti-rabbit IgG horseradish peroxidase 
conjugate, produced in goat 
60 RT TBS-T 
Monoclonal Anti-poly histidine antibody 
produced in mouse 
60 RT PBS-T 
Mouse IgG, horseradish peroxidase 
linked whole antibody (sheep) 
60 RT PBS-T 
s-protein HRP conjugate 30-45 min RT TBS-T 
5.49 Protein concentration and purification using Amicon Ultra filters 
Proteins were purified and concentrated using Amicon Ultra-0.5 mL Centrifugal Filters from 
Millipore with a MWCO of 30000 Da. Filters were centrifuged at 14000 x g for 10-20 min 
during concentration and at 1000 x g for 2 min during elution of proteins. 
5.50 Dissolving synthesized peptides 
Synthesized MvdE, from Planktothrix agardhii and MdnA(2)-triple PFFARFL mutated 
precursor from Microcystis aeruginosa Nies843 were dissolved in sterile PBS buffer pH 7.4 
to a concentration of 20 µg/µl. MdnA-original Nies298 precursor was obtained as a 
dissolved peptide in Tris-HCl buffer pH 7-8. MdnA(1)-original Nies843 precursor was 
insoluble in PBS buffer pH 7.4. For SPR studies 3 µl of precursor were mixed with 50 µl 
DMSO and 450 µl sodium acetate buffer (pH 4.0) and further diluted as necessary. For in 
vitro enzyme assays the MdnA(1)-original precursor was mixed 1:2 with 1 % SDS and heated 
for 5 min at 95°C to mediate solubility. 
5.51 Surface plasmon resonance 
Surface plasmon resonance analysis was carried out with a BIACORE 2000 and a sensor chip 
CM5, using the control software 2.1 and evaluation software 3.0 (GE Healthcare). 
Synthesized MvdE, from Planktothrix agardhii, MdnA(1)-original and MdnA(2)-triple 
PFFARFL mutated precursor from Microcystis aeruginosa Nies843 in 10 mM sodium acetate 
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buffer (pH 4.0) were immobilized on the sensor chip via amine coupling at 410-494 
response units per flow cell. HEPES buffer (pH 8.0) containing NaCl and KCl was used as a 
running buffer. MdnB and MdnC from Microcystis aeruginosa Nies298, each separately 
expressed and purified from pACYCDuet-1, were assessed for their activity towards the 
immobilized ligands. Both proteins with concentrations 0.15, 0.3, 0.6, 1.25, 2.5, 5.0, 10.0 
and 20.0 µM were injected at a flow rate of 30 µl/min, followed by dissociation and 
regeneration of the sensor surface with HCl. BSA, POD, TusA, Mvn and ActM, proteins not 
expected to bind to the precursor molecules, were used as controls.  
5.52 In vitro enzyme assay 
Synthesized microviridin precursors MdnA(1)-original Nies843, MdnA-original Nies298 and 
MvdE from Planktothrix were dissolved, as described in 5.50. MdnB and MdnC from 
Microcystis aeruginosa Nies298 were separately expressed from pACYCDuet-1 using E. coli 
BL21 (DE3) cells, as described in paragraph 5.41. In vitro cyclization of MdnA was made 
similar as previously described [Philmus, et al., 2008] using up to twice as much protein 
MdnB, MdnC and MdnEcytosolic. Aliquots were analyzed by C18 RP-HPLC under conditions 
described in paragraph 5.30 and verified by mass spectrometry. The cytosolic domain of 
MdnE (MdnEcytosolic) was cloned into the NdeI/BglII site of pACYCDuet-1, expressed in 
BL21 (DE3), purified over S-protein agarose and kindly provided as a purified protein by 





At the beginning of this study it was known that microviridins were produced through a 
ribosomal pathway biosynthesis, commonly in the presence of the genes mdnABCDE. Two 
ATP-grasp ligases, MdnB and MdnC, cross-link the microviridin precursor peptide MdnA in a 
strict order and establish two -ester followed by one -amide bond. Additionally the N-
acetyltransferase MdnD was believed to modify microviridins posttranslationally, although a 
proof in vivo was still missing. At that time MdnE, the ABC-transporter, was assumed to 
participate in the peptide cleavage itself, maybe carrying a so far uncharacterized 
peptidase domain or being supportive in a different manner. 
6.1 Microviridin L production and structure elucidation  
A new microviridin gene cluster has been detected from the genome sequence of 
Microcystis aeruginosa Nies843 [Kaneko, et al., 2007]. To analyze these genes, 
heterologous expression was chosen. This strategy is a feasible alternative to fermentation 
process development and molecular manipulation of the native producer strain, as the 
cyanobacterium is slowly growing and additionally highly resistant to genetic engineering 
strategies. Genomic DNA of the cyanobacterial producer was isolated and fragments of 30-
40 kb were directly ligated to the fosmid vector pCC1FOS. The primary library was made by 
infection of E. coli Epi300T1R. Plating and selection for chloramphenicol resistant clones 
revealed about 800 colonies, of which 5 were randomly picked and subjected to DNA 
isolation and restriction enzyme digestion. Thus, the average insert size of the library was 
determined to be in the range of 40-43 Kb (data not shown), which was later proven by 
sequence analysis and comparison to the available complete genome sequence of Nies843 
[Kaneko, et al., 2007]. A total of 518 fosmid clones were screened by colony PCR to 
identify Fos303N843, carrying the genes mdnABCDE for microviridin L production (Figure 
6-1, A). Heterologous expression of Fos303N843 next to a control fosmid, lacking the 
machinery for microviridin production, showed the following HPLC chromatogram (Figure 
6-1, B). Peak fractionation and mass analysis showed the presence of several different 
tricyclic microviridin-like peptides which all differed, in correspondence to the amino acid 
sequence encoded by MdnA, in their length at the N-terminus, as given in (Figure 6-1, C). 
Four peaks were further investigated. Their structures were elucidated and named 
following the common nomenclature as microviridin L, L1, L2 and L3. As all identified 
microviridins from original producers so far consist of 13-14 amino acids (Figure 1-9) 
microviridin L and L1 were considered to be the completely processed peptides. A 
microviridin structure with highlighted two -ester and the secondary -amide bond is 
shown in Figure 6-1, C. The longer microviridin-like peptides were considered as 
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incompletely processed microviridins as a result from heterologous expression, and are 
further referred under this nomenclature. In E. coli, they appear in a large proportion 
compared to the correctly processed microviridins, which is completely different in the 
original producer, where only microviridin L and L1 can be detected by HPLC. Figure 6-2 
shows an HPLC profile of a Nies843 cell extract compared to a microviridin L standard, 
previously isolated and purified from Fos303N843. None of the additional small peaks could 
be identified as a microviridin-like compound by mass spectrometry (data not shown). 
 
Figure 6-1: Heterologous expression of microviridin L from Fos303N843 
A schematic illustration of Fos303N843 carrying the microviridin expression cassette is shown in A) 
Dots indicate the fosmid carries additional genes from Nies843, totally about 43 kbp. Microviridin L 
and its derivatives were expressed from Fos303N843 in E. coli, separated by RP-C18 chromatography 
and detected at 210 nm. The numbers indicate microviridin L (1), L1 (2), L2 (3), L3 (4) as given in 
B). The chemical structure of microviridin L and its derivatives L1, L2, L3 is illustrated in C). The 




Figure 6-2: HPLC chromatogram of microviridin L production in Microcystis aeruginosa Nies843 
Mdn was separated by RP-C18 chromatography and detected at 210 nm. The microviridin L standard 
was isolated from E. coli carrying Fos303N843. The numbers indicate microviridin L (1) and L1 (2). 
6.2 Microviridin gene knockouts on the fosmid Fos303N843 
To analyze the function of the mdnABCDE genes previously cloned into the fosmid 
backbone and to later replace certain genes from the cluster by mutated versions, the 
Red/ET based recombination system provided by the Counter-Selection BAC Modification 
Kit (Gene Bridges) was used to knockout every single gene by homologous recombination. 
An rpsLneo resistance cassette was inserted maintaining about 50 bases of N- and 
C-terminal sequence of every gene. The resulting mutants Fos303N843-mdnA, -mdnB, 
-mdnC, -mdnD, -mdnE were first analyzed by PCR for the presence of the rpsLneo 
cassette (data not shown) and positive clones were further characterized by HPLC (Figure 
6-3) and mass spectrometry (data not shown). The effect of Red/ET recombination is 
clearly visible, as the production of microviridin L was completely abolished when mdnA 
was knocked out. Similar results were obtained for Fos303N843-mdnC, which was 
expected at that point and in correspondence to the results previously published [Philmus, 
et al., 2009]. As MdnC is the ester bond introducing enzyme, it catalyzes the first 
cyclization step in microviridin biosynthesis. MdnB can introduce the amide bond only once 
the ester bonds are established. Interestingly, Fos303N843-mdnB showed a similar result 
as Fos303N843-mdnC, as no peaks were detectable in the chromatogram although the 
ester ligase remained untouched. Mass spectrometry confirmed the presence of trace 
amounts of bicyclic microviridin L and L1 from the Fos303N843-mdnB mutant (data not 




Figure 6-3: HPLC chromatogram of Red/ET mediated recombination in Fos303N843 
Microviridins were separated by RP-C18 chromatography and detected at 210 nm. Original 
Fos303N843 is shown together with the corresponding knockout mutants of mdnABCD genes 
generated by Red/ET recombination in the fosmid. The numbers indicate microviridin L (1), L1 (2), 
L2 (3), L3 (4). 
 
 
Figure 6-4: Chemical structure of bicyclic microviridin L and L1 
Ac: acetyl 
The knockout of mdnD was accompanied by the loss of the two acetylated microviridins, L 
and L1, which was the first indication in vivo for a function of MdnD in the acetylation of 
microviridin L and L1. In vitro the function of MvdB, which is an ortholog of MdnD from 
Planktothrix agardhii, has been previously shown [Philmus, et al., 2008]. Furthermore, 
nonacetylated forms of microviridin L and L1 were detected by mass spectrometry. These 
variants are not displayed in the HPLC profile, as they eluted together with the 
incompletely processed microviridins, which led to very poor separation of the peaks. 
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Several attempts were made to knockout mdnE, because MdnE was so far assumed to be 
the most probable candidate for peptide processing and cleavage of microviridins. This 
assumption was based on previously published data [Ziemert, et al., 2008]. There it was 
shown, that in the absence of mdnD and mdnE only incompletely processed microviridins 
were produced from an MRC-derived fosmid carrying exclusively mdnABC genes. 
Unfortunately, no reliable knockout of mdnE was obtained in this study. All candidates 
seemed to be heterozygous. The regions of homology at the end of the linear fragment 
probably annealed to more than the one site considered for recombination. Internal 
sequencing of fosmids starting from the inserted resistance cassette into adjacent regions 
was challenging. Restriction analysis was tried, but did not yield any clarifying result. 
Maybe the cells contained more than one fosmid at the time. 
The replacement of the inserted rpsLneo cassette by a nonselectable DNA, meaning a 
mutated version of the knocked out microviridin genes mdnA to D, was never achieved.  
Several attempts were made to complement the fosmid knockouts using copies of mdnA, 
mdnB and mdnC expressed from pET15b, pET40b(+) or pDrive vector, which were 
transferred into the Epi300T1R strain carrying a knockout fosmid. The microviridin 
expression at different incubation times, temperatures and in presence and absence of 
induction solution for fosmid and plasmid was analyzed by HPLC but microviridin 
biosynthesis has never been reactivated by this strategy (data not shown). 
Thus, the fosmid system was not useful as a background to analyze mutations in the 
microviridin expression cassette. 
6.3 Duet vector system 
Another microviridin expression system was necessary to be established for further 
mutational analysis of the microviridin gene cluster. The Duet vector system (Merck) was 
previously shown to be suitable for the expression of the ribosomally synthesized 
patellamides [Donia, et al., 2006]. In a similar approach 3 compatible expression vectors 
with independent T7 promoter sites were chosen to express the Microcystis aeruginosa 
Nies298 genes mdnABCDE, mdnABCD, mdnABCE and mdnABDE as a control in E. coli BL21 
cells. The genes of Nies298 were chosen instead of Nies843, because at that point it was 
believed that Nies298 tended to result in higher microviridin expression levels. The genes 
were amplified by PCR using primers P91 to P100 and cloned into pDrive, before they were 
excised with the appropriate restriction enzymes and cloned in frame into the Duet-1-
vector backbones. Multiple clones of the Duet-1 vectors were cultured under varying 
conditions with different temperatures, IPTG concentrations and incubation times. HPLC 
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analysis, including Nies298 microviridin B standard, revealed no detectable microviridin-
like peptides from any vector combination tried. As microviridin expression from fosmids 
was successfully shown in the Epi300T1R library host strain, the DE3 prophage was 
integrated into the genome of this strain to express target genes cloned in T7 expression 
vectors, like the Duet-1 vectors are. Duet-1 vectors were transferred to Epi300T1R (DE3) 
and analyzed as described before, but again no microviridin expression was detected. 
Thus, the use of BL21 cells was excluded to be the reason for the lack of expression. 
When protein expression was inspected using Western blot analysis and immunodetection 
from total cell extracts of the Duet-1-vectors, positive results were exclusively obtained 
for MdnC (data not shown). It was assumed, the linear peptide MdnA was rapidly degraded 
and thus did not give any signals. Later during this work, MdnB has been expressed, but in 
very low concentration that made detection from small sample volumes, even as a purified 
protein, impossible. Very low expression of MdnD and maybe also MdnE was later shown in 
co-expression studies from fosmid and Duet vectors, as described in the next chapters.  
6.4 Co-expression of fosmid and Duet vectors 
In parallel to the expression studies of microviridin from the Duet vector system, 
pCOLADuet-1-mdnD, pCOLADuet-1-mdnD-E and pCOLADuet-1-mdnE were chosen to be 
expressed simultaneously with the MRC-derived fosmid carrying mdnABC genes for 
microviridin J production. The MRC-derived fosmid was reported to produce cyclized but 
incompletely processed microviridins [Ziemert, et al., 2008]. Indeed, the external addition 
of mdnD and DE on pCOLADuet-1 resulted in the production of comparatively very little 
amounts of correctly processed and cyclized microviridin J compared to the incompletly 
processed proportion. Microviridin J production was verified by mass spectrometry (data 
not shown). A comparison of the curves from MRC-derived fosmid-pCOLADuetmdnD-E with 
the MRC-derived fosmid plus pCOLADuet—1-mdnD showed a slightly higher level of 
microviridin production in presence of both enzymes, indicating they are both important 
for the correct biosynthesis of acetylated microviridin J. The low level of microviridin J 
production showed that MdnD was indeed expressed from the Duet vector and furthermore 
it was proven to be the acetylating enzyme in microviridin biosynthesis. The involvement 
of the ABC-transporter MdnE could not be clarified from this experimental set-up. It was 
also not clear, if MdnE was really expressed under these experimental conditions, which is 




Figure 6-5: Co-expression experiments with MRC-derived fosmid and pCOLADuet-1 vector 
MRC-derived fosmid carrying mdnABC and plasmid pCOLADuet-1 carrying mdnDE, E or D were 
expressed in E. coli. Microviridins were purified, separated by RP-C18 chromatography and detected 
at 210 nm. MRC-derived fosmid and pCOLADuet-1-vectors are shown schematically on the right, the 
HPLC profile is shown on the left. Microviridin J production is shown in (7). 
Next, Fos303N843 carrying the genes mdnABCDE was transformed with 
pCOLADuet-1-mdnD-E, pCOLADuet-1-mdnE and pCOLADuet-1-mdnD and analyzed by HPLC 
and mass spectrometry (MS data not shown). The microviridin L and L1 production was 
faintly increased when extra copies of mdnD were added. The production was enhanced 
when mdnDE was co-expressed with Fos303N843, as shown in Figure 6-6. This phenomenon 
already appeared after short time expression for 3 hours at 37°C. Commonly, fosmid 
expression lasted for at least 5 hours at 37°C. These data again suggested that both the 
N-acetyltransferase MdnD and the ABC-transporter MdnE play a relevant role in 
microviridin biosynthesis. MdnD could be responsible for the stabilization of correctly 




Figure 6-6: Co-expression experiments with Fos303N843 and pCOLADuet-1 vectors 
Fos303N843 carrying mdnABCDE and plasmid pCOLADuet-1 carrying mdnDE, E or D were co-
expressed in E. coli. Microviridins were purified, separated by RP-C18 chromatography and detected 
at 210 nm. Fos303N843 and pCOLADuet-1-vectors are shown schematically on the right, the HPLC 
profile is shown on the left. The numbers indicate microviridin L (1) and L1 (2). 
To further analyze the ABC-transporter, a deletional PCR approach of mdnE was carried 
out. ABC-transporters from Gram-negative bacteria including the related cyanobacterium 
Nostoc sp. PCC7120 are known to carry N-terminal domains, which belong to the C39 
protein family commonly involved in the processing of conserved leader peptides carrying a 
double glycine motif [Dirix, et al., 2004]. The microviridin leader peptides of Microcystis 
aeruginosa strains do not carry a double glycine motif and domain search analysis using 
BLASTP did not reveal any hits for protease domains at the N- or C-terminus of MdnE or in 
the close vicinity of the other proteins. It was assumed, for the processing of the cross-
linked microviridin pre-stages to the mature compound, that a yet unidentified domain 
might be involved in the peptide cleavage. Therefore, N- and C-terminal deletions of mdnE 
were constructed and ligated to unmodified pCOLADuet-1-mdnD, resulting in pCOLADuet-1-
mdnD/Edeletion3 and pCOLADuet-1-mdnD/Edeletion4. E. coli cells carrying the MRC-derived 
fosmid were transformed with one of the two pCOLADuet constructs at a time and 
analyzed by HPLC and mass spectrometry (MS data not shown). N- and C-terminal deletions 
in mdnE did not show an impact on the cleavage pattern of microviridins compared to the 
control with nonmutated pCOLADuet-1 vector. Microviridin J and the proportion of 
incompletely processed microviridins were produced in nearly the same amounts as before, 
which indicated there was no so far unknown N- and C-terminal peptidase domain located. 
But again, it has to be considered that it was not clear, if MdnE was really expressed from 




Figure 6-7: Co-expression experiments of the MRC-derived fosmid with mutated pCOLADuet-1 
vectors 
MRC-derived fosmid carrying mdnABC, pCOLADuet-1-mdnD-E original vector and the 2 pCOLADuet-1-
mdnD-E vectors carrying N- and C-terminal deletions in mdnE, highlighted in orange, were co-
expressed in E. coli. Microviridins were purified, separated by RP-C18 chromatography and detected 
at 210 nm. The MRC-derived fosmid and the pCOLADuet-1-vectors are shown schematically on the 
right, the HPLC profile is shown on the left. The production of microviridin J is shown in (7). 
6.5 Construction of a small microviridin expression platform in pDrive 
The Duet vector system was not applicable and the fosmid system previously used for the 
controlled and successful heterologous expression of microviridins was no longer suitable 
as the following work was aimed on the investigation of the microviridin gene cluster using 
site-directed mutagenesis. As fosmids are highly restrictive for point mutations, the small 
generic and available cloning vector pDrive (Qiagen) was chosen to serve as the backbone 
of the prospective small microviridin expression platform. The Nies843 microviridin gene 
cluster based on the genes mdnABCDE was amplified with primer pair P166-P167 including 
169 bp of promoter region, representing the intergenic space between mdnA and the next 
annotated ORF MAE24120. The gel-purified PCR product was directly ligated into pDrive, 
transformed into E. coli XL1 Blue cells and selected on ampicillin, X-Gal, IPTG 
supplemented agar plates. Several white clones were first analyzed by restriction digests 
using EcoRI to cut out the insert. Potential candidates were sequenced to ensure the 
presence of the complete microviridin gene cluster. 8 clones carrying the desired insert 
were obtained. The plasmid was named pARW066-mdnABCDE-short (a plasmid map is given 
in the appendix). The candidates were analyzed by HPLC, but once more there was no 
evidence for microviridin expression. At the same time Katharina Makower (group of Prof. 
Dittmann, University of Potsdam) started to work on the transcriptional organization of the 
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microviridin gene cluster. Using Northern hybridization the transcriptional analysis of the 
gene clusters in Microcystis revealed the reason for the lack of microviridin expression 
from the pDrive construct. Two transcripts of about 450 and 600 bp were detected for 
mdnA. The larger one was missing from pARW066-mdnABCDE-short construct carrying only 
about 169 bp of promoter region [Makower, 2010]. With this data in hand, a second small 
microviridin expression platform was constructed, including again the genes mdnABCDE 
with about 714 bp of promoter region up to ORF MAE24140.  
 
Figure 6-8: Agarose gels with the mdnABCDE PCR products 
A schematic representation of the amplified mdn clusters is given in A). A Lambda–PstI digest was 
used as a size standard, shown in B) and L. The mdnABCDE cassettes were amplified with primer 
pair P166-P167 to include a short promoter region as given in C). Primer pair P173-P167 amplified 
the genes mdnABCDE with a long promoter region as shown in D). 
Sequencing was carried out to ensure that the whole cluster is present and mdnA is not 
mutated, as the cluster was amplified with a nonproofreading Taq polymerase. None of the 
proofreading enzymes as Pfu DNA polymerase (Qiagen) or Phusion High-Fidelity DNA 
Polymerase (Thermo Scientific) managed to amplify this gene cluster. The plasmid was 
named pARW071-mdnABCDE (a plasmid map is shown in the appendix). It was transformed 
into E. coli and analyzed by HPLC. In comparison to the fosmid Fos303N843 a similar peak 




Figure 6-9: Microviridin expression from a the small pDrive based platform 
A schematic representation of Nies843 microviridin gene cluster as it is present in Fos303N843 and in 
the microviridin expression platform constructs pARW066-mdnABCDE-short and pARW071-mdnABCDE 
is given in A). The dots indicate, the fosmid carries additional genes from Nies843, totally about 43 
kbp. B) shows the HPLC profiles of the microviridin test expression from the small microviridin 
expression platform vectors pARW066-mdnABCDE-short and pARW071-mdnABCDE compared to the 
fosmid Fos303N843. Microviridins were separated by RP-C18 chromatography and detected at 
210 nm. The numbers indicate microviridin L (1) and its derivatives L1 (2), L2 (3), L3 (4). 
MALDI-TOF MS, conducted by Dr. Keishi Ishida from the Leibniz Institute for Natural Product 
Research and Infection Biology, attested the presence of microviridin-like peptides, as 




Figure 6-10: MALDI-TOF MS spectrum of microviridin L, L1, L2 and L3 expressed from the small 
microviridin expression platform pARW071-mdnABCDE 
The presence of microviridin L is shown in A), L1 in B), L2 in C) and L3 in D) as m/z with ion charges 
[M+H]+, [M+Na]+ and [M+K]+. 
6.6 Analysis of the microviridin leader peptide 
As a stable small expression platform was constructed, the investigation of the microviridin 
leader peptide could start. Till these days, not a single recognition sequence for the 
posttranslationally modifying enzymes or the protease has been reported from any 
microviridin leader peptide, which is why the discovery of those gained a legitimate 
interest. In order to analyze this aspect, sequences of the available microviridin precursor 
molecules were collected from the NCBI database and aligned using ClustalW, as shown in 




Figure 6-11: Microviridin precursor alignment 
23 sequences collected from 16 potential and confirmed microviridin producers are shown in the 
alignment. Conserved PFFARFL and TxK(W/Y)PSDx regions, with x being different amino acids, are 
highlighted in green and blue boxes, whereas single yellow letters display a C-terminal proline-rich 
region in the leader peptides of Microcystis strains. Variable parts from the ends were replaced by 
numbers. M: Microcystis, N: Nodularia, P: Planktothrix, S: Sorangium, M: Microscilla 
The alignment represented 3 interesting regions, first being the PFFARFL region, secondly 
the proline-rich region, both belonging to the leader peptide, and the TxK(W/Y)PSDx 
region (x being different amino acids), which is located in the microviridin core peptide.  
6.6.1 N-terminal investigation of the microviridin leader peptide 
The investigation of the N-terminal microviridin leader peptide started with the 
manipulation of single amino acids in the PFFARFL motif and C-terminal proline-rich region 
followed by additional techniques, as described in the next paragraphs. 
6.6.1.1 Site-directed mutagenesis in the PFFARFL region of MdnA 
By comparing all these precursor sequences it was noticed that Microscilla marina 
ATCC23134, a marine gliding bacterium and Alteromonas sp. B-10-31, also isolated from a 
marine habitat, carry aberrant amino acids in the PFFARFL region. As Alteromonas sp. 
B-10-31 is known to produce a microviridin-related compound called marinostatin that 
carries only the -ester bonds [Kanaori, et al., 2005], it was assumed, together with the 
fact that the PFFARFL motif is not ubiquitously present in ribosomally synthesized peptides 
that this region could serve as a recognition sequence for the ATP-grasp ligases. The 
genetic basis for marinostatin production furthermore does not encode an amide ligase. 
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Quik change mutagenesis (Agilent) was initiated using plasmid pARW071-mdnABCDE. First 
an arginine (R) was exchanged against an asparagine (N). HPLC analysis revealed a 
modified HPLC pattern (Figure 6-12). MALDI-TOF MS and MALDI-TOF/TOF MS (PSD) (PSD 
data not shown) were conducted by Dr. Keishi Ishida (HKI, Jena). Bicyclic microviridin L and 
L1, lacking the amide bond, was detected (Figure 6-13). With this result in hand, the 
remaining 6 amino acids in the PFFARFL region were successively exchanged, commonly 
using small and simple amino acids as glycine (G) and alanine (A). All recombinant strains 
were analyzed by HPLC (Figure 6-12) and mass spectrometry (MS data not shown). 
Independent from the amino acid exchanged, exclusively bicyclic microviridins namely L 
and L1, but also L2, L3 and incompletely processed versions, carrying the -ester bonds, 
appeared in even higher amounts compared to the original tricyclic microviridins (Figure 
6-12 and Figure 6-14). Anyway microviridins carrying only the amide or one of each bond 
were not expected as the amide ligase is only active after the ester linkages are 
established [Philmus, et al., 2009]. Traces of tricyclic correctly processed microviridins 
were not noteworthy. In order to see what happens if several amino acids were exchanged, 
a double and a triple mutant of the PFFARFL region were constructed. HPLC was conducted 
followed by MALDI-TOF MS and MALDI-TOF/TOF MS (PSD) (MS data not shown). The resulting 
double mutant was still able to produce bicyclic microviridin L and L1 in matchable 
amounts, as seen before for the single mutants. The triple mutant showed a different 
result. Microviridin production was completely suppressed. Taken these data together, the 
PFFARFL region was shown to be important for both of the ATP-grasp ligases serving as a 
recognition sequence. MdnB is preferentially sensitive to changes in this region, which 
means the cooperation of MdnB with the leader peptide or between both of the ligases and 
the leader peptide is earlier disordered, whereas MdnC is more tolerant to mutations. At 





Figure 6-12: Microviridin production from PFFARFL motif mutants 
The original PFFARFL sequence and its localization in the microviridin precursor molecule are given 
in A). An HPLC chromatogram of original pARW071-mdnABCDE and PFFARFL region mutants 
separated by RP-C18 chromatography, detected at 210 nm is shown in B). Amino acid exchanges are 
indicated adjacent to each of the HPLC runs. Produced microviridins are labeled with numbers 1-4 
for tricyclic microviridin L, L1, L2, L3 and 5-6 for bicyclic microviridin L1 and L. The chemical 





Figure 6-13: MALDI-TOF MS of bicyclic microviridins expressed from pARW071-mdnABCDE 
PFFARFL region mutants 
The presence of bicyclic microviridin L (6) is shown in A) and bicyclic microviridin L1 (5) in B) as m/z 
with ion charges [M+H]+, [M+Na]+ and [M+K]+ 
 
Figure 6-14: Quantification of tricyclic microviridin L, L1, L2, L3 (1-4) and bicyclic microviridin 
L1 and L (5-6) 
Microviridins were produced from original pARW071-mdnABCDE and PFFARFL region mutants of 
pARW071-mdnABCDE. Values were determined by HPLC analysis including a standard of microviridin 




6.6.1.2 Studying peptide-protein interactions using SPR 
To analyze interactions between the precursor molecule and the ATP-grasp ligases in more 
detail, surface plasmon resonance was chosen to unravel further functions of the PFFARFL 
region. Several attempts were made to express the microviridin precursor molecule of 
Nies298 in commonly used expression vectors like pET15b or from pETDuet-1-mdnA under 
native conditions, as already described (chapter 6.3), [Ziemert, et al., 2008]. Successful 
expression has never been seen, probably due to rapid degradation of the linear precursor 
peptide, which had not undergone cyclization through the ATP-grasp ligases. To circumvent 
the problem of proteolytic attack, peptide release into the periplasm was considered as a 
good strategy. The precursor molecule of Nies843 was expressed from pET40b(+), which is 
an expression vector using a DsbC-tag designed to create fusions to the enzymes that 
catalyze isomerization of disulfide bonds in the periplasm. Strong expression from that 
vector was observed, and although culture conditions were varied several times, 
degradation products were always present which is why pET40b(+) was also unsuitable for 
the purification of pure over-expressed MdnA under native conditions (data not shown). As 
the group of Hawaiian colleagues managed a faint but successful expression of the MdnA 
ortholog MvdE of Planktothrix argardhii from a pET-type vector [Philmus, et al., 2009], it 
was tried to express MvdE from a pET-vector. But unfortunately, these results were not 
reproducible, which led to the decision to use synthesized precursor molecules, named 
MvdE, MdnA(1)-original Nies843 and MdnA(2)—triple PFFARFL manipulated Nies843. 
Problems also appeared with the expression of MdnB under native conditions. No 
expression has been seen from pACYCDuet-1-mdnB from Microcystis aeruginosa Nies298, 
when cloned into the MCS I as a His-tag fusion protein, as described in paragraph 6.3. 
When expressed from MCS II in the same vector using an S-tag and enlarged culture 
volumes of 2 liters, relatively pure MdnB could be obtained in humble amounts (Figure 
6-15, A). MdnC from Microcystis aeruginosa Nies298 was immediately and without any 
difficulty expressed from pACYCDuet-1-mdnC as an S-tag fusion protein under native 
conditions and in appropriate amounts (Figure 6-15, C). The presence of both proteins was 
verified by Western blot and immunodetection using S-protein HRP-conjugate (Figure 6-15, 




Figure 6-15: MdnB and MdnC purification and immunodetection against the S-tag 
A) represents the SDS-PAG of Nies298 MdnB purification from pACYCDuet-1-mdnB using S-agarose. 
MdnB is shown in the black framed box. In B) the immunodetection of MdnB using S-protein HRP-
conjugate is demonstrated. The SDS-PAG of Nies298 MdnC purification from pACYCDuet-1-mdnC 
using S-agarose is given in C). MdnC is shown in the black framed box. Immunodetection of MdnC 
using S-protein HRP-conjugate is shown in D). L: Page ruler prestained (Fermentas), F: flow-through, 
W1-W3: wash fractions 1-3; E1-E5: elutions 1-5 
Once the proteins were purified and visualized by SDS-PAGE, fractions containing the most 
pure protein were pooled, concentrated and the buffer was changed to HEPES (pH 8.0) 
using Amicon filter units. Protein concentrations were measured by Bradford assay prior to 
the start of surface plasmon resonance analysis. The precursor molecules MvdE from 
Planktothrix agardhii, MdnA(1)-original Nies843 and MdnA(2)—triple PFFARFL manipulated 
Nies843 were immobilized on a CM5 sensor chip via amine coupling. MdnB and MdnC, 
injected in concentrations ranging from 0.15-20 µM, were analyzed for their capability to 
interact with the target. BSA was used as an initial control protein and later Mvn, ActM, 




Figure 6-16: SPR analysis of specific protein interactions of MdnA variants with MdnB and MdnC 
The microviridin prepeptides were immobilized on a CM5 sensor chip via amine coupling and tested 
for the interaction with MdnB and MdnC. Shown are MvdE with MdnB (A) and MdnC (B), MdnA(1)-
original Nies843 precursor with MdnB (C) and MdnC (D) and MdnA(2)-triple-PFFARFl-manipulated 
precursor with MdnB (E) and MdnC (F). The proteins were introduced onto the surface at a 
concentration of 20.0, 10.0, 5.0, 2.5 and 1.25 µM. RU: response units. 
Interactions between the ATP-grasp ligases and the 3 different microviridin precursor 
molecules were detected in each of the measurements, whereas no interaction with BSA 
was observed. In case of MvdE with MdnB and MvdE with MdnC (Figure 6-16, A/B) the 
response units were increased by increasing the concentration of MdnB and C, respectively, 
as shown through the different curve colors. The interactions of the original and 
manipulated MdnA from Nies843 with the ATP-grasp ligases showed a similar result, 
although it seems the most labile interactions with both ligases were observed with the 
manipulated precursor molecule. It was noticed that MdnC seems to make stronger 
interactions with the microviridin precursor molecules than MdnB. These data were in 
accordance to the results from the PFFARFL region mutagenesis and supported the 
hypothesis that the PFFARFL motif serves as a recognition sequence. Later in repetitive 
experiments further controls were included to rule out the possibility of nonspecific 
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interactions. The cyanobacterial proteins Mvn and ActM, as well as commercially available 
highly purified POD and the sulfurtransferase TusA from E. coli were used as control 
analytes. Unfortunately, some interactions were observed (data not shown). Nevertheless, 
differences were detected between the 3 tested microviridin prepeptides and the ligases, 
which make the results not completely invalueable, but they need to be verified with a 
different experimental technique, to ensure their relevance. PFFARFL region mutagenesis 
already showed the cooperation of the ATP-grasp ligases with the microviridin prepeptide 
(6.6.1.1). 
6.6.1.3 Construction of a C-terminal leader peptide processing site 
It has been seen from the fosmid and minimal expression system that microviridin 
production in E. coli always resulted in large amounts of incompletely processed products, 
compared to the correctly processed versions of microviridin L and L1. To improve the yield 
of correctly processed and to minimize the production of incompletely processed 
microviridins, first incubation conditions and media were varied several times without any 
success. Next, the construction of an engineered cleavage site was expected to solve the 
problem. Two enzymatic cleavage sites for trypsin (RYGG) and Factor Xa Protease 
(-IEGRIYGG-) and a chemical cleavage site for hydroxylamine (-NGG-) were successively 
constructed close to the proline region using site-directed mutagenesis, as illustrated in 
Figure 6-17. As shown in the HPLC profile, the insertion or the exchange of one amino acid 
decreased the amount of tricyclic microviridin L and L1, respectively, as shown for the 
construction of the trypsin and hydroxylamine cleavage sites. Tricyclic microviridin 
production completely disappeared when 3-5 amino acids were introduced for the Factor 
Xa processing site. Instead, low amounts of bicyclic microviridins were produced. Taking 
these facts together, it is obvious that the length of the leader peptide plays an important 
role in microviridin biosynthesis and cannot be simply changed. After the constructs were 
made, microviridins were purified from these candidates and incubated with the 
appropriate enzyme or chemical under various incubation conditions. However, under all 
tested conditions cleavage of the leader from the coding region could not be successfully 
shown. HPLC chromatograms remained unchanged before and after the digests were 
performed (data not shown). Probably, the cyclic structure of the microviridins and some 
steric arrangements effectively prevent cleavage. Microviridin itself is known to be a 
trypsin inhibitor which is why trypsin was used in excessive amounts. The lysine within the 
core was rather unexpected to be cleaved, as the microviridin cage-like structure was 




Figure 6-17: Mdn production in E. coli from MdnA carrying an engineered cleavage site 
Microviridins were separated by RP-C18 chromatography and detected at 210 nm. The corresponding 
precursor with an amino acid insertion or an exchange, indicated in bold black letters, is shown next 
to the HPLC run. N-terminal regions of the leader peptide are omitted and given in numbers. 
Tricyclic microviridins L (1), L1 (2), L2 (3), L3 (4) are shown next to bicyclic microviridin L (6) and L1 
(5.) 
6.6.2 C-terminal investigation of the microviridin leader peptide 
In Microcystis the C-terminus of the microviridin leader peptide is highly rich in prolines, 
as shown in yellow in Figure 6-11. From the literature several facts are known. First proline 
residues may serve as recognition sites for peptidases with specificity for 
proline-containing substrates [Vanhoof, et al., 1995]. Furthermore, the microviridin 
prepeptide exhibits some similar features commonly known from eukaryotic and 
prokaryotic signal peptides. There is a hydrophobic core region comprising 6-15 amino acid 
residues, which is essential for targeting and membrane insertion. The rather polar N-
terminus has a positive net charge and is joined to the hydrophobic core. On the 
C-terminal side the hydrophobic core is flanked by a relatively polar region, which often 
contains helix-breaking residues as prolines or glycines [Martoglio and Dobberstein, 1998]. 
This information justified a closer look at the C-terminal region to analyze the importance 
for peptide cleavage and secondary structure formation in the microviridin biosynthesis. 
6.6.2.1 Site-directed mutagenesis in the proline-rich region of mdnA 
To analyze the impact of the 3 prolines at the C-terminus of the microviridin prepeptide, 
site-directed mutagenesis was again applied to construct a double and a triple proline 
region mutant. Prolines in the positions -2, -4, -6, starting from the core region, were 
exchanged against alanines. HPLC analysis showed that the double mutant was still able to 
produce correctly processed and cyclized microviridins, although simultaneously increasing 




Figure 6-18: Microviridin production from proline region mutants 
The proline-rich region at the C-terminus of the microviridin leader peptide is shown in yellow 
boxes in A). The HPLC profile of the leader peptide proline region mutants is shown in B). 
Microviridins were separated by RP-C18 chromatography and detected at 210 nm. The numbers 1-4 
represent the tricyclic microviridins L, L1, L2 and L3. Number 5 and 6 indicate the bicyclic 
microviridins L1 and L. The amino acid exchanges are given on the right. 
The triple proline region mutant lost the ability to produce tricyclic microviridins and 
instead produced large amounts of bicyclic microviridin L (6) and L1 (5). These data 
showed that the exchange of these amino acids had a minor influence on the cleavage 
efficiency and concision. It seems, a proline-specific endopeptidase is not primarily 
involved in the processing at that site. Nevertheless, the organisation of the C-terminal 
part of the leader peptide plays a key role in microviridin biosynthesis. It is assumed that 
the presence of repeated proline residues is possibly necessary for the formation of a β-
turn at the C-terminus of the leader peptide. Such a conformational arrangement might be 
required for the two PFFARFL-binding ATP-grasp ligases to establish the cyclizations. 
6.7 Towards the understanding of the role of the ABC-transporter 
As reported in this work and earlier [Ziemert, et al., 2008], the MRC-derived fosmid 
carrying only the genes mdnABC, was not able to produce correctly processed microviridin 
J, whereas Fos303N843 containing the complete cassette of mdnABCDE expressed 
completely processed microviridin L. The addition of extra copies of mdnD and E to 
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Fos303N843 resulted in increased microviridin production, as described in paragraph 6.4. 
Furthermore, complementation experiments with the MRC-derived fosmid and pCOLADuet-
1-vector carrying mdnDE resulted in the production of microviridin J. These data suggested 
that effective microviridin production was somehow influenced and dependent on the 
presence of the ABC-transporter MdnE. These transporters are not only located in the same 
gene cluster as the structural gene but also exhibit dual functions. In bacteriocin 
biosynthesis they are involved in the removal of a double glycine containing leader peptide 
and the translocation across the cytosolic membrane [Havarstein, et al., 1995]. Thus, it 
was assumed that the ABC-transporter belonging to the microviridin gene cluster, although 
lacking a double glycine motif in the leader, is somehow involved in the maturation process 
of microviridins. Therefore, the role of MdnE was again analyzed using a small microviridin 
pDrive based platform. Analysis in the heterologous host was conducted, as no 
cyanobacterial mutant was available. PCR with primer pair P173-P97 was used to amplify 
the genes mdnABCD and about 714 bp of promoter region, as previously described for 
pARW071-mdnABCDE.  
 
Figure 6-19: Agarose gels with the mdnABCD PCR product 
A schematic representation of the amplified microviridin gene cluster is given in A). A Lambda–PstI 
digest was used as a size standard, as shown in B) and L. The mdnABCD cassette was amplified with 
primer pair P173-P97 to include a long promoter region as given in C). 
The gel-purified PCR product was cloned into pDrive (Qiagen) and several clones were 
sequenced. The obtained plasmid was named pARW081-mdnABCD (a plasmid maps is shown 
in the appendix). Microviridin production was analyzed by HPLC and mass spectrometry (MS 
data not shown), revealing a completely different expression pattern compared to 
pARW071-mdnABCDE. Microviridins were still produced but as a large proportion of bicyclic 
versions, which are incompletely processed at their N-termini. Thus, changes not only 
occurred in the cleaving but also in the cyclization process. Traces of bicyclic microviridin 




Figure 6-20: HPLC profile of microviridin expression from pARW081-mdnABCD 
A schematic representation of pARW071-mdnABCDE and pARW081-mdnABCD constructs is shown in 
A). Microviridin production of pARW081-mdnABCD is shown next to pARW071 carrying the genes 
mdnABCDE in B). The numbers 1-4 represent the tricyclic microviridins L, L1, L2 and L3. Number 5 
shows bicyclic microviridin L1. Microviridins were separated by RP-C18 chromatography and 
detected at 210 nm. 
The phenomenon to produce only incompletely processed bicyclic microviridins was 
analyzed in 3 different strains of E. coli including the fosmid library host strain Epi300T1R 
as well as XL1 Blue and Top10 cells with always the same result. BLASTP showed MdnE is a 
membrane-spanning protein with a cytosolic ATP-binding domain. It seemed to be likely 
that MdnE assists in the formation of a putative microviridin biosynthesis and maturation 
complex associated to the membrane. MdnE may provide support for the correct 
positioning of the microviridin precursor to be cyclized by both or at least one ligase. Such 
membrane-associated complexes are known from ribosomally synthesized lantibiotics as 
nisin [Siegers, et al., 1996].  
6.7.1 The role of MdnE in peptide processing and cleavage 
To further investigate if MdnE-dependent peptide maturation and processing occurs during 
ATP-dependent transport, the sequence G-PSGR-GKS, popularly known as Walker A motif, 
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was manipulated. Therein, the essential lysine (K) was exchanged against an alanine (A), 
to prevent ATP hydrolysis, which is the driving force in active transport processes. ATP 
hydrolysis is a cooperative process between the two ATPase domains, meaning the activity 
of one domain activates the second domain. The knockout of one motif usually leads to a 
complete loss of transport function [Schneider, 2000]. Mutants generated by site-directed 
mutagenesis were still able to produce correctly processed tricyclic microviridins, 
indicating that peptide cleavage is not related to transport and does not require ATP 
hydrolysis, as shown in the following figure. 
 
Figure 6-21: Microviridin expression from pARW112-mdnABCDE-Walker A motif mutant 
A schematic representation of the two E. coli constructs carrying mdnABCDE genes with (pARW112) 
and without (pARW071) a Walker A motif mutation is given in A). Microviridin production of 
pARW112-mdnABCDE-Walker A mutation is shown next to pARW071 carrying the genes mdnABCDE in 
B). The numbers 1-4 represent the tricyclic microviridins L, L1, L2 and L3. Microviridins were 
separated by RP-C18 chromatography and detected at 210 nm. 
6.7.2 The role of MdnE in microviridin transport 
To analyze first if MdnE plays a role in microviridin transport independently from the 
processing process, the constructs pARW071-mdnABCDE and pARW081-mdnABCD were 
comparatively expressed in E. coli. The different cell compartments as the cytosol, the 




Figure 6-22: The role of MdnE in microviridin transport 
An HPLC profile of the microviridin expression and detection in the cytoplasm (Cy), periplasm (P), 
membrane fraction (M) and the total extract (T) from E. coli construct pARW071-mdnABCDE is 
shown in A). An HPLC profile of the microviridin expression and detection in the cytoplasm (Cy), 
periplasm (P), membrane fraction (M) and the total extract (T) from E. coli construct 
pARW081-mdnABCD is given in B). The HPLC profile of the microviridin expression and detection in 
the culture supernatant (S), cytoplasm (Cy), periplasm (P), membrane fraction (M) and the total 
extract (T) from Microcystis aeruginosa Nies843 carrying the genes mdnABCDE compared to a 
microviridin L standard is represented in C). All microviridins were separated by RP-C18 
chromatography and detected at 210 nm. Number 1-5 indicate tricyclic microviridin L (1), L1 (2), L2 
(3), L3 (4) and bicyclic microviridin L1 (5) and L3 (8). 
Microviridins were detected in the cytoplasm (Cy) and the periplasm (P) of E. coli, but not 
in the membrane fraction (M), independent from the presence of the ABC-transporter. In 
contrast, microviridins expressed from the original producer Microcystis aeruginosa 
Nies843, harboring the genes mdnABCDE, were only detected in the cytoplasm (Cy), as 
shown in Figure 6-22, part C. The same was observed when Microcystis aeruginosa Nies298 
was analyzed (data not shown). SDS-PAGE was conducted to ensure that the periplasm and 
cytoplasm were strictly separated from each other, revealing a different pattern for both 
compartments in E. coli and cyanobacteria (data not shown). Transporter analysis in the 
cyanobacterium is so far impossible, because this strain is hardly amenable to genetic 
manipulations. Additionally the cyanobacterial culture supernatant (S) was analyzed but no 
microviridin-like peptides were detected under the applied standard growth conditions, as 
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shown in the figure above. Supernatant analysis of the E. coli cultures, using different 
minimal media with defined supplements, including M9 and a special minimal medium, 
failed under various growth conditions. Microviridins were detected in the cell pellet, 
when minimal medium was supplemented with LB medium, which made HPLC supernatant 
analysis impossible due to purification problems. In absence of LB as a supplement, E. coli 
cultures grew poorly and no microviridin-like peptides at all were detected after several 
days of culture incubation. 
As similar amounts of microviridins were located in the periplasm from both E. coli strains 
(Figure 6-23) no matter if the transporter was present or not, it was assumed that 
microviridins may interact with another transport system. Microviridin amounts were 
calculated using triple biological replicates from HPLC purifications of microviridin L and 
L1 of pARW071-mdnABCDE, and bicyclic microviridin L3 from pARW081-mdnABCD. 
 
Figure 6-23: Microviridin quantification from periplasm and cytoplasm in E. coli constructs 
Triple replicates of E. coli cultures carrying pARW071-mdnABCDE and pARW081-mdnABCD were 
analyzed by HPLC for their quantitative allocation of tricyclic microviridin L, L1 and bicyclic 
microviridin L3 in the cytoplasm and periplasm. Arrow bars indicate the standard deviation. 
As another transport system for microviridins, the Sec system would be a nearby 
presumption. For that, biostatistic prediction tools as pSORTb and SignalP were employed 
to justify this assumption. The localization of MdnA and B was analyzed by pSORT but 
resulted in an insecure prediction. Both showed the possibility to be either located in the 
cytoplasm or the periplasm or even attached to the membrane. The use of SignalP, to 
predict potential signal sequences did not exclude the possibility of those in MdnA. Thus, 
the transport of MdnA could not be excluded. Taken together, so far under the conditions 
tried, there is no indication MdnE is neither involved in the transport of microviridins 
through the inner membrane in the cyanobacterium nor in the E. coli strains, but transport 
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to other parts of the cell or under different conditions is not entirely excluded. Transport 
might also occur under very special conditions not examined in the lab experiments. 
6.7.3 The role of MdnE as a proposed scaffolding protein 
To clarify the function of MdnE as a scaffolding protein, the presence and localization of 
the ATP-grasp ligase MdnB was analyzed in E. coli and the cyanobacterium. From 
experiments conducted by Katharina Makower (group of Prof. Dittmann, University of 
Potsdam) it was known that the expression levels of both microviridin cassettes in pDrive 
containing mdnABCDE and mdnABCD were akin to each other. E. coli constructs 
pARW071-mdnABCDE and pARW081-mdnABCD were analyzed using Western blot and 
immunodetection with the polyclonal antibody Anti-MdnB previously generated.  
 
Figure 6-24: Subcellular localization and stability of MdnB in presence and absence of MdnE 
pARW071-mdnABCDE and pARW081-mdnABCD were analyzed for the localization and stability of the 
ATP-grasp ligase MdnB in the cytoplasm (Cy), periplasm (P) and total extract (T) using Western blot 
analysis and immunodetection by the Anti-MdnB antibody. Plain E. coli cells were used as a control. 
MdnB was mainly detected in the cytoplasm in both constructs, but obviously MdnB 
expression was significantly decreased in absence of the ABC-transporter MdnE. In 
cyanobacterial strains Microcystis aeruginosa Nies298 and Nies843 containing the complete 
microviridin expression cassette, the same result was obtained. Data were not shown as 
the bands are rather faint due to the lower copy number in the cyanobacteria compared to 
E. coli, where genes were expressed from a high copy plasmid. A cyanobacterial construct 
lacking the transporter is not available. The fact indicated one more time that MdnE plays 
an important role and may act as a scaffolding protein, stabilizing the putative 
microviridin biosynthesis complex or parts of it at the inner membrane on the cytosolic 
side. 
6.7.4 In vitro activities of the ATP-grasp ligases and the ABC-transporter 
The activity of the ATP-grasp ligases has been previously analyzed in vitro [Philmus, et al., 
2008]. There, it has been shown that the two ligases, MvdD and MvdC from Planktothrix 
agardhii catalyze, although with rather low activity, the formation of a tricyclic compound 
from the 48-mer synthetic MvdE precursor peptide, with MvdD being the foremost working 
enzyme. Additionally, the acetyltransferase MvdB, has been shown to acetylate a 14-mer 
microviridin at the N-terminus, to result in the complete conversion into a product named 
 Results 
 95 
microviridin K. A similar approach was conducted by Nadine Ziemert [Ziemert, 2009] using 
the ATP-grasp ligases MdnB and MdnC and a synthesized MdnA precursor peptide from 
Microcystis aeruginosa Nies298, but unfortunately without any success of cyclization. From 
the current work several new insights into the mechanism of microviridin biosynthesis in 
Microcystis were gained and justified to repeat in vitro assays under modified conditions. 
MvdE, with its different organization in the C-terminal part of the leader peptide and the 
cytosolic domain of the ABC-transporter were included into a new serial of enzyme assays.  
In order to establish an in vitro expression system, suitable for mechanistic studies and 
useful later for the investigation of certain mutations in the core peptide excluding the 
background of E. coli, an enzyme assay, similar to the one published by [Philmus, et al., 
2008], was performed. As already described, there were certain difficulties to express and 
purify the microviridin precursor molecule heterologously. Thus, synthesized microviridin 
precursors (Genescript), MdnA(1)-original Nies843 precursor, MdnA(2)—triple PFFARFL 
manipulated precursor from Nies843, MdnA-original Nies298 precursor and MvdE from 
Planktothrix were analyzed together with the heterologously expressed ATP-grasp ligases 
from Microcystis aeruginosa Nies298 for cyclization events. 
It has to be mentioned that all precursors but MdnA(1)-original were solubilized in either 
Tris-HCl or phosphate buffer pH 8.0. MdnA(1)-original was water insoluble and only the use 
of SDS in the enzyme assay mediated solubility. This concentration was assumed to be not 
inhibiting to the ligases, as concentration up to 0.1 % were used in previously reported 
reactions [Crimmins, et al., 2001]. Common detergents as Nonidet P-40 or Triton X did not 
improve solubility.  
In none of these assays cross-linked microviridins were detected by HPLC and mass 
spectrometry. A mix of precursor from Planktothrix and ATP-grasp ligases from Microcystis 
did not result in any microviridin K-like compounds. Unconverted precursor molecules were 
detected without exception. In vivo at least the first cyclization in Microcystis occurs in 
the absence of MdnE, as demonstrated for microviridin expression from pARW081-
mdnABCD. Nevertheless, as the ABC-transporter was shown before to be highly important 
for the correct assembly of microviridins, the cytosolic domain of the membrane protein 
was additionally expressed from a pACYC-Duet-1 vector and included in the enzyme assay. 
But again no cross-linked microviridin-like compounds were detected. As surface plasmon 
resonance experiments showed better interaction in the presence of higher ligase 
concentrations, different concentrations of ligases and the cytosolic domain of MdnE were 




6.8 Manipulation of the microviridin core peptide and bioactivity tests 
The carboxy terminus of MdnA is representing the core sequence that is cleaved and 
enzyme-modified, resulting in the 14 amino acid short peptide microviridin, which exhibits 
bioactivity against serine proteases. In the past, Thomas Hemscheidt and coworkers 
already worked on the manipulation of certain amino acids in this area to analyze the 
substrate specificity of the ATP-grasp ligases in vitro [Philmus, et al., 2009]. They showed 
that the ligases exhibit a marginal flexibility for manipulations in the KYPSD region of 
MvdE. With the small microviridin expression platform pARW071-mdnABCDE it was possible 
to further manipulate and analyze the core region in vivo to broaden and deepen the 
knowledge about the substrate specificity of the ligases. The possibility to cut and paste 
precursor peptides of cryptic microviridins into the established expression system was 
analyzed. Furthermore, the bioactivities of the resulting mutants were dissected to 
determine certain amino acid positions to be highly important to maintain, to increase or 
even change bioactivities through the introduction of new and prospectively unusual 
residues. This information could guide the construction of microviridin peptide libraries 
with potential pharmacological use in the future.  
6.8.1 The impact of crosslink reduction for production yield and bioactivity 
First of all, the bioactivities of tricyclic heterologously expressed microviridins L, L1, L2 
and L3 were analyzed against eukaryotic serine proteases as trypsin, chymotrypsin and 
elastase by Dr. Keishi Ishida (HKI, Jena). Cultures of about 2 liters of E. coli carrying the 
fosmid Fos303N843 microviridin expression platform were grown for several hours. In 
comparison, expression of sufficient amounts from the original producer would take weeks. 
Microviridins were purified and bioactivity tests were conducted. It has been shown that 
microviridin L and its derivatives exhibit moderate bioactivity in the micromolar range 
against serine proteases, compared to other microviridins reported in the literature 
[Ziemert, et al., 2010]. Stable amounts of bicyclic microviridins lacking the amide bond 
were successfully produced from the PFFARFL region single and double mutants, described 
in paragraph 6.6.1.1. To determine the impact of the lactam ring on the bioactivity, these 
candidates were tested against the same proteases, but additionally subtilisin was 
included. Indeed, bicyclic microviridin mutants were slightly more potent against 
subtilisin, whereas the other inhibitory characteristics compared to tricyclic microviridins 
were almost unchanged. Thus, the influence of the lactam ring forming amide bond on the 
inhibitory pattern of microviridins has been shown to be marginal. To further analyze the 
impact of the number of cyclizations on stability and bioactivity, a mutant producing 
monocyclic microviridins has been constructed by site-directed mutagenesis. A serine 
residue (S) of the KYPSD region was exchanged against an alanine (A). Similar attempts 
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were previously reported by [Philmus, et al., 2009]. Several mutants were analyzed by 
HPLC and mass spectrometry (MS data not shown). They showed almost no production of 
monocyclic microviridin L1 type.  
 
Figure 6-25: Alterations in the cage-like structure of microviridins 
Tricyclic, bicyclic and monocyclic microviridins were produced from precursor molecules shown on 
the left. Exchanged amino acid residues are indicated in green and blue. The amino acid sequence 
of the leader was omitted, unless the mutation was located there, as shown in the middle. The 
PGFARFL mutation is shown as one example for bicyclic microviridins. Numbers in the leader 
sequence explain the number of the following amino acids belonging to the leader. The HPLC profile 
corresponding to the precursor sequences is shown on the right. Numbers indicate tricyclic 
microviridin L (1), L1 (2), L2 (3), L3 (4), bicyclic microviridin L (6) and L1 (5) and monocyclic 
microviridin L1 type (9). All microviridins were separated by RP-C18 chromatography and detected 
at 210 nm. 
Again large E. coli mutant cultures were grown for 10 hours. Microviridins were purified 
and analyzed for their inhibitory potential. N- and C-terminal degraded structures were 
mainly detected, indicating that monocyclic microviridins, lacking the smaller ester and 
the amide bond, are more unstable. Nevertheless, bioactivity against chymotrypsin has 
been faintly increased, whereas no inhibitory effect against subtilisin, trypsin and elastase 
was discovered. Thus, the formation of the smaller lacton ring is of high importance to 
maintain structure stability and bioactivity. 
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Table 6-1: Serine protease inhibitory activity of tri-, bi- and monocyclic microviridins 
  inhibitory activity (IC50) in µmol/l 
sequence cyclization elastase chymotrypsin trypsin subtilisin 
Ac-YGGTFKYPSDWEDY tri-mdnL >58 42 58 8.7 
Ac-GGTFKYPSDWEDY tri-mdnL1 >64 24 >64 5.8 
Ac-YGGTFKYPSDWEDY bi-mdnL >57 >57 >57 2.3 
Ac-GGTFKYPSDWEDY bi-mdnL1 >63 41 >63 2.5 
GTFKYPADWE-OH mono-mdn >63 16 >63 >63 
Ac-GGTFKYPADWE-OH mono-mdn >84 20 >84 >84 
6.8.2 Mutations in the TxKxPSDx region 
In order to analyze how far changes in the highly conserved TxKxPSDx region can be 
expanded and how bioactive the resulting mutants are, this region has been manipulated 
step by step using site-directed mutagenesis in the small microviridin expression platform 
pARW071-mdnABCDE. First, aromatic phenylalanine in position 5 (F5) in the core region has 
been exchanged against hydrophobic leucine (L5). The most potent microviridins, in terms 
of bioactivity, carry a leucine at this position, whereas microviridin L originally has a 
phenylalanine (F). Indeed, the resulting mutant produced stable amounts of tricyclic 
microviridin L and L1 corresponding to the amino acid exchanges.  
 
Figure 6-26: Microviridin production from TFTL mutant 
Original and TFTL mutated microviridins were produced from precursor molecules shown on the 
left. The exchanged amino acid residue is indicated in blue. The HPLC profile corresponding to the 
precursor sequences is shown on the right. Numbers indicate tricyclic microviridin L (1), L1 (2), L2 
(3), L3 (4) and microviridin L TFTL type (10) and microviridin L1 TFTL type (11). All microviridins 
were separated by RP-C18 chromatography and detected at 210 nm. 
The bioactivity was increased about a 100-fold against elastases and to a lower degree also 
against chymotrypsin and subtilisin. The activity against trypsin remained unchanged. 
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Thus, a strong inhibitory activity was obtained by intentionally altering the phenylalanine 
in position 5 by introducing a leucine. 
Table 6-2: Serine protease inhibitory activity of TFTL microviridin mutant 
  inhibitory activity (IC50) in µmol/l 
sequence cyclization elastase chymotrypsin trypsin subtilisin 
Ac-YGGTFKYPSDWEDY tri-mdnL >58 42 58 8.7 
Ac-GGTFKYPSDWEDY tri-mdnL1 >64 24 >64 5.8 
Ac-YGGTLKYPSDWEDY tri-mdnL type 0.433 17 >63 3.4 
Ac-GGTLKYPSDWEDY tri-mdnL1 type 0.133 18 >59 3.8 
In order to further analyze the possibility to mutate the core region, rarely occurring 
amino acids detected in the natural library of sequences from the KxPSDx region, as shown 
in the alignment below, where chosen to be introduced into the precursor sequence of 
microviridin L. The microviridins from the organisms harboring the presented precursor 
sequences are so far cryptic. 
 
Figure 6-27: Precursor sequences of cryptic microviridins carrying rare amino acids 
Microviridin encoding precursor sequences and their hosts are shown. Rarely occurring aberrant 
amino acids in the KxPSDx region are highlighted in blue. The amino acid sequences were obtained 
from the NCBI Blast server and aligned using ClustalW. M.: Microcystis, sp.: species 
The small microviridin platform pARW071-mdnABCDE was again used to alter the highly 
conserved KYPSDx core sequence of MdnA by a genetic engineering technique. The 
aromatic tyrosine in position 7 (Y7) was exchanged against aromatic residues like 
tryptophane (W7) and phenylalanine (F7), whereas original aromatic tryptophane in 
position 11 (W11) was replaced by hydrophilic cysteine (C11) or serine (S11). The resulting 
mutants were analyzed by HPLC, as shown in the following figure and verified by mass 




Figure 6-28: Manipulations in the KxPSDx region of microviridin L 
Original and KxPSDx mutated microviridins were produced from precursor molecules shown on the 
left. Exchanged amino acid residues are indicated in blue. The HPLC profile corresponding to the 
precursor sequences is shown on the right. Numbers indicate tricyclic microviridin L, L1, L2, L3 (1, 
2, 3, 4), microviridin L and L1 KWPSDW type (12, 13), microviridin L and L1 KFPSDW type (14, 15) 
and traces of microviridin L and L1 KYPSDS type (16, 17). KYPSDC mutant did not produce any 
microviridin-like compounds. All microviridins were separated by RP-C18 chromatography and 
detected at 210 nm. 
New tricyclic microviridin L and L1 types corresponding to the amino acid exchanges in 
position 7 were stably produced from KWPSDx and KFPSDx mutants. Thus, ligase flexibility 
has been shown for position 7 when amino acids with similar properties compared to the 
original were introduced into the peptide chain. In contrast, substitutions in position 11 led 
to a breakdown of microviridin biosynthesis. Trace amounts of bicyclic (not shown) and 
tricyclic mdnL and L1 structures were mainly detected by mass spectrometry (data not 
shown) from the KYPSDS mutant. For the insertion of cysteine, carrying a highly reactive 
thiol group in the side chain, no microviridin-like peptides were detected. Thus, the amino 
acid exchanges in position 11, using amino acids with more distant characteristics, showed 
a stronger effect. Due to the low microviridin production level from KYPSDS mutant, 




Table 6-3: Serine protease inhibitory activity of KWPSD and KFPSD mutants 
  inhibitory activity (IC50) in µmol/l 
sequence cyclization elastase chymotrypsin trypsin subtilisin 
Ac-YGGTFKYPSDWEDY tri-mdnL >58 42 58 8.7 
Ac-GGTFKYPSDWEDY tri-mdnL1 >64 24 >64 5.8 
Ac-YGGTFKWPSDWEDY tri-mdnL type >58 >58 >58 >29 
Ac-GGTFKWSDWEDY tri-mdnL1 type >64 20 >64 5.0 
Ac-YGGTFKFPSDWEDY tri-mdnL type >59 24 >59 6.6 
Ac-GGTFKFPSDWEDY tri-mdnL1 type >65 13 >65 5.1 
As shown by the results in Table 6-3 compared to original microviridin L, there were no 
remarkable alterations detected in the inhibitory profile of the KWPSD and KFPSD mutants 
against the tested serine proteases. Thus, position 7 seemed to be not primarily important 
for the bioactivity.  
6.8.3 Construction of a core peptide detected from a field sample 
Previously, a microviridin precursor encoded in the amino acid sequence YNVTLKYPSDWEEF 
was detected from field sampling, occurring in more than half of 50 analyzed clones, from 
the Braakman reservoir (Netherlands) and from the Baltic Sea in Mecklenburg-Vorpommern 
(Germany) [Ziemert, 2009]. It was assumed that the high abundance of this particular 
amino acid sequence might correlate with beneficial properties in terms of bioactivity for 
the harboring organisms. Several rounds of site-directed mutagenesis were performed to 
convert the small microviridin expression platform pARW071-mdnABCDE, carrying the 
precursor sequence YGGTFKYPSDWEDY of Microcystis aeruginosa Nies843 into the new 
sequence. The final construct as well as a construct carrying the sequence 
YNVTLKYPSDWEEY was analyzed by HPLC and mass spectrometry (MS data not shown). 
Tricyclic microviridins from both engineered precursors were produced in E. coli cells, 





Figure 6-29: Microviridin production from an unknown core peptide detected in the field 
Original and microviridin L/L1 field Y14/F14 type microviridins were produced from precursor 
molecules shown on the left. Exchanged amino acid residues are indicated in orange. The HPLC 
profile corresponding to the precursor sequences is shown on the right. Numbers show tricyclic 
microviridins, microviridin L field Y type (18), microviridin L1 field Y type (19), microviridin L field F 
type (20) and microviridin L1 field F type (21). All microviridins were separated by RP-C18 
chromatography and detected at 210 nm. 
Large 6 liter E. coli cultures carrying both field sample core peptides were grown and 
microviridins were isolated to determine their inhibitory profile. It was noticed that 
microviridins from large cultures were degraded at the N-terminus and did undergo partial 
methylation as shown with * in the table below. Both has never been detected from smaller 
cultures. Degradation was supposed to result from technical cooling problems during the 
purification process, as microviridins are reported to react sensitively to higher 
temperatures [Rohrlack, et al., 2003]. Indeed, especially the inhibitory activity towards 
elastase was significantly increased from the micromolar to the nanomolar range. Thus, 
the initial hypothesis seems to be very likely. The predominant microviridin variant was 
shown to be the very active. The stepwise mutagenesis showed that the amino acid in 
position 5 is highly important for the bioactivity. The other bioactivities remained 




Table 6-4: Serine protease inhibitory activity of YNVTLKYPSDWEE(Y/F) mutants 
  inhibitory activity (IC50) in µmol/l 
sequence cyclization elastase chymotrypsin trypsin subtilisin 
Ac-YGGTFKYPSDWEDY tri-mdnL >58 42 58 8.7 
Ac-GGTFKYPSDWEDY tri-mdnL1 >64 24 >64 5.8 
VTLKYPSDWE*EY tri-mdn 4.6 >63 >63 >63 
Ac-NVTLKYPSDWE*EY tri-mdn 0.379 >60 >60 13 
VTLKYPSDWEEF tri-mdn 4.8 37 >69 >69 
VTLKYPSDWEEF bi-mdn 5.0 68 >68 >68 
* indicates the formation of a methylester 
6.8.4 Cut and paste of microviridin precursor molecules 
In order to analyze the possibility to express cryptic microviridin core sequences with their 
own corresponding leader peptides in the backbone of pARW071-mdnABCDE, the small 
microviridin expression platform was again manipulated by site-directed mutagenesis. 
Performing several rounds of mutagenesis, EheI and AatII restriction sites were introduced 
into the intergenic space surrounding the 5´and 3´ends of mdnA. The construct was named 
pARW089-mdnA-exchange platform. Microviridin L production was verified by HPLC. It was 
noticed from all candidates analyzed, that production levels were faintly decreased 
compared to the pARW071-mdnABCDE platform. Cryptic microviridin precursor molecules 
of Nostoc sp. PCC7120 (GenBank: BAB78097.1), Cyanothece sp. PCC7822 (NCBI Reference 
Sequence: YP_003890018.1 and YP_003890026.1) and Microcystis aeruginosa PCC7806 
(GenBank: CAO86268.1) were amplified by PCR using primers with the appropriate 
restriction site at the 5´-end. Products were first cloned into pDrive and transferred from 
there into the microviridin expression platform, resulting in the plasmids named 
pARW097-PCC7120-1, pARW098-PCC7822-2, pARW099-PCC7822-3 and pARW100-PCC7806-4. 
Candidates were analyzed for their ability to express the obtained precursors, as shown in 
Figure 6-30. No microviridin production was detected from the structurally most distant 
precursor of Nostoc sp. PCC7120 carrying a double glycine motif and three potential 
microviridin core sequences. Traces of bicyclic, acetylated microviridins of the mdnL and 
L1 type (Ac-YQNTLKYPSDWEDY, Ac-QNTLKYPSDWEDY) were detected from 
Cyanothece sp. PCC7822-2 precursor. Traces of nonacetylated, bicyclic N-terminally 
shortened microviridins (PIFTLKFPSDWEDS) were produced by Cyanothece sp. PCC7822-3 
precursor. The presence was mainly detected by mass spectrometry (data not shown) as 
peaks are hardly visible in the HPLC chromatograms. Bicylic, N-terminally truncated 
microviridins (WTWKWPSDWEDS) were detected from the most closely related Microcystis 
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aeruginosa PCC7806 prepeptide. Tricyclic microviridins were never detected from any of 
the precursors.  
 
Figure 6-30: Expression of cryptic mdn precursors using the pARW071-mdnABCDE platform 
A) MdnA from Nies843 was excised from the pARW089-mdn-exchange platform using EheI and AatII 
and replaced by cryptic microviridin precursors from Nostoc sp. PCC7120-1, Cyanothece sp. 
PCC7822-2/3 and Microcystis aeruginosa PCC7806-4. Cryptic precursors are shown as protein 
sequences. The conserved PFFARFL region is shown in green, helix-breaking polines are shown in 
yellow, a double GG-motif is shown in orange and the TxKxPSDx region is shown in blue. B) HPLC 
profile of microviridin production from the inserted precursor molecules. No mdn production was 
detected from PCC7120-1. Traces of bicyclic microviridins, microviridin L PCC7822-2 type (22), 
microviridin L1 PCC7822-2 type (23), microviridin L PCC7822-3 short type (24) from Cyanothece sp. 
PCC7822 and microviridin L PCC7806-4 short type (25) are shown compared to the microviridin 
production from pARW089-mdnA-exchange platform. All microviridins were separated by C18-RP 
chromatography and detected at 210 nm. 
Taken together, the production of bicyclic microviridins from different precursor sequences 
was successfully shown, although most of them were produced in rather low 
concentrations. 
6.9  A knockout of mdnB in the small microviridin expression platform 
It has been observed in the fosmid system before that a knockout of mdnB resulted in 
almost no production of microviridin-like structures, although bicyclic microviridins, 
lacking the amide bond, were later detected to be produced in appropriate amounts from 
PFFARFL region mutants. Furthermore, co-expression studies with knockout fosmids and 
extra copies of mdnABC expressed from a vector never led to reactivation of microviridin 
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production. In contrast, addition of mdnD an E was successfully shown. At one point it was 
suggested, the genes mdnABC need to be transcribed together from one operon. To go for 
a more detailed analysis the small microviridin platform was used as a template to 
eliminate mdnB. Using site-directed mutagenesis a second AatII restriction site was 
introduced at the 3´end of mdnB in the pARW089-mdnA-exchange platform. MdnB was 
removed by an AatII digest followed by self-ligation of the plasmid. Candidates were 
sequenced to confirm the removal. The obtained plasmid was named pARW103-mdnBko. 
HPLC analysis was conducted and revealed a similar result to that obtained from the 
fosmid system. Traces of bicyclic microviridin were detected by mass spectrometry (data 
not shown).  
 
Figure 6-31: MdnB knockout in the small microviridin expression platform 
A schematic representation of the small microviridin platform, carrying the genes mdnABCDE and 
the two constructs lacking mdnB is given in A). The dots indicate the fosmid carries about 43 kbp of 
Nies843 sequence. HPLC profile of microviridin production from pARW071-mdnABCDE, 
Fos303N843-mdnB and pARW106-mdnACDE is given in B). Numbers indicate the production of 
microviridin L (1), L1 (2), L2 (3) and L3 (4) and bicyclic microviridin L (6) and L1 (5). All 
microviridins were separated by C18-RP chromatography and detected at 210 nm. 
Several attempts were made to knockout the ATP-dependent carboxylate–amine ligase 
activity of MdnB by the exchange of a highly conserved lysine (K) in the 127-AKNKLLQL-90 
region of MdnB (numbers indicate omitted sequence) that is known to be involved in ATP-
binding [Galperin and Koonin, 1997]. Unfortunately, mutants were never successfully 
constructed. It was impossible to find a functional pair of primers that could anneal and 
introduce the desired mutation, probably due to the high AT-content in this region. Again 
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Attempts were made to study and manipulate a new microviridin gene cluster from the 
toxic cyanobacterium Microcystis aeruginosa Nies843. 
7.1 In search of an appropriate expression system 
Three different expression systems were tested for microviridin production in E. coli. Two 
of them, the fosmid and the small pDrive expression platform made use of the 
cyanobacterial promoter of the microviridin gene cluster, whereas in the Duet vectors the 
genes were expressed under the control of an E. coli T7 derived promoter. The use of 
compatible Duet vectors for microviridin expression has never been successful. Expression 
was only achieved when a cyanobacterial promoter was used. In terms of the efficiency 
factor in time, fosmids in contrast to the small pDrive based expression platform emerged 
to be unsuitable and ineffective for a large mutagenic approach of the microviridin gene 
cluster. Nevertheless, some results were obtained. First, MdnD was proven to be the 
acetylating enzyme in microviridin biosynthesis, which resembled results from in vitro 
studies by [Philmus, et al., 2008]. Secondly, the sequential arrangement of the genes 
mdnABC is essential for microviridin production. Thirdly, MdnE has no N- or C-terminal 
peptidase domain, as described for the ABC-transporter encoded as part of the cryptic 
microviridin gene cluster in Nostoc sp. PCC7120 and other bacteriocins [Havarstein, et al., 
1995]. 
7.2 What can be learned from the transcriptional organization of the 
microviridin gene cluster? 
Microviridin expression in E. coli has been shown to depend on the presence of a long 
untranslated leader region [Weiz, et al., 2011]. Northern hybridization showed two 
transcripts for mdnA of around 450 and 600 nucleotides in Microcystis aeruginosa, which 
both clearly exceeded the size of the coding region of mdnA [Makower, 2010]. The longer 
one could not be shown in pARW066-mdnABCDE-short. Instead a smear typical for 
degradation products appeared. Thus, the necessity of a longer upstream region in 
pARW071-mdnABCDE is assumed to have a positive effect on RNA transcript stability. It is 
believed this region accomodates regulatory elements [Makower, 2010]. Hints for 
secondary structure formation could not be found (Fehler! Verweisquelle konnte nicht 
gefunden werden.). 
Functional expression of microviridin has never been seen if mdnA and B were separated 
from each other. Microviridin has never been expressed from Duet vectors and 
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co-expression studies with mdnB were ineffective. Although extensively tried, the 
construction of a point mutant in the active center of MdnB, which would have answered 
many questions, failed. In their native cyanobacterial producers, the gene orthologs of 
mdnABC are often clustered together (Figure 7-1), whereas mdnD and E orthologs are 
either located within the gene cluster, in the close vicinity or elsewhere in the genome.  
 
Figure 7-1: Organisation of selected putative microviridin gene clusters [Philmus, et al., 2008] 
Commonly orthologs of the genes MvdE, MvdD and MvdC cluster together, whereas ABC-transporters 
and acetyltransferases are not necessarily located within the borders of the gene cluster. MvdE: 
ortholog to MdnA, MvdD: ortholog to MdnC, MvdC: ortholog to MdnB, N.: Nostoc, A.: Anabaena; M.: 
Microcystis 
The related nisin gene is reported to be part of a polycistronic operon (Steen et al. 1991). 
A similar result was reported from investigations into the transcriptional organization of 
the microviridin gene cluster, conducted in parallel to this work. The genes mdnABC are 
transcribed together with the resulting polycistronic message functioning as mRNA. It 
seems coding sequences of mdnA and B overlap [Makower, 2010] (Fehler! Verweisquelle 
konnte nicht gefunden werden.). Such polycistronic structures of prokaryotic mRNA have 
profound regulatory consequences for both, transcription and translation [Kozak, 1983]. 
The polycistronic rule permits the translation of cotranscribed genes to be coupled closely, 
which enables a simple regulation and effective use of resources. MdnA would be rapidly 
degraded in the absence of MdnB and C. MdnD and E, located within the microviridin gene 
cluster, seem to be controlled by different regulatory sequences [Makower, 2010]. 
Thus, the use of any in vivo expression system that carries mdnABC in different backbones 






Figure 7-2: Investigations into the transcriptional organization of the microviridin gene cluster  
A) Transcription of mdnA in microviridin J producing strain Microcystis aeruginosa MRD and in E. coli 
strain harboring plasmid pARW066-mdnABCDE-short with a 169 bp promoter region, nt: nucleotides; 
B) Schematic representation of the polycistronic operon of the microviridin gene cluster in 
Microcystis aeruginosa MRD; figure adapted from [Makower, 2010]. Arrows indicate primer positions 
used to map the operon. PCR on cDNA from Microcystis aeruginosa MRD detected products for all 
primer combinations and thus showed the transcription unit of the gene cluster comprises all 3 
genes and a long region upstream of mdnA. 
7.3 Analysis of the microviridin leader peptide 
7.3.1 The PFFARFL motif 
With the small expression platform in hand, a large mutagenic approach was started. This 
study represents the first detailed analysis of a microviridin leader peptide in terms of the 
presence of recognition motifs for the posttranslationally modifying enzymes and the 
protease.  
A bioinformatic analysis conducted at the beginning of this mutational project disclosed 
that the microviridin leader peptide showed rather unusual constitutional similarities to 
common signal peptides in its N- to C-terminal organization, in contrast to what is known 
from other leader peptides [Oman and van der Donk, 2009]. Mutational analysis of the 
microviridin leader peptide uncovered the unique PFFARFL motif to play a key role in 
microviridin biosynthesis, serving as a recognition sequence for the ATP-grasp ligases 
(Figure 6-12). A precise collaboration of the ligases and the precursor peptide MdnA has 
been shown through mutational analysis of the PFFARFL region. It is well known that leader 
peptides of different ribosomally synthesized small peptides share some general features, 
for example the presence of motifs for secretion and recognition for the posttranslationally 
modifying or cleaving enzymes, although they are not well conserved in their primary 
sequence. Short sequences, such as the F(N/D)(L/V)(D/Q/E) motif of class I lantibiotics, 
the ELXX(B/V/I)X motif for class II lantibiotics, the FXXXL motif for microcins or the FXXXB 
motif for cytolysins are known to be critical for the binding of the leader to the 
biosynthetic enzymes, but they show some variability in their primary sequence [Müller, 
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2011: ; Oman and van der Donk, 2009]. In contrast, the PFFARFL region in microviridin 
leader peptides is highly conserved. The exchange of any individual amino acid led to 
profound changes in microviridin expression patterns. The activity of MdnB was 
immediately disabled, and thus the efficiency of microviridin production was decreased to 
bicyclic peptides. In contrast, point mutations introduced into other leader peptides, such 
as those from lacticin 481 [Patton, et al., 2008] and the microcin B17 [Cheung, et al., 
2010] indicated larger plasticity, which in most cases still enabled a complete peptide 
processing. The exchange of two amino acids still allowed MdnC to be active, whereas 
mutation of three amino acids finally also abolished its activity. Thus, the PFFARFL region is 
of essential importance not only for MdnB, but also for MdnC. The fact that MdnC is more 
tolerant to changes indicates broader substrate specificity, compared to MdnB. 
Interestingly, bicyclic microviridins from PFFARFL mutants were produced in larger amounts 
compared to the tricyclic microviridins. It might be speculated that the whole amount of 
otherwise available ATP can go into the formation of ester bonds, which results in 
increased bicyclic peptide amounts.  
7.3.2 The C-terminal region 
The organization of the C-terminal part of the microviridin leader peptide is crucial for a 
certain orientation of the precursor peptide to the PFFARFL bound enzymes and thus for 
the correct assembly of tricyclic microviridins.  
Inserting one amino acid, introduced to create an artificial cleavage site downstream of 
the proline in position -2 at the C-terminus of the leader, immideately decreased the level 
of correctly processed microviridins. Insertion of a stretch of 5 amino acids inhibited not 
only MdnB but severely downregulated the activity of MdnC (Figure 6-17). The dramatic 
effects on both ligases not only point to the need of a correct spacing between the 
PFFARFL and KYPSD regions for both enzymes to introduce cyclizations, but also to the 
basic necessity of binding to the PFFARFL region. In contrast, the introduction of an 
alternative C-terminal cleavage site into the nisin and haloduracin leader peptide did not 
hamper the modifying enzymes [McClerren, et al., 2006: ; Plat, et al., 2010]. 
Mutagenesis in the proline-rich region led to lowered activity of the lactam ring forming 
enzyme MdnB. MdnC, responsible for lactone ring formation, seemed to be nonaffected. As 
prolines may function as turn-inducing amino acids [Martoglio and Dobberstein, 1998], it is 
assumed that changes in this region interfere with the correct orientation or confirmation 




7.4 What role does the ABC-transporter play? 
Initial experiments conducted by Ziemert and coworkers [Ziemert, et al., 2008] pointed to 
an accentuated need of MdnE to obtain completely processed microviridins. Thus, a more 
detailed analysis for the function of the ABC-transporter was set-up. Microviridin 
expression from the small expression platform, lacking the ABC-transporter, showed the 
production of only incompletely processed bicyclic microviridins. The fact that the activity 
of MdnB was inhibited in the absence of MdnE indicated an interaction between both 
enzymes (Figure 6-24). The formation of membrane-associated biosynthetic complexes has 
been shown numerous times for related ribosomally synthesized peptides, such as for nisin, 
nukacin ISK-1 and microcin B17 [Duquesne, et al., 2007: ; Nagao, et al., 2007: ; van den 
Berg van Saparoea, et al., 2008]. Thus, it has been speculated, the Microcystis prepeptide-
enzyme complex requires a defined architecture provided through conformational support 
by the scaffolding protein MdnE.  
7.4.1 Do the in vitro activities depend on the presence of MdnE? 
In parallel to in vivo analysis of the microviridin gene cluster, an in vitro enzyme assay was 
intended. Initial experiments conducted in this study and by [Ziemert, 2009] involving only 
the proteins MdnA, B and C from Microcystis failed, which is now in accordance to the 
assumption the ABC-transporter may function as a scaffolding protein. Similarly, in vitro 
reconstitution of heterocyclization activity for microcin B17 was shown to require not only 
the precursor McbA, the cyclodehydrase McbB and the dehydrogenase McbC, but also 
McbD, that probably functions as a conformational switch [Milne, et al., 1999]. Philmus and 
collegues [Philmus, et al., 2008] in their experiments showed, in contrast to Microcystis, 
the orthologous Planktothrix microviridin machinery is able to conduct macrocyclization 
without additional components in vitro. These differences might be explained by the 
different C-terminal leader peptide organization in Microcystis. Secondary structure 
formation for MdnA is not given, as the peptides were synthesized. It has been shown in 
this work, the proline residues at the C-terminus of the leader peptide play an important 
role in a putative turn formation. The use of Planktothrix precursor and Microcystis 
enzymes and vice versa failed (Douglas Gatte-Picchi, personal communication), which 
indicated at that point the precursor peptide and the processing enzymes work very well 
synchronized. Of course, it could be tried to express MvdE in the pARW089-mdnA-exchange 
platform in vivo, to see whether it would function at all. If one would assume the lack of 
in vitro activity was at least partly associated with the absence of MdnE, it should be 
considered that including a single cytosolic domain has not been enough to detect in vitro 
activities. The potential dimeric architecture, described for the majority of related 
ABC-transporters [Rees, et al., 2009] cannot evolve from this set-up. Additionally, it cannot 
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be excluded further cofactors are needed. This experiment should be repeated using the 
complete ABC-transporter. As MdnE is a membrane protein, strategies like fusion to a 
maltose-binding protein or expression in micelles should be preferred. Furthermore, cell-
free membrane protein expression systems are commercially available. Again it could be 
tried to express MdnA heterologously as a DsbC-fusion protein carrying an N- and a C-
terminal tag, maybe in one of the numerous other protease deficient strains of E. coli 
designed for unstable proteins. This would help to obtain the secondary structures in the 
prepeptides that have been shown to be highly important.  
7.4.2 Does MdnE function as a stabilizing protein? 
The impact of MdnE on the stability of the putative biosynthetic complex has been 
analyzed using exemplarily the detection of the amount of MdnB in both, presence and 
absence of the transporter in E. coli. Higher amounts of MdnB were detected in the 
presence of the ABC-transporter (Figure 6-24), which indicated that the stability of the 
putative biosynthetic complex is increased. The fact that MdnB was only detected in the 
cytosol supports the assumption of MdnE, consisting of a membrane-spanning and a 
cytosolic ATP-binding domain, might anchor the putative complex at the inner membrane. 
So far, it can only be speculated that the complex is located at the inner cytosolic 
membrane of cyanobacteria, as they contain further membranes, like those of the 
thylakoid, which could also harbor the complex. A better knowledge about the function of 
microviridins or the localization of the transporter would help to narrow speculations. The 
design of an antibody against MdnE could be useful to analyze MdnE in the native host. 
7.4.3 Does MdnE exhibit a function in cleavage and transport? 
Beside the role of MdnE in biosynthesis, the function in processing, cleavage and transport 
of microviridins was analyzed. Several times ABC-transporters belonging to ribosomal 
biosynthetic gene clusters have been shown to exhibit a bifunctional role [Havarstein, et 
al., 1995]. Correct processing of microviridins has been previously shown to depend on the 
presence of MdnD and MdnE [Ziemert, et al., 2008]. Mutagenesis of the proline-rich region, 
conducted earlier, rather excluded the possibility of processing performed by a 
proline-specific peptidase (Figure 6-18) and supported the hypothesis the ABC-transporter 
might be involved. Thus, advanced studies were necessary to study the role in cleavage 
and transport. 
All experiments, carried out in the course of this work, indicated the transporter is not 
involved in an ATP-dependent cleavage reaction related to transport. Under all conditions 
tried, the transporter is further not involved in transport, which may independently occur 
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from processing of microviridins, as similar amounts of microviridins were found in 
presence and absence of MdnE in the cytoplasm and periplasm of E. coli (Figure 6-22). 
Supernatant analysis of E. coli LB-cultures was impossible, due to purification problems. 
These results indicated, microviridins use another transport route, most likely the Sec-
system, which has been also considered by bioinformatic prediction tools. 
In contrast, in the cyanobacterium microviridins were exclusively found in the cytosol. 
Cyanobacterial culture supernatant did not contain microviridins. Studies conducted by 
Katharina Makower supported these results [Makower, 2010]. As Microcystis is hardly 
amenable to mutagenesis the construction of an MdnE deletion mutant was so far 
unsuccessful. In E. coli a variety of peaks for microviridin production were obtained, 
whereas the cyanobacterium produces only microviridin L and L1. This shows the E. coli 
processing machinery cannot manage to cleave large amounts of microviridins. It seems, 
the executing protease differs in the different host bacteria and is probably located 
outside the microviridin gene cluster. It remains to be analyzed if the protease cleaving 
microviridins in E. coli depends on the assistance of MdnE, as only in the presence of MdnE 
correctly processed microviridins were obtained. In consequence, E. coli is probably not 
the appropriate host to analyze cleavage and transport of microviridins. Future work 
should clearly go into the establishment of a cyanobacterial expression system, using a 
faster growing strain. It could be tried to identify the protease to be included into the 
E. coli system. All attempts to use artificial enzymatic cleavage sites directly constructed 
in the microviridin leader peptide failed. Searching for a completely new expression host 
would need a long time, as explained in this study. 
The only function currently assumed and so far not reported for any ABC-transporter from 
a microviridin gene cluster is that of a scaffolding protein, holding the microviridin 
biosynthetic complex at the inner membrane. As it might be, this ABC-transporter is used 
to transport other and unrelated products, further studies are clearly necessary to come to 
a final result. 
7.5 Two models for the formation of a putative microviridin maturation 
complex 
As the presented data are the very first report about complex formation in microviridin 
biosynthesis, there is a need to conduct further experiments. Protein-protein interaction 
studies involving MdnB, C and E are necessary to understand the organization of the 
putative maturation complex. So far interactions were only analyzed for MdnA with MdnB 
and MdnC. The results are considered as preliminary data, as the synthetic precursor 
peptides showed some unspecific interactions. From the new insights into the mechanism 
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of microviridin biosynthesis and compared to what is known from literature [Duquesne, et 
al., 2007: ; Nagao, et al., 2007: ; Pearson, et al., 2004: ; Siegers, et al., 1996], two initial 
putative models for the formation of a membrane-bound maturation complex could be 
imagined, as shown in Figure 7-3.  
 
Figure 7-3: Proposed partial models for the microviridin L biosynthesis 
The putative formation of an inner membrane located biosyntethic complex is shown. MdnE (E) 
plays a crucial role as a scaffolding protein. MdnB shown in blue (B) probably binds to MdnE. MdnC 
shown in purple (C) may cross-link MdnA in the cytosol. The main difference between the two 
models is the spatial arrangement of the prepeptide. The N-terminus of MdnA may integrate into 
the membrane (model II) or not (model I). The helix-breaking prolines at the C-terminus of the 
leader peptide introduce a turn, allowing approximation of PFFARFL and KYPSD. Once the first 
cyclization reaction is made, MdnC is released and the prepeptide may move closer to the 
membrane as the amide bond formation needs the support and presence of the transporter MdnE. 
Cleavage occurs by an unknown peptidase, as shown by the scissors in I and IIb. Finally MdnD, 
probably located within the complex, conducts acetylatation. I and IIc show the final product mdnL. 
The ABC-transporter MdnE is proposed to play an essential role exhibiting putative 
scaffolding function and thus being the main component in complex formation. Similarly, 
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for most of the ABC-transporters of related peptides a dimeric channel formation is 
assumed or even proven [Havarstein, et al., 1995: ; Siegers, et al., 1996]. The cytosolic 
membrane is expected to accommodate MdnE, but the localization in another membrane 
system, especially in the cyanobacterium, cannot be excluded. The removal of MdnE led to 
an inhibition of MdnB, which might be directly stabilized by MdnE. MdnC may temporarily 
bind to MdnA to introduce the ester bonds. Once MdnC is released from the precursor, it is 
further matured by MdnB. MdnC has been shown to work in the absence of MdnB in vitro 
[Philmus, et al., 2008]. Nevertheless, MdnC worked ineffectively in vivo in this study, when 
MdnB was missing from the system (Figure 6-31). If MdnB and C interact in the putative 
maturation complex, the presence of MdnB is essential for complex formation. MdnB could 
function as an important component between MdnE and C of the putative MdnBCE 
complex, as MdnC can work without any difficulties in the absence of MdnE, but not in the 
absence of MdnB. Similar “teamwork” has been described for the proteins of the nisin 
biosynthetic complex [van den Berg van Saparoea, et al., 2008]. 
The hydrophobic PFFARFL motif, as a recognition sequence for the two ATP-grasp ligases 
may need to be in the close spatial vicinity to the KYPSD region that carries the amino 
acids involved in cyclization. The original proline-rich region in the leader peptide is 
indispensable, probably to induce the formation of a β-turn that allows PFFARFL and KYPSD 
to come together. The formation of the proposed defined architecture within the putative 
membrane-associated complex, involving MdnE, B, C and the precursor peptide finally 
enables microviridin biosynthesis. The localization of the acetyltransferase remains so far 
unknown, as also the prediction tool PSORTb showed ambiguous results. Detailed studies 
are still outstanding, but it is assumed MdnD is part of the complex, as the possible benefit 
of complex formation for all enzymes might be that the precursor peptide MdnA is cyclized 
and processed in a well-coupled chronology, as similarly described for the nisin 
biosynthesis [Siegers, et al., 1996]. Processing of microviridins may occur through a 
cytoplasmic E. coli protease, which may also use MdnE as a scaffolding anchor. 
In contrast to the first model, the second one shows a different hypothesis about the 
spatial arrangement of the precursor peptide MdnA. Maybe, the rather hydrophilic 
N-terminus of the precursor peptide is roped into the channel formed by MdnE to stabilize 
the arrangement of the precursor peptide in complex formation. The PFFARFL region with 
its hydrophobic character may remain outside the channel. As no transport function has 
been observed for the ABC-transporter, it might be this precursor organization helps the 
ligases to get better access to the PFFARFL region or the precursor in general to introduce 
macrocyclizations. Integration of a precursor peptide into the channel has been reported 
for nisin biosynthesis [van den Berg van Saparoea, et al., 2008]. The NisBTC complex 
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enzymatically dehydrates and cyclizes prenisin, but subsequently also secretes it to the 
periplasm for final cleavage by NisP concomitant with release of the active peptide, which 
has never been observed for microviridins. Compared to nisin, bacteriocins include ABC-
transporters in their gene clusters that carry an N-terminal peptidase domain, located in 
the cytoplasm. After cytoplasmic cyclization of the small peptides, the same are cleaved 
and secreted by their transporters to release the active form. As microviridins were neither 
found in the periplasm of any cyanobacterial culture analyzed in this and other studies 
[Makower, 2010] nor in the culture supernatant, there is no evidence the ABC-transporter 
situated within the biosynthetic gene cluster translocates microviridins into the periplasm 
or even outside the cell. Completely processed microviridins, in contrast to bacteriocins 
and lantibiotics, were exclusively found in the cytoplasm in cyanobacteria. So far the only 
putative function for MdnE is that of a scaffolding protein. Similarly, the transporter 
encoded in the microcystin gene cluster, McyH, seems to function primarily as a scaffolding 
protein. A knockout of McyH resulted in a complete loss of microcystin production, which 
may cause the assumption these transporters fulfil more than only transport and cleavage 
function [Pearson, et al., 2004].  
From the data published in literature, less facts point to the second model, for which 
reason the first model would be preferentially proposed. As a proof of principle the 
N-terminus of the leader peptide could be shortened or mutated through the exchange of 
hydrophilic to rather hydrophobic amino acids.  
7.6 Manipulation of the microviridin core sequence 
In the second part of this study, the microviridin core sequence was analyzed for its 
flexibility with regard to the bioactivities and stability of the resulting peptides.  
The activity of original microviridin L has been estimated to be moderate against trypsin, 
chymotrypsin and subtilisin in comparison to the known microviridins. An inhibitory activity 
against elastase has not been detected up to an IC50>58 µM. To conduct initial in vivo 
manipulation of the microviridin core peptide the strategy of introducing subtle changes, 
instead of profound manipulation has been chosen. More than once it has been reported in 
the past, strong manipulation and alteration involving residues participating in cyclization 
led to a decrease and more often even to complete loss of peptide production [Cooper, et 
al., 2008]. The same phenomenon has been seen for microviridin biosynthesis in vitro 
[Philmus, et al., 2009], although bioactivities of the obtained peptides were not analyzed. 
The choice of amino acids to be introduced by site-directed mutagenesis was mainly 
influenced by variants detected from the natural library during microviridin screening 
programs and sequence analysis. 
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Several changes have been successfully introduced into the KYPSDx region (KYPADx, 
KFPSDx, KWPSDx, KYPSDS). Microviridins were produced from most of the mutants, albeit 
some of them with decreased efficiency. Mutations in the PFFARFL region of the leader 
peptide led to bicyclic microviridins, as previously described (Figure 6-12). Thus, it is 
possible to generate stable bicyclic and also monocyclic variants of microviridin simply by 
introducing a point mutation. These data illustrate a manipulation capacity of microviridins 
is given, although at some points limited. Microviridin biosynthesis is a well synchronized 
process, involving the precursor peptide and the posttranslationally modifying enzymes. A 
tight co-expression and collaboration of leader and core peptide allow a constricted 
variability. The nisin leader peptide, which has been used in fusion with designed and novel 
core sequences, demonstrated a higher flexibility as ring formation and secretion for most 
of the medically relevant nonlantibiotic peptides has been observed [Kluskens, et al., 
2005: ; Kuipers, et al., 2004]. 
Substitution of a residue involved in cross-linking (KYPSDxKYPADx), led to rather inactive 
monocyclic peptides with decreased stability (Table 6-1). This observation has been 
reported from other engineered peptides as well [Cooper, et al., 2008: ; Philmus, et al., 
2009]. The ligases are inflexible to changes in the crosslink-participating amino acids, as 
the correct ring formation serves as a stabilizer of conformations essential for bioactivity 
and protection against proteases of the producing strain [Bierbaum, et al., 1996].  
Substitutions in the KYPSDx region using amino acids with similar characteristics that were 
not involved in crosslinks (KYPSDxKWPSDx or KFPSDx) showed flexibility of the system 
(Figure 6-28). The efficiency of microviridin production was decreased, but the bioactivity 
remained unchanged or was even 2-fold increased against chymotrypsin. This position 
could potentially be used to engineer improved chymotrypsin inhibitors. The exchange 
against rather unrelated amino acids in KYPSDxKYPSDS or KYPSDC was less successful. 
Serine and cysteine, for instance, carry a hydroxyl and a highly reactive thiol group, 
respectively. Thiol groups commonly play an important role in protein folding and other 
biological processes and are rather rarely occurring in a free form. It might be that the loss 
of production correlates with the presence of this group. Substitutions using other amino 
acids for this position could give a completely different result. Taken together, successful 
changes in the KYPSDx region have been shown, although amino acids to be introduced 
need to be well selected.  
An amino acid exchange in position 5 (TFTL) gave an outstanding result (Figure 6-26, 
Table 6-2). Several different highly potent elastase inhibiting microviridins, including 
microviridin B, C, G, H and I, carry a leucine in this position. It has been discussed in 
literature about this hypothesis earlier [Rohrlack, et al., 2003], but this study presents the 
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first prove for this assumption. After the exchange of TFTL the activity against elastase 
increased to the nanomolar range, which is a factor of more than 100. Furthermore, 
chymotrypsin inhibitory activity increased about 2-fold. Thus, position number 5 is 
excellent to model the bioactivity of microviridins and shows great potential to study 
structure-function relationships. It remains open at that point, if the introduction of 
leucine already led to the optimum inhibitory activity that can be obtained, or not. As 
there are 20 proteinogenic amino acids, out of which only one has been used to show the 
importance of this position, there is a great potential to investigate the other residues. 
Furthermore, it is conceivable to introduce different functional groups or a designed side 
chain, if impossible in vivo, than it could be tried prospectively in vitro to generate a 
variety of new peptides. 
The reconstructed field sample mutant of the microviridin L1 type (Ac-NVTLKYPSDWEEY) 
carried a leucine in position 5 and showed highly potent activity against elastases as well 
(Table 6-4). The initial assumption, the most abundant precursor peptide in field exhibits a 
beneficial bioactivity for the producing strain was confirmed. This mutant could potentially 
provide access to variants for structure-function relationships.  
7.6.1 Expression of cryptic microviridins 
Experiments, which involved a complete exchange of the precursor peptide MdnA against 
orthologs from other cyanobacteria, disclosed an enormous so far unutilized potential for 
the construction of large peptide libraries of microviridins (Figure 6-30). The expression of 
the closely related Microcystis aeruginosa PCC7806 precursor resulted in the production of 
large amounts of bicyclic microviridins. The diversity of Microcystis precursor peptides so 
far detected in lab strains and field samples is large and the number of precursors that still 
await discovery in the field is assumed to be tremendous and offers the possibility to 
detect novel microviridins with potentially better pharmaceutically useful characteristics. 
As all Microcystis leader peptides share high similarity in their organization, they are 
valueable candidates to be tested in this system. In an ongoing metagenomic project, 
conducted by Douglas Gatte-Picchi, several new precursor peptides were already 
discovered that now await their insertion into the precursor exchange platform pARW089-
mdnA-exchange (Douglas Gatte-Picchi, personal communication). The expression of the 
precursor peptides from Cyanothece sp. PCC7822 has been shown. Cyanothece sp. PCC7822 
carries about 7 different microviridin precursor-like peptides that could potentially lead to 
the discovery of a broad spectrum of bioactivities expressed from a single organism. Maybe 
another or an improved expression system for Cyanothece microviridins could be 
established in the future to isolate appropriate amounts of these microviridins.  
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Taken together, microviridins show high potential for bioengineering approaches, as several 
positions were detected to be flexible to amino acid exchanges. A mutant with a 100-fold 
increased inhibitory activity has been constructed. Future work is necessary to introduce 
more and different mutations for the design of whole libraries of highly attractive, 
optimized peptides to be used as anti-protease drugs or even as a proteasome inhibitor. It 
is believed, a systematic search and expression of so far cryptic microviridin precursors 
from different habitats will unravel further valueable features of these interesting 
compounds. An expression system for those candidates is established and ready to use. 
7.7 Hypothesis about the inhibiting mechanism of microviridin 
From the data obtained during this study and compared to what is known about the binding 
mechanism of other cyanobacterial serine protease inhibitors, such as scyptolin A from 
Scytonema hofmanni PCC7110 (Figure 7-4) or A90720A from the terrestrial cyanobacterium 
Microchaete loktakensis [Lee, et al., 1994], some speculation about the interaction of 
microviridin with the serine proteases can be drawn. A report about the crystal structure of 
an elastase—scyptolin A complex revealed, scyptolin A uses the 4 N-terminal amino acid 
residues to bind specifically, but not covalently to the target at subsites S1 to S4, by 
forming main chain hydrogen bonds like in an antiparallel β-sheet. The active center 
pocket is occupied by the macrocycle of scyptolin A and thus hydrolysis is prevented 
[Matern, et al., 2003]. 
 
Figure 7-4: Structure of scyptolin A [Matern, et al., 2003] 
The 4 N-terminal amino acids used to bind at subsites S1 through S4 of elastase are indicated. But: 
butyrate; Ahp: 3-amino-6-hydroxy-piperidone; cmTyr: 3`chloro-N-methyl-Tyr 
Elastase consists of two β-barrels, joined in position 126 in a sequential numbering system 
starting with valine at the first position and asparagine being the last amino acid in 
position 255. The active site residues, located between the two domains, consists of a 
catalytic triad with Asp108, His60 and the eponymous Ser203, the oxyanion hole and 
 Discussion 
 120 
several subsites for amino acid residues. S subsites are located C-terminally and S`subsites 
N-terminally of the cleavage site [Mattos, et al., 1994]. 
 
Figure 7-5: Elastase and elastase-scyptolin A inhibitor complex 
A) Crystal structure of an elastase molecule. The C-terminal domain is shown in blue, the N-
terminal domain in purple. The catalytic triad (Asp108, His60, Ser203, from left to right), located 
between the two domains, is given in yellow [Mattos, et al., 1994]; B) Stereo view of 
elastase-scyptolin A complex. The catalytic triad is shown beneath the surface. Scyptolin A is 
located in the active center pocket [Matern, et al., 2003]. 
As microviridins show structural and size similarities to scyptolin A, a similar binding 
mechanism might be assumed (Dr. Keishi Ishida, personal communication). It could be 
imagined, elastase interacts with microviridins in a substrate-like manner. The elastase 
may recognize the amino acid in position 5 of microviridins at the S1 site, whereas the 
remaining side chain potentially binds to the other S subsites. The macrocycle may occupy 
the active center pocket with the ring structure. The elastase might be capable of cleaving 
the peptide bond behind the amino acid in position 5, but the cyclic structure of 
microviridin could be saved through the potential formation of intermolecular hydrogen 
bonds, similar as described for scyptolin A and A90720A [Lee, et al., 1994: ; Matern, et al., 
2003]. The elastase inhibitory activity of microviridins was analyzed using porcine pancreas 
elastase, which preferentially cleaves behind leucine, methionine and phenylalanine and 
resembles the attractive drug target human neutrophile elastase. Aberrant expression of 
this type of elastase can cause emphysema or emphysematous changes that finally lead to 
a disorganization of the lung structure and a breakdown of all functions. Position 5 being 
filled with a leucine has been shown to be more efficient compared to a phenylalanine. A 
methionine has not been tried, but the precursor peptide of microviridin D carries a 
methionine in position 5 (Figure 1-9, Table 1-1) and elastase inhibitory activity has been 
detected, although less efficient compared to the leucine type microviridin. In general, 
different amino acids in this position could be introduced to create the favorable 
 Discussion 
 121 
recognition site for the different types of elastases. Neutrophile elastase for example 
preferentially recognizes the small amino acids valine and alanine 
(http://www.uniprot.org/uniprot/P08246), which could be tried to be introduced in this 
position. The C-terminal part of the microviridins, including the last three amino acids, did 
not show any relevance for the inhibitory activity, whereas the composition of the 
N-terminal part was important for elastase and also chymotrypsin inhibition. The shorter 
the N-terminal side chain is the higher is the loss of bioactivity against elastase (Figure 
7-6). The loss of the amide bond, as well as further mutations in position 7 did not 
significantly influence the inhibitory profile of microviridins towards the tested serine 
proteases.  
As a proof of this binding hypothesis, a monocyclic mutant with the sequence 
Ac-(Y)GGTLKYPSDW should be constructed and analyzed for its elastase inhibitory activity. 
In case this one could keep activity, the binding mechanism would be shown to be similar 





Figure 7-6: The importance of the N-terminal amino acid composition for the elastase inhibitory 
activity of microviridins (Dr. Keishi Ishida, personal communication) 
A) Original microviridin L with its inhibitory activity against elastase. B) The TFTL mutant of 
microviridin L shows about a 100-fold increased inhibitory activity against elastase, compared to 
original microviridin L. C) and D) represent N-terminally manipulated and shortened microviridins 
with gradually decreased elastase inhibitory activity. E) shows one possibility to be analyzed, if 
microviridin and scyptolin A have a similar inhibitory mechanism. Ac: acetylation 
In comparison to other inhibitors of porcine pancreas elastase that are kept in the Brenda 
data base (on November 1th, 2011), the new microviridin (Ac-GGTLKYPSDWEDY) beside 
lyngbyastatin 7 (IC50=8.3±5.4 nmol/l) [Taori, et al., 2007], isolated from the marine 
cyanobacterium Lyngbya spp., is one of the most potent peptides for elastase inhibition 
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(IC50=133 nmol/l). Microviridin B, which is not included in the data base, also reaches the 
nanomolar range (IC50=26 nmol/l) [Okino, et al., 1995]. 
 
Figure 7-7: Structure of lyngbyastatin 7 [Taori, et al., 2007] 
Furthermore, microviridin shows moderate inhibitory activity against trypsin, chymotrypsin 
and subtilisin, which are serine proteases as well. All conducted steps towards engineering 
microviridins did not show significant effects on the inhibitory profile against these 
proteases. Probably other amino acids or positions than those used and analyzed during 
this study are important. Subtilisin inhibition seems to depend on the presence of both 
ester bonds, as monocyclic microviridins lost the ability to inhibit subtilisin. Some amino 
acid exchanges showed a marginal increase of inhibitory activity against chymotrypsin, 
including those in position 5 and 7, as well as in position 9, which led to monocyclic 
microviridins, and thus uncovered the fact that several positions in the molecule could be 
analyzed and further optimized. The length of the N-terminus of the peptide seemed to be 
important for both. The trypsin inhibitory activity has not been modified by any of the 
conducted mutations. It remains questionable, if microviridin might be optimized as a 
trypsin inhibitor. Further studies involving substitutions in different positions using more 
and other amino acids are necessary to get a final result. 
It could be speculated the binding mechanism of microviridin to chymotrypsin or subtilisin 
is not much different from the one proposed for elastase. In contrast, the serum 
glycoprotein alpha-1-antitrypsin, which is a well-known inhibitor of the neutrophile 
elastase in the lung, irreversibly binds to the serine protease by forming a covalent 
complex. The mechanism of inhibition involves a profound conformational change 
[Huntington, et al., 2000]. 
7.8  The potential of microviridin 
7.8.1 In vitro synthesis as a future prospect 
In vitro synthesis of ribosomal peptides is a forward looking trend in biology. Several 
successful reports about partial characterization of enzymatic processing of lantibiotic 
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precursor peptides are known [McClerren, et al., 2006: ; Müller, et al., 2010: ; Xie, et al., 
2004]. Problems encountered by conventional in vivo biosynthesis, including poor growth of 
the expression host, toxic side effects, as well as proteolytic degradation of the peptide of 
interest could thus easily be circumvented. One of the main advantages of ribosomal 
biosynthesis is the possibility to custom-synthesize precursor peptides, even with expanded 
chemical diversity by introduction of nonproteinogenic amino acids, as it has been 
reported the first time in an in vitro mutasynthetic approach [Levengood, et al., 2009]. 
While this technology used to be very expensive, improved methods in peptide chemistry 
have made chemical synthesis more available and less expensive in recent years. To 
manufacture short sequences is significantly more economical than for longer peptides. 
Microviridin precursor peptides are relatively long, which is why heterologous expression in 
E. coli is still a competing technique. Philmus and coworkers showed MvdC and MvdD, 
which are orthologs of MdnB and MdnC, exhibit low in vitro activity [Philmus, et al., 2008]. 
Similar experiments conducted in this study and by Douglas Gatte-Picchi, using the same 
enzymes and precursor peptide (University of Potsdam, personal communication) rather 
pointed to inactive enzymes. So far the complex biosynthetic process of microviridin 
production has not proven amenable to in vitro reconstitution, which is why future work is 
necessary. 
The ester bond forming ATP-grasp ligase MdnC is a unique enzyme with characteristics that 
have never been reported from any enzyme of the other ribosomal pathways. Once the 
right conditions for an in vitro (muta)synthesis of microviridins are established, MdnC could 
be manipulated to recognize substrates with broader specificity and thus might provide a 
system to engineer peptides and proteins unrelated to microviridins. 
7.8.2 The bioactive potential 
Microviridins with their potent inhibitory activity against elastases and other serine type 
proteases are considered to be particularly suitable in the treatment of degenerative and 
degradative diseases like pancreatitis, arthritis, lung emphysema, psoriasis or even cancer, 
caused by an uncontrolled proteolysis in the absence of a natural enzyme inhibitor 
[Reboud-Ravaux, 2001]. These low molecular weight peptides show bioactivity in the 
nanomolar range, which makes them interesting drug candidates. The small size of the 
compound is well suited for a simple take-up. To prevent rapid urinary excretion of very 
small peptides, the use of PEG in conjugation with the molecule has been shown to 
improve the half-life [Webster, et al., 2007]. A small dosage volume of a specific drug in 
general minimizes severe side effects for the consumer. The bacterial origin of 
microviridins makes it easy to produce large amounts of peptide. Problems of aberrant 
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glycosilation patterns, as reported from attempts to produce recombinant human 
proteinase inhibitors can be excluded [Karnaukhova, et al., 2006].  
In the past, extracts of Microcystis aeruginosa were analyzed for their cytotoxicity. 
Whereas the microcystin producing strains showed cytotoxicity in a mouse model, extracts 
of microcystin-deficient mutants lost their strong cytotoxic properties (Prof. Elke 
Dittmann, personal communication). Thus, it is so far rather assumed, microviridins 
belonging to the spectrum of secondary metabolites produced by Microcystis strains are 
noncytotoxic protease inhibitors, which is vitally important for a potential drug 
development for in vivo application. Of course this needs to be analyzed again in more 
detail. 
Position 5 in the microviridin core sequence showed potential for the construction of 
therapeutic agents with improved bioactivity. Furthermore, extensive field sampling and 
metagenomic studies recently conducted by Douglas Gatte-Picchi (group of Prof. Dittmann, 
University of Potsdam), pointed to a broader spectrum of bioactivities than so far reported 
for microviridins. A number of detected microviridin precursor peptides could not be 
cloned and expressed in E. coli. It was assumed, these peptides may have potential 
antibacterial properties that interfere with E. coli as an expression host (Douglas Gatte-
Picchi and Prof. Elke Dittmann, personal communication). 
Taken together, microviridins show pharmaceutical useful characteristics to be further 
analyzed as potential alternative drug candidates to especially replace currently available 
protease or even proteasome inhibitors in the future.  
It is hoped that this work will provoke future studies to complete the investigation of the 
microviridin biosynthetic pathway, the organization of the putative maturation complex 
and the potential use as a powerful drug. Such efforts could clearly expand the knowledge 
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Oligonucleotides used in this study 
Primer 5`3`sequence Application / specificity 
M13 RV AACAGCTATGACCATG pDrive sequencing 
M13(-20) FW GTAAAACGACGGCCAGT pDrive sequencing 
FW-pCC1/pEpiFOS GGATGTGCTGCAAGGCGATTAAGTTGG pCC1Fos sequencing 
RV-pCC1/pEpiFOS CTCGTATGTTGTGTGGAATTGTGAGC pCC1Fos sequencing 
mdnB fw TTGGCTGGTTTTTGGGATAG Library screening; 
mdnB 
mdnB rv CGATCGCATTGGAAATAGGT Library screening; 
mdnB 




GGATCTCGACGCTCTCCCT Duet-1 vector 
sequencing 
P84-DuetDOWN1 Primer GATTATGCGGCCGTGTACAA Duet-1 vector 
sequencing 
P85-DuetUP2 Primer TTGTACACGGCCGCATAATC Duet-1 vector 
sequencing 
P86-T7 Terminator Primer GCTAGTTATTGCTCAGCGG Duet-1 vector 
sequencing 
P91-mdnANies298FW ggatccGATGGCATATCCCAACGATCA PCR, mdnA N298 
P92-mdnANies298RV gaattcTTAATACTCTTCCCAGTCAGAAG
G 
PCR, mdnA N298 
P93-mdnBNies298RV ggatccgATGAAAGAATCGCCTAAAGT PCR, mdnB N298 
P94-mdnBNies298RV gaattcTTAGCATACTAAAAAATCAGCGA PCR, mdnB N298 
P95-mdnCNies298RV catatgACCGTTTTAATTGTTACTTT PCR, mdnC N298 
P96-mdnCNies298RV agatctCGTGAGTTGACGAGGACTTCAG
C 
PCR, mdnC N298 
P97-mdnDNies298RV ggatccgATGAAAGCACTGGAAAAACTG
G 
PCR, mdnD N298; PCR 
N843 mdn cluster with 
long promoter 
P98-mdnDNies298RV gaattcTCAGCAAACCCTACTTAATTTCC PCR, mdnD N298 
P99-mdnENies298RV catatgCCTCAATATACTACTAAACAAGCA
ACG 
PCR, mdnE N298 
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Primer 5`3`sequence application / specificity 
P100-mdnENies298RV ctcgagTATTCTCACCCATTTTAAGGTTT
TTG 
PCR, mdnE N298 
P101-mdnESequFW TTTGTTGTTCTCCGAGGGATA N298 mdnE sequencing  
P102-mdnESequRV TCCCGATCAAAGATTATCTCAA N298 mdnE sequencing 
P103-mdnESequFW GGCTCTTCACTGGCAACTTT N298 mdnE sequencing 


















































PCR N843 mdnA 
 
   
 Appendix 
 145 
Primer 5`3`sequence Application / specificity 
P122-rpsLneo FW GGCCTGGTGATGATGGCGGGATCG Fosmid mutagenesis, 
PCR rpsLneo cassette 
P123-rpsLneo RV TCAGAAGAACTCGTCAAGAAGGCG Fosmid mutagenesis, 
PCR rpsLneo cassette 
P126-N843mdnAManiFW ggatccgATGGCATATCCCAACGATCA PCR, N843 mdnA 
P127-Nies843mdnAManiRV gaattcTTAATAATCTTCCCAGTCAG PCR, N843 mdnA 
P149-mdnENies298-
108bpdelRV 
ctcgagAGAATAATCAGTTAGGGACTGCA Deletional PCR, N298 
mdnE 
P150-S•Tag primer CGAACGCCAGCACATGGACA pET40b(+) sequencing 
P151-mdnENies298-
138bpdelFW 






Qc mutagenesis of N843 






Qc mutagenesis of N843 
mdnA PFFARFL region 
(LFFARFL) 
P166-MAE24120FW GGCCGGATTAGTGCTTATGA PCR and sequencing 
N843 mdn cluster with 
short promoter  
P167-MAE24060RV AGGAATTCGCCCTGAGAGTC PCR and sequencing 
N843 mdn cluster with 
short promoter 
P173-MAE24140N843FW ggatccgATGGCATATCCCAACGATCA PCR and sequencing 






Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 
mdnA KYPSD region 
(KWPSD) 
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Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 






Reconstruction of a 
microviridin precursor 
previously detected in 
field samples; Qc 





Reconstruction of a 
microviridin precursor 
previously detected in 
field samples; Qc 





Reconstruction of a 
microviridin precursor 
previously detected in 
field samples; Qc 





Reconstruction of a 
microviridin precursor 
previously detected in 
field samples; Qc 






construction of trypsin 







construction of trypsin 









Reconstruction of a 
microviridin precursor 
previously detected in 
field samples; Qc 





Reconstruction of a 
microviridin precursor 
previously detected in 
field samples; Qc 





















Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 






Reconstruction of a 
microviridin precursor 
previously detected in 
field samples; Qc 
mutagenesis, 4. step 
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Reconstruction of a 
microviridin precursor 
previously detected in 
field samples; Qc 




construction of an AatII 
restriction site 





construction of an AatII 
restriction site 







construction of an EheI 
restriction site 







construction of an EheI 
restriction site 






























Primer 5`3`sequence Application / specificity 
P216-PCC7806mdnprec-
FW 











construction of a 
hydroxylamine cleavage 






construction of a 
hydroxylamine cleavage 





Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 










Qc mutagenesis of N843 
mdnA PFFARFL region 
(PFFLRFL) 
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Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 







construction of an AatII 
restriction site 







construction of an AatII 
restriction site 




GGTGCTTGGCAACATCATACT Sequencing across the 
Qc constructed AatII 







construction of a Factor 
Xa Protease cleavage 
site arranged at the C-
terminus of the N843 
mdnA leader peptide, 
1. step  
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construction of a Factor 
Xa Protease cleavage 
site arranged at the C-
terminus of the N843 







construction of a Factor 
Xa Protease cleavage 
site arranged at the C-
terminus of the N843 







construction of a Factor 
Xa Protease cleavage 
site arranged at the C-
terminus of the N843 







construction of a Factor 
Xa Protease cleavage 
site arranged at the C-
terminus of the N843 







construction of a Factor 
Xa Protease cleavage 
site arranged at the C-
terminus of the N843 






Qc mutagenesis; N843 
mdnB active center 
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Qc mutagenesis; N843 










Qc mutagenesis; N843 





Qc mutagenesis; N843 
mdnB active center 
P248-
mdnBSTaqNies298FW 
catatgAAAGAATCGCCTAAAGTTGT PCR, N298 mdnB 
P249-mdnBSTaqNies298RV agatctcgGCATACTAAAAAATCAGCGATC
G 






Qc mutagenesis; N843 






Qc mutagenesis; N843 
mdnB active center 
P252-QcmdnEWalkerA_FW CCAGTGGTCGAGGAGCAAGTTCCTTGT
TACGA 
Qc mutagenesis; N843 
mdnE Walker A motif 
P253-QcmdnEWalkerA_RV TCGTAACAAGGAACTTGCTCCTCGACC
ACTGG 
Qc mutagenesis; N843 
mdnE Walker A motif 
P254-
mdnEWalkerASequ_FW 
CCTACAAACTCCCGATTATGA Sequencing of Qc 
mutagenesis of N843 





Qc mutagenesis of N843 






Qc mutagenesis of N843 






Qc mutagenesis of N843 
mdnA PFFARFL region 
(PGFLRAL) 
   
   
 Appendix 
 153 





Qc mutagenesis of N843 




Qc mutagenesis of N843 
mdnA proline region 
PSPEPT vs. ASAEPT 
P260-QcProlinregion1_RV GTAGGTAGGCTCAGCGGAAGCAGACTT
GATGGAAGATTC 
Qc mutagenesis of N843 
mdnA proline region 
PSPEPT vs. ASAEPT 
P261-QcProlinregion2_FW CTTCCGCTGAGGCTACCTACGGGGGCA
C 
Qc mutagenesis of N843 
mdnA proline region 
PSPEPT vs. ASAEAT 
P262-QcProlinregion2_RV GTGCCCCCGTAGGTAGCCTCAGCGGAA
G 
Qc mutagenesis of N843 
mdnA proline region 
PSPEPT vs. ASAEAT 
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Figure 1-1 A) http://kentsimmons.uwinnipeg.ca/16cm05/1116/27-11x1a-Gloeothece.jpg; 
date: 220911 
 B) Annika R. Weiz 
















sch:1&ei=--k3TZ74IcOW8QODn_CfCA; date: 220911 
Figure 1-2 A) http://www-cyanosite.bio.purdue.edu/images/images.html; date: 220911 
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